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Abstract
Receptors for the constant region of immunoglobulin G (FcyRs) expressed on myeloid 
cells play a pivotal role in the clearance of immune complexes and cell activation. In this 
thesis, the human monoblastic cell line, U937, has been used as a model system to study 
the coupling of Fey receptors to specific signal transduction events. These cells are 
known to express both the high affinity receptor, FcyRI, and the low affinity activation 
receptor, FcyRIIa. Previous work has shown that the nature of the signalling cascades 
initiated by FcyRI fundamentally changes as U937 cells differentiate from a monocyte to 
a more macrophage phenotype. This thesis describes mechanisms that underlie this 
developmental switch.
In IFNy primed U937 cells, FcyRI is coupled to the activation o f phospholipase D 
(PLD). As the subsequent calcium mobilisation is independent of measurable inositol 
trisphophate production and is not coupled to calcium influx, we examined a potential 
role for the 5’ inositol phosphatase, SHIP, which has been characterised to block both 
PLCy activation and calcium influx in mast and B-cells. Here, I demonstrate that 
following immune complex stimulation, SHIP is tyrosine phosphorylated and associates 
with the adapter protein. She, and immune complexes at the plasma membrane. In B-cells 
and mast cells, SHIP is recruited by the inhibitory Fc receptor, FcyRIIb. However, in 
IFNy primed U937 cells, no FcyRIIb could be found. Interestingly, FcyRIIb expression 
was induced following differentiation of U937 cells to a more macrophage phenotype 
using dibutyryl cyclic AMP (dbcAMP). This was surprising as here immune complexes 
activate PLCy and induce calcium influx. In these cells, FcyRIIb appears to modulate 
rather than inhibit immune complex activation.
In IFNy primed U937 cells, activation of PLCy was coupled to FcyRIIa but not to FcyRI. 
The mechanism of this coupling was investigated. I demonstrate that FcyRIIa recruits 
preformed SLP76:PLCy complexes to the plasma membrane whereas FcyRI does not. I 
further show that FcyRI and FcyRIIa induce distinct activation patterns of the MAP 
kinase cascades.
Finally I have demonstrated that the signalling pathway initiated by FcyRI depends 
entirely on the recruited accessory molecule. Thus, in IFNy primed cells, FcyRI 
physically and functionally associates with the y-chain. Conversely, in dbcAMP 
differentiated cells, FcyRI no longer uses the y-chain but is coupled to PLCy activation by 
the recruitment of FcyRIIa. The y-chain in these differentiated cells is preferentially 
associated with the IgA receptor and appears to define receptor coupling to PLD.
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Chapter 1 
General Introduction 
1.1 Fc Receptors
1.1.1. Fc receptors and the immune response
Immune responses are initiated when an individual encounters antigenic material, generally 
in the form of an infectious agent. A major facet of this immune response is the 
production and secretion of antigen specific antibodies (immunoglobulins) by B- 
lymphocyte derived antibody secreting cells. Secreted immunoglobulins (Ig) serve to bind 
the antigenic material to form immune complexes. These immune complexes are then 
targeted to cells bearing specific receptors which recognise Ig. These receptors are 
collectively known as Fc receptors as they bind to the constant region (Fc) of Ig, while 
the variable region (Fab) binds to the antigen (Figure 1.1). Fc receptors thus provide a 
bridge between the humoral (extracellular) and cellular arms of the immune response.
1.1.2. Fc Receptors -  overview
Fc receptors (FcRs) recognise the constant region (Fc) of immunoglobulins (Ig). There are 
five main classes of Ig; IgG, IgA, IgE, IgM and IgD. Each class of Ig has a different Fc 
region and these are recognised by a specific set of receptors. Thus, IgG is recognised by 
FcyRs, IgA by FcaRs, IgE by FceRs and IgM by FcpRs (Raghavan & Bjorkman, 1996). 
Several different classes of structurally and functionally distinct Fc receptors have been 
identified. These include the lectin like IgE receptors (CD23) and the immunoglobulin 
transporters, exemplified by the neonatal IgG transporter (FcRn) and the 
poly immunoglobulin transporter for IgM and IgA (Raghavan & Bjorkman, 1996). The 
largest and best characterised group of Fc receptors, however, belong to the Ig domain 
super family (IgSF) of receptors (Ravetch & Kinet, 1991, Vandewinkel & Anderson, 
1991, Daeron, 1997b, Daeron, 1997a). This group includes the high affinity IgE receptor
1
Fab
Fc
F(ab)’;
= disulphide bond
□  = light chains
□  = heavy chains
Figure 1.1. Schematic Structure of an Ig molecule. Each coloured oval 
symbolises a complete IgSF domain. The two heavy chains (green) each 
comprise four IgSF domains. The two light chains each comprise two IgSF 
domains. The four chains are linked by disulphide bonds as indicated.
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(FceRI), the high affinity receptor for IgA (FcaRI) and high and low affinity receptors for 
IgG (FcyR). These receptors generally exist as multisubunit receptor complexes, 
comprising a ligand binding a-chain and associated signalling chains (i.e. y-chain). The 
ligand binding chains of these receptors, with the exception of FcyRIIIb (section 1.1.3.3) 
are all type I membrane glycoproteins comprising highly conseiwed extracellular 
immunoglobulin domains of the V class, and less conserved transmembrane and 
cytoplasmic domains. The main focus of this thesis lies on Fey receptors of the IgSF 
family (Table 1.1). However, due to analagous functions and mechanisms of action, 
FcaRI and FceRI will also be discussed in some detail (Table 1.1).
1.1.3. F ey  receptors
Structurally and functionally, the Fey receptors represent the most diverse group of Fc 
receptors. At least 8 separate genes have been identified in man, all mapped to 
chromosome 1, with each gene giving rise to multiple splice variants (Figure 1.2). Fey 
receptors can be divided into three main subgroups, based on their affinity for IgG and 
mAh reactivity, termed FcyRI, FcyRII and FcyRIII (Table 1.1) (Hulett & Hogarth, 1994, 
Ravetch, 1994).
Ll.3.1. FcyRI (CD64)
FyRI is a high affinity receptor which binds monomeric IgG at physiological 
concentrations (Allen & Seed, 1989). FcyRI is constitutively expressed on monocytes 
and macrophages where its expression is tightly regulated by IFN-y (Harris et aL, 1985). 
FcyRI expression can also be induced by IFN-y on neutrophils and eosinophils (Hulett & 
Hogarth, 1994, van de Winkel & Capel, 1993). The unique ability of FcyRI to bind 
monomeric IgG may reflect a role for this receptor in triggering effector functions at low 
concentrations of IgG (Shen, Guyre & Fanger, 1987). It has been proposed that the high 
affinity binding of FcyRI is conferred by the presence of the third extracellular domain 
(Allen & Seed, 1989) (Figure 1.2). Three human FcyRI genes have been identified and 
mapped to chromosome lq21.1 (Hulett & Hogarth, 1994, van de Winlcel & Capel, 1993). 
Only one of these genes, FcyRIa, encodes a membrane anchored high affinity receptor.
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This receptor comprises three extracellular IgSF domains, (unlike all other FcRs which 
have two IgSF domains) a short transmembrane region and a short cytoplasmic domain. 
Stop codons in the coding region of the third IgSF domain (membrane proximal) of the 
other two genes, FcyRIb and FcyRIc, predict soluble forms of FcyRI. Alternative splicing 
o f FcyRIb has also been proposed to generate a truncated low affinity membrane bound 
receptor lacking the third extracellular domain (Ernst et al., 1992) (Figure 1.2).
The cytoplasmic tail of FcyRI contains no known signalling motif (Allen & Seed, 1989). 
To couple to signalling pathways, FcyRI associates at the cell surface with y-chain 
homodimers (Ernst, Duchemin & Anderson, 1993, Scholl & Geha, 1993, Ra et al., 1989). 
The y-chain, initially found in association with FceRI, contains a cytoplasmic 
immunoreceptor tyrosine based activation motif (ITAM) responsible for the recruitment 
of tyrosine kinase dependent signalling pathways (discussed in Section 1.2.1.1) (Cambier, 
1995).
I.I.3.2. FcyRII (CD32)
The FcyRII receptors represents by far the most widely distributed and functionally 
diverse group of human IgG receptors (Stuart et a l, 1989, Brooks et a l, 1989). Three 
human FcyRII genes have been identified, FcyRIIa, FcyRIIb and FcyRIIc; each giving rise 
to multiple splice variants. All tliree genes are mapped to chromosome lq23-24. All 
isoforms of FcyRII, with the exception of FcyRIIa2 (which encodes a soluble form of 
FcyRIIa), are integral type I membrane proteins comprising two extracellular IgSF 
domains, a short membrane spanning region and a cytoplasmic region of vaiiable length 
(44-77 amino acids) (Figui'e 1.2). Unlike FcyRI, FcyRII is a low affinity receptor, 
incapable of binding monomeric IgG. Physiologically, this low affinity ensures that 
FcyRII is only engaged by IgG that has been aggregated by multivalent antigens (Raghavan 
& Bjorlanan, 1996, van de Winkel & Capel, 1993, Hulett & Hogarth, 1994).
While the extracellular domains of all FcyRII isoforms are highly homologous (>95%), the 
cytoplasmic tails are highly divergent. The divergence of the FcyRII proteins exemplifies 
how near identical receptors can give rise to highly divergent biological responses (Brooks
Chapter 1
et aL, 1989). Unlike FcyRI and FcyRIII, the FcyRII receptors encode signalling motifs 
within their cytoplasmic tails, and are capable of triggering signalling cascades (Van den 
Herik-Oudijk «/., 1995a). Differences in the cytoplasmic motifs encoded by the tliree 
FcyRII genes specifies recruitment of distinct pathways (Figure 1.2). Thus, FcyRIIa has 
an ITAM (immunoreceptor tyrosine based activation motif) within its cytoplasmic tail. 
This motif is capable of triggering tyrosine kinase dependent signalling cascades 
(discussed in section 1.2.1.2). Conversely, FcyRIIb 1 has an ITIM (immunoreceptor 
tyrosine based inhibitory motif) within its cytoplasmic tail which recruits an inhibitory 
signalling pathway (discussed in section 1.2.8) (Muta et al., 1994b, Daeron, 1996, Van 
den Herik-Oudijk et aL, 1995a).
Further diversity of function is generated by alternative splicing of the FcyRIIa and 
FcyRIIb transcripts (Brooks et aL, 1989). Thus FcyRIIa gives rise to both a membrane 
associated receptor (FcyRIIa 1 - referred to as FcyRIIa) and a soluble form (FcyRIIa2). 
FcyRIIb gives rise to three alternatively spliced transcripts (FcyRIIb 1-3) (Brooks et aL, 
1989). FcyRIIb 1 and FcyRIIbS give rise to identical mature proteins though their signal 
sequences differ. FcyRIIb2 however lacks a cytoskeletal attachment domain responsible 
for modulating receptor internalisation (Daeron, 1997a) (Figure 1.2). FcyRIIa expression 
is generally limited to myeloid cells, including monocytes, macrophages, and neutrophils. 
FcyRIIb iso forms are widely expressed on cells of hematopoietic origin, including B-cells 
and mast cells, where the inhibitory properties of these receptors have been extensively 
studied (section 1.2.8).
Interestingly, analysis of the gene structure for FcyRIIc indicates high homology to 
FcyRIIa at the 3’ end and high homology to FcyRIIb at the 5’ end implying that this gene 
resulted from an unequal crossover event between the genes for FcyRIIa and FcyRIIb (van 
de Winlcel & Capel, 1993). The result is a gene product with extracellular domains like 
FcyRIIb bearing an ITAM containing cytoplasmic tail homologous to FcyRIIa. FcyRIIc 
expression has recently been reported in natural killer (NK) cells where they are co­
expressed with FcyRIIIa (Metes et aL, 1994, Metes et aL, 1999). Four known splice 
variants of FcyRIIc have been identified (FcyRIIc 1-4) though the biological importance of 
these variants is unknown.
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Table 1.1 Fc receptor ligands, affinities and cell distribution
Receptor Ligand Affinity ( K a ) Cell Distribution
FcyRIa
CD64
IgG high 2-5x10’ M‘‘
IgGl=IgG3>IgG4 
IgG2 does not bind
Monocytes, macrophages
IFN-y induced neutrophils, eosinophils
FcyRIIa
CD32
IgG low
IgGl=IgG3>IgG2* 
IgG4 does not bind
monocytes, macrophages, neutrophils, 
platelets
FcyRIIb
CD32
IgG low
IgGl=IgG3>IgG4 * 
IgG2 does not bind
widely expressed - B-cells, mast cells
FcyRIIc
CD32
IgG low NK cells
FcyRIIIa
CD16
IgG low NK cells, macrophages, mast cells
FcyRIIIb
CD16
IgG low neutrophils
FcaRI
CD89
IgA med/high -5x10^ M"‘ monocytes, maerophages, neutrophils 
and eosinophils
FceRI IgE high -IxlO^^M"^ mast eells, basophils
* For low affinity receptors, binding refers to immune complexes, not monomeric Ig.
FcyRI
la sibl Ib2 sic
---------- 1 I— I — I I 1 I— I — I
FcyRII
Hal slla2 IIbl/3 IIb2 IIcl-4
I 1 I 1 I--------- 1 I--------- 1 I--------- 1
I HI I
FcyRIII
Ilia mb
1 I—I---- 1
I
GPl
FcaRI FceRI
Figure 1.2. Fc receptors and their associated signalling chains. ITAM and 
ITIM motifs are indicated, y-chain associates with FcyRI, FcyRIII, FcaRI and 
FceRI as indicated (y). * indicates that FcyRIII also associates with (! -^chain. 
The (3-chain o f FceRI is indicated (3.
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Importantly, differences between mouse and human Fey receptor expression are most 
notable for FcyRII. In mouse only one gene for FcyRII exists, encoding the inhibitory 
FcyRIIb receptor. As in humans this gene gives rise to alternative splice variants. No 
ITAM bearing FcyRII receptor isoforms exists in mouse.
1.1.3.3. FcyRIII (CD16)
FcyRIII, like FcyRII, is a low affinity receptor recognising only IgG aggregated to 
multivalent antigens (Daeron, 1997a, van de Winkel & Capel, 1993, Hulett & Hogarth, 
1994). Two, highly homologous genes for FcyRIII exist in man, FcyRIIIa and FcyRIIIb, 
mapped to chromosome lq23-24. While both receptors share similar' extracellular 
domains, comprising two IgSF domains, they differ dramatically in their anchoring to the 
cell surface (Ravetch & Perussia, 1989) (Figui’e 1.2). Thus, FcyRIIIa is anchored via a 
single transmembrane region with a short (25 aa) cytoplasmic tail, whereas FcyRIIIb is 
attached to the membrane via a glycophosphatidyl inositol (GPI) anchor. The receptors 
also differ in their cellular distribution, with FcyRIIIa expression found on macrophages, 
natural killer cells (NK) and mast cells while Fcylllb expression is limited to neutrophils. 
As with FcyRI, FcyRIIIa associates with y-chain homodimers though interestingly, 
FcyRIIIa can also associates with the related Ç-chain in NK cells (Lanier, Yu & Phillips, 
1989). The lack of a transmembrane region prevents FcyRIIIb from associating with 
either y or Ç chains (Figure 1.2). Of note, mice express only a single form of FcyRIII 
which is analagous to human FcyRIIIa being anchored by a transmembrane region and 
associating with the y-chain (Figure 1.2).
1.1.3.4. Fey receptors have different affinities for IgG subtypes
The specific effector mechanisms elicited by immune complexes depends on the Ig class 
produced. Fey receptors bind to the constant region of IgG. However, four subclasses of 
IgG are produced by both man (IgGl, IgG2, IgG3 and IgG4) and mouse (IgGl, IgG2a, 
IgG2b and IgG3). In addition to differences in factors such as size and half life, these IgG 
subtypes have different affinities for specific Fey receptors (Table 1.1) ] (van de Winlcel 
& Capel, 1993). Thus, FcyRI binds IgG3 and IgGl with liigh affinity, IgG4 more weakly
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and fails to bind IgG2 at all. Similarly, FcyRII binds both IgGl and IgG3 complexes. 
FcyRII is the only Fey receptor to recognise IgG2 and this binding is complicated by 
allelic differences (van de Winkel & Capel, 1993). Interestingly, though the extracellular 
domains of FcyRIIa and FcyRIIb are 96% identical, these receptors show differences in 
affinity for IgG4. Thus, FcyRIIb binds IgG4 complexes in addition to IgGl and IgG3 
complexes, whereas FcyRIIa does not.
Thus, cellular response to IgG immune complexes not only depends on the repertoire of 
Fey receptors expressed, but also on the IgG subtype(s) involved. While different 
antigenic stimuli give rise to the production of different IgG subtypes, the functional 
outcome of these differences remains unclear.
1.1.4. Fca receptors
FcaRI (CDS 9), with the exception of the polyimmunoglobulin transporter, is the only 
known receptor for IgA(Daeron, 1997a). The gene for FcaRI exists as a single copy, 
though multiple splice variants have been reported (de Wit et aL, 1995). Further, FcaRI 
is subject to heterogenous glycosylation with the apparent molecular weight varying 
considerably (45-100 kDa). FcaRI is an integral type I membrane protein with two 
extracellular IgSF domains, a short transmembrane region and a short cytoplasmic tail 
(Daeron, 1997a). Expression of this receptor is limited to myeloid cells, with constitutive 
expression found on monocytes, macrophages, neutrophils and eosinophils. Further, 
FcaRI expression has also been reported in mesangial eells provoking much interest in a 
potential role for this receptor in the human kidney disease, IgA nephropathy (Barratt et 
aL, 2000). The receptor possesses medium to high affinity (Ka~1x 107 M"^) and it can 
thus bind both monomeric and polymeric forms of both IgAl and IgA2 (Monteiro, 
Kubagawa & Cooper, 1990). In common with many other Fc receptors, FcaRI has been 
shown to associate with y-chain homodimers (Morton et aL, 1995) (Figure 1.2). O f 
interest, no equivalent to human FcaRI has been identified in the mouse.
Chapter 1
1.1.5. Fc£ receptors
IgE is recognised by both a high affinity receptor (FcsRI) and a low affinity receptor 
(CD23/Fc8RII). These receptors are unrelated. FceRI belongs to the IgSF family, along 
with the FcyRs and FcaRI. In contrast, CD23 is a lectin like molecule (Conrad, 1990). 
The discussion here is limited to FceRI. The single gene for the FceRI a-chain is found, 
clustered with the gene for the y-chain, on chromosome lq22. Expression of FceRI is 
predominantly limited to mast cells and basophils (Raghavan & Bjorkman, 1996). Due to 
its central role in mediating allergic responses, this receptor is probably the most studied 
of the Fc receptors (Metzger, 1999). FceRI shares significant homology with FcyRs 
(-40%) and in common with FcyRI, FcyRIII and FcaRI, this receptor associates with the 
y-chain (Blank et aL, 1989) (Figure 1.2). In addition, FceRI associates in mast cells with a 
second signalling chain, the P-chain, which also bears an ITAM motif (section 1.2.1.1) 
(Blank et aL, 1989, Cambier, 1995, Turner & Kinet, 1999).
Interestingly, the mouse low affinity IgG receptor, FcyRIIb, has also been reported to 
bind IgE with low affinity (Takizawa, Adamczewski & Kinet, 1992). The role of 
FcyRIIb in the modulation of FceRI signalling has been the focus of considerable work and 
will be discussed separately in section 1.2.8.5.
1.1.6. The y-chain associates with multiple signalling receptors
Aggregation of Fc receptors results in the activation of tyrosine kinases as evidenced by 
tyrosine phosphorylation of proteins and tyrosine kinase dependent calcium transients. 
The majority of Fc receptors do not have a cytoplasmic ITAM motif, known to be 
involved in recruitment of Src kinases. To couple to tyrosine kinases, these receptors 
must therefore recruit an accessory signalling molecule, and for many of these receptors, 
the y-chain fulfills this role (Figure 1.2). The ITAM containing y-chain, a 7 kDa protein, 
was originally found in association with FceRI (Blank et aL, 1989). The y-chain is now 
known to associate with other Fc receptors including FcyRI (Ernst et aL, 1993, Scholl & 
Geha, 1993), FcyRIII (Lanier et aL, 1989) and FcaRI (Morton et aL, 1995) as well as the 
TCR and most recently the collagen receptor glycoprotein VI (Nieswandt et aL, 2000). 
The y-chain, belongs to the same family of signal transducing molecules as the Ç-chain and
10
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p-chain of the T-cell receptor. These proteins form disulphide linked homo- or 
heterodimers. The interactions governing receptor:y-chain interactions differ for each 
receptor and are discussed further in Chapter 6. Interestingly, some receptors, including 
FceRI and FcyRIII require y-chain association for surface expression (Lanier et aL, 1989).
1.1.7. Fc receptor crystal structures
The last year has seen the solution of a number of Fc receptor crystal structures, both 
alone and in complex with immunoglobulin Fc fragments. These structures have provided 
valuable insights into the molecular basis of ligand specificity, binding affinity and 
receptor function. Three independent groups have separately solved the structures of the 
extracellulai* domains of FceRI (Garman, Kinet & Jardetzky, 1999), FcyRIIa (Maxwell et 
aL, 1999) and FcyRIIb (Sondermann, Huber & Jacob, 1999). The overall fold of these 
receptors is very similar with the two immunoglobulin domains folded at an acute angle to 
each other, biinging them into contact over a broad ai'ea. Interestingly, FcyRIIa 
crystallized as a dimer and an analysis of the dimérisation interface has suggested this 
may be a functional interaction. In this model, FcyRIIa dimers bind to a single IgG 
molecule. FcyRIIa, unlike all other IgSF Fc receptors, bears an ITAM signalling motif 
within its cytoplasmic tail. While no crystallographic evidence was reported for FcyRIIb 
dimérisation, a stoichiometry of 2:1 for the receptor:IgG complex has been proposed on 
the basis of computer modeling and gel filtration data. Solution of FceRI in complex with 
the Fc fragment of IgE (Garman et aL, 2000) and FcyRIII in complex with the Fe fragment 
of IgGl (Sondermann et aL, 2000) has indicated a 1:1 ratio of receptor to ligand. 
Comparison of the two complexes reveals a high degi’ee of structural similarity between 
the receptor-Fc interactions. It has been proposed that dimérisation of FcyRII, but not 
FceRI and FcyRIII, might be a functional requirement, as FcyRIIa and FcyRIIb, unlilce aU 
other IgSF Fc receptors, bear signalling motifs in their cytoplasmic domains. As FceRI 
and FcyRIII (along with FcyRI and FcaRI) associate with preformed y-chain dimers, such 
receptor pairing may not be required for these receptors. The possible heterodimerisation 
of FcyRIIa with FcyRIIb has also been proposed.
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A structure for FcyRI, which contains a third extracellular IgSF domain, has yet to be 
solved. The high degree of homology between FcyRII and the first two Ig-like domains of 
FcyRI however suggests that structural similarity is likely. This is supported 
experimentally as mutant FcyRI, lacking the third extracellular domain, binds IgG with 
low affinity (Hulett & Hogarth, 1994).
1.1.8. Fc receptor effector functions.
The biological responses triggered by Fc receptor stimulation appears to depend more on 
the cell type than the receptor. Thus, different receptors will often stimulate the same 
responses when expressed in the same cell. Conversely, when expressed in different 
types of cells, Fc receptors tend to trigger a cell type specific response (Daeron, 1997a). 
The biological responses to immune complexes can be broadly divided into the two 
categories of internalisation and activation. Internalisation can occur by the process of 
endocytosis or phagocytosis. Responses resulting from Fc receptor mediated activation 
include antibody-directed cellular cytotoxicity (ADCC), degranulation, the respiratory 
burst and induction of cytokine gene transcription.
1.1.8.1. Phagocytosis
Phagocytosis is the uptake of large particles (0.5 pm or greater) which is mediated by 
reorganisation of the actin-based cytoskeleton and by definition is inhibited by 
cytochalasins (Silverstein et aL, 1989). In higher organisms, phagocytosis is limited to 
specific phagocytic cells which include monocytes, macrophages and neutrophils. 
Phagocytosis is initiated by interaction between specialised cell suiTace receptors and 
ligand coated particles. Thus, Fc receptor mediated phagocytosis involves the uptake, 
and subsequent disposal, of immunoglobulin opsonised particles. Following initiation by 
receptor ligand interactions, local actin rearrangements result in pseudopod extension and 
particle engulfrnent. The resulting internalised phagosomes are able to fuse with 
endosomes and/or lysozomes where the contents are exposed to low pH and hydrolytic 
enzymes. Antigenic peptide products resulting from degradation may then be presented 
to T-cells via MHC class II molecules.
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FcyRI, FcaRI, FceRI and FcyRIII are all capable of mediating phagocytosis in a 
mechanism dependent on association with the ITAM bearing y-chain. Conversely, 
FcyRIIa and FcyRIIc are capable of mediating phagocytosis independent of the y-chain by 
virtue of the cytoplasmic ITAMs (Figui’e 1.2) (Ravetch, 1994, Daeron, 1997a).
1.1.8.2. Endocytosis
Endocytosis is the process of internalising small particles or soluble complexes through 
receptor ligand interactions. Generally this process occurs tlirough formation of clathrin 
coated pits at the plasma membrane containing ligand-receptor complexes. These pits 
bud off into the cytoplasm where the internalised vesicles fuse with early endosomes. 
Unlike phagocytosis, endocytosis does not require actin polymerisation and so is 
unaffected by cytochalasins. Most Fc receptors are capable of mediating the endocytosis 
of immune complexes. Following endocytosis, immune complexes are targeted to 
appropriate subcellular compartments for antigen presentation and/or immune complex 
degradation. Interestingly, the requirements for Fc receptor mediated endocytosis differ 
depending on the specific Fc receptor involved. Thus, FcyRI and FcyRIIa internalise 
immune complexes independent of accessory molecules whereas murine FcyRIIIa requires 
association with the y-chain (Harrison et aL, 1994, Anderson et aL, 1990, Amigorena et 
aL, 1992b). Further, FcyRIIbl, inliibits immune complex endocytosis while its splice 
variant, FcyRIIb2 (which lacks a short cytoplasmic signal sequence) mediates efficient 
endocytosis (Daeron, 1997a). The factors which govern receptor mediated endocytosis 
and endocytic vesicle trafficking to specific subcellulai’ compartments lie beyond the 
scope of this introduction.
1.1.8.3. ADCC
Antibody-directed cellular cytotoxicity (ADCC), a process whereby antibody coated 
cells are destroyed, is mediated by Fc receptors. This process is most commonly 
mediated by natural killer cells (NK cells) via FcyRIIIa. Monocytes and macrophages aie 
also capable of mediating ADCC through FcyRI (Fanger et aL, 1989). This response is
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important in cancer surveillance and the clearance of virus infected cells (Valerius et aL, 
1993, Ely et aL, 1996, van de Winkel & Capel, 1993),
1.1.8.4. Degranulation and the respiratory burst
Fc receptors on phagocytic cells, including monocytes, macrophages and neutrophils, can 
activate a number of mechanisms for destroying internalised pathogens. These include the 
release of proteases and other anti-bacterial proteins from preformed granules into the 
phagosome through a process known as degranulation. Further, Fc receptors can activate 
the NADPH oxidase system to produee highly toxic reactive oxygen species (ROIs), 
important in the killing of pathogens. Similarly, Fc receptors can induce the production 
of iNOS (inducible nitric oxide synthase) to produce potent anti-microbial reactive 
nitrogen intermediates (reviewed in Daeron, 1997a).
The process of degranulation is also important in the release of inflammatory mediators. 
This is most studied for the activation of mast cells by FceRI. Here receptor aggregation 
induces the release of pre-formed mediators, such as histamine, from the cell (Metzger, 
1999).
1.1.8.5. Induction of cytokine gene transcription
Fc receptors play an important role in coordinating the immune response by inducing the 
transcription and secretion of cytokines (Daeron, 1997a). For example, stimulation of 
Fey receptors on monocytes and macrophages leads to the synthesis of proinflammatory 
cytokines such as IL-1, IL-6, and TNF-a. Fey receptors have also been linked to the 
synthesis of the anti-inflammatory cytokine, IE-10 (Sutterwala et aL, 1998) and the 
neutrophil chemoattractant IL-8 (Marsh et aL, 1995).
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1.2. Fc Receptor Signalling
The multiple signal transduction pathways activated by different Fc receptors and the B- 
cell and T-cell antigen receptors show remarkable similarity. Thus, understanding of Fc 
and antigen receptor signalling has moved forward in parallel. For this reason, this section 
deals largely with signalling pathways common to both antigen and Fc receptors. Due to 
the complex interplay between distinct signalling pathways it is important not to consider 
them in isolation. Rather, signalling should be considered as a dynamic circuit with 
multiple independent events heing integrated to give a concerted response. Here, the 
major signalling pathways activated by both Fc and antigen receptors are discussed.
1.2.1. Initiation of Fc Receptor Signalling
1.2.1.1. The ITAM motif
The initiation of signal transduction by the structurally and functionally diverse immune 
receptors as the TCR, BCR and Fc receptors is mediated through strikingly similar 
mechanisms. One common feature of all these receptors is that, unlike the growth factor 
receptors, they lack intrinsic enzymic activity within their cytoplasmic domains. The 
breakthrough in this field came in 1989 with the recognition, by Micheal Reth, of a 
common sequence motif within the cytoplasmic tails of many components of antigen and 
Fc receptor complexes (Reth, 1989). This motif, which was known by diverse names 
such as ARAM, TAM, and the Reth motif, has generally come to be loiown as the 
immunoreceptor tyrosine based activation motif (ITAM), has revolutionised the field of 
immune receptor signalling (Cambier er n/., 1995, Cambier, 1995). The ITAM is defined 
by 6 conserved amino acids generally spaced over 18 amino acids with the consensus, 
(D/E)XXYXX(L/I)X7YXX(I/L), where X is any amino acid. This motif is found in other 
membrane proteins, including the CD3 and Ç-chains of the TCR, the a  and P chains of the 
BCR, and the y-chain found associated with multiple Fc receptors. An atypical ITAM  
motif is also found in the tail of FcyRIIa where the spacing between the key YXX(I/L) 
repeats is increased from 7 to 12 amino acids (Van den Herik-Oudijk et aL, 1995b,
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Cambier, 1995). Table 1.2 shows an alignment of a number of key ITAM containing 
sequences.
1.2.1.2. IT AMs mediate signal transduction
Following the recognition of the ITAM motif a number of independent groups 
demonstrated, using chimeric receptor constructs, that the ITAM motif was necessary 
and sufficient to initiate signal transduction (review in Cambier, 1995). It was also 
demonstrated that phosphorylation of the two tyrosines within the ITAM motif was 
critical for function. This, along with the observation that immune receptors recruit and 
activate Src (Section 1.2.2.1) and Syk (Section 1.2.2.2) family tyrosine kinases has led to 
a conserved model for immune receptor mediated signal transduction (Cambier & 
Johnson, 1995, Johnson et a l, 1995, Agarwal, Salem & Robbins, 1993).
Table 1.2 Immune receptor ITAM sequences
Receptor/Subunit ITAM sequence Residues between 
YxxL/I motifs
y-chain * DGVYTGLSTRNGETYETL 7
FcyRIIa DGGYMTLNPRAPTDDDKNIYLTI 11
FceRI p-chain DRVYEELNIYSATYSEL 6
BCR a-chain ENLYEGLNLDDCSMYEDI 7
BCR p-chain DHTYEGLDIDQTATYEDI 7
Consensus D /E X X Y X X L  X (7-11)Y X X L/I 7-11
* y-chain associates with FcyRI, FcyRIII, FcaRI and FceRI
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1.2.1.3. Immune receptors are activated by receptor elustering
Immune receptors, including the BCR, and Fc receptors propagate signals in response to 
receptor ligation or clustering. In the case of Fey receptors such receptor clustering occurs 
when cells, such as macrophages, encounter IgG immune complexes. In the case of the 
BCR, such ligation occurs when the B-cell encounters specific multivalent antigen. In the 
current model, partially active Src family kinases associated with resting IT AMs are 
activated on receptor clustering, leading to phosphorylation of the two key ITAM  
tyrosines. The phosphorylated ITAMs, then recruit and activate further Src kinases and 
Syk family kinases through SH2 domain interactions. This results in a cascade of 
tyrosine phosphorylation events which initiate multiple signalling pathways and 
subsequent effector functions (Figure 1.3) (Cambier, 1995, Agarwal et aL, 1993).
1.2.1.4. Lipid rafts provide a microenvironment for immune receptor activation
Recent advances in membrane biology have led to the identification of sphingolipid and 
cholesterol rich microdomains on the surface of immune cells. These microdomains, 
termed rafts, are emiched for specific signalling molecules, including the acylated Src 
family kinases, GPI anchored membrane proteins and G a subunits of heterotrimeric G- 
proteins (Langlet et aL, 2000). Following ligation, many immune receptors, including to 
date the BCR, TCR, FceRI and FcaRI relocate to these microdomains. Further, confocal 
microscopy has demonstrated that tyrosine phosphorylation events, and recruitment of 
many signalling components, occur specifically in these microdomains. These lipid rafts 
therefore appear to provide a microenvironment for receptor mediated activation of 
tyrosine kinases and subsequent signalling events ( reviewed in Langlet et aL, 2000).
1.2.2. Tyrosine kinases
Many of the earliest signal transduction responses of Fc and antigen receptors are 
dependent on the activation of protein tyrosine kinases. The focus o f this section is to 
discuss the role of Src and Syk family tyrosine kinases in the initiation of Fc and antigen 
receptor signalling. The role of the Tec family tyrosine kinases as effectors of PI 3-kinase 
will be discussed separately in section 1.2.3.4.
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1.2.2.1. Src family tyrosine kinases
The src family of tyrosine kinases (Src, Lyn, Fyn, Lck, Blk, Fgi', Hck and Yes) ai’e 
expressed widely though with some degree of cell-type specificity (Bolen, 1995). These 
kinases are all membrane associated by virtue of post translational N-terminal 
myristoylation and also, in most cases, palmitylation. These kinases contain an SH2 
domain and an SH3 domain to allow association with tyrosine phosphorylated proteins, 
and proline rich regions, respectively. The localisation o f these kinases at the plasma 
membrane, along with considerable evidence that these kinases are pre-associated with 
ITAM bearing receptors has placed them as likely candidates for mediating ITAM  
phosphorylation. Thus, Lck pre-associates with the TCR (Kane, Lin & Weiss, 2000), 
while Lyn preassociates with the Fe receptor y-chain (Duchemin & Anderson, 1997) and 
the BCR (Clark et aL, 1992). Recent studies using transgenic mice lacking specific Src 
kinases has indicated the importance of these kinases in immune receptor function 
(Fitzer-Attas et aL, 2000). Of particular relevance, a dominant role for Lyn in Fey 
receptor mediated y-chain ITAM phosphorylation and Syk activation has been reported. 
These studies have also revealed significant redundancy of function between family 
members of Src kinases (Fitzer-Attas et aL, 2000).
1.2.2.2. Syk family kinases
The Syk family of tyrosine kinases comprises Syk and ZAP-70 (Turner et aL, 2000). 
Syk is widely expressed cells of haematopoietic origin while ZAP-70 is restricted 
primarily to T-cells and NK cells. Syk family kinases are cytosolic proteins which 
contain a C-terminal kinase domain and two tandem SH2 domains that bind 
phosphorylated ITAMs (Cambier, 1995, Agarwal et aL, 1993). In addition, Syk contains 
multiple inter-domain tyrosines which act as docking sites for multiple signalling proteins, 
such as PLCy and Vav, which are likely to be substrates for phosphorylation. The 
essential roles of Syk in mediating Fc receptor functions has been demonstrated using 
targeted disruption of the Syk gene in mice (Crowley et aL, 1997). These mice show an 
embryonic lethal phenotype. Almost all signalling and effector pathways activated by 
Fey receptors, including phagocytosis, ADCC, PLCy activation and calcium mobilisation.
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have been shown to be diminished or absent in ceils derived from these mice. Defects in 
BCR, TCR and FceRI function have also been observed. Surprisingly, Fey receptor 
ligation in Syk deficient mouse macrophages does not induce y-chain ITAM  
phosphorylation. Conversely, FceRI induced y-chain phosphorylation in mast cells was 
unaffected in Syk deficient cells (reviewed in Turner et aL, 2000).
1.2.3. PI 3-kinase dependent signalling
Phosphoinositide-3 kinases (PI 3-kinases) play an important role in the generation of 
lipid second messengers critical for the transduction of multiple signalling pathways 
(Toker & Cantley, 1997, Leevers, Vanhaesebroeck & Waterfield, 1999). PI 3-kinases 
phosphorylate phosphatidylinositol (PI) lipids at the D3 position on the inositol ring to 
generate PI(3)P, PI (3,4)?2 and PI (3,4,5)Pg (depending on the substrate phosphorylated). 
In resting cells, 3’ phosphoinositides are generally absent, and accumulate rapidly 
following diverse agonist stimulation (including Fc and antigen receptor engagement). 
Further, inhibition of PI 3-kinase activity results in inhibition of multiple cellular 
responses indicating a critical role for these enzymes in signal transduction (Figure 1.4).
1.2.3.1. Classes of PI 3-kinase
There are thi'ee classes of PI 3-kinase, being defined by their substrate specificities (Toker 
& Cantley, 1997). Class I PI 3-kinases phosphorylate phosphatidyl inositol (PI), PI(4)P, 
PI(4,5)P% to generate PI(3)P, PI(3,4)P% and PI(3,4,5)P] respectively. Class I PI 3-kinases 
can be further subdivided into Class lA and Class IB. Class lA PI 3-kinases comprise a 
pi 10 catalytic subunit (pi 10a, pllOP or pi 106) and a regulatory SH2/SH3 containing 
p85 family (p85a, p85p, p55a or p55 PIK) adapter subunit. The p85 adapter proteins 
facilitate binding to other proteins via SH2 and SH3 domain interactions. These isoforms 
of PI 3-kinase are generally activated by tyrosine kinase coupled receptors, including 
antigen receptors, Fc receptors and receptor tyrosine kinases (e.g. Insulin receptor). 
Class IB isoforms of PI 3-kinase comprise a p i lOy catalytic subunit. Activity of p i lOy 
is facilitated by interaction with the Py subunits of heterotrimeric G-proteins, and are
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thus activated by G-protein coupled receptors. Class II PI 3-kinases phosphorylate PI 
and PI(4)P but not PI(4 ,5)P2 and Class III PI 3-kinases phosphoiylate only PI.
1.2.3.2. Targets of PI 3-kinase signalling
It is now widely recognised that the products of PI 3-kinase, and in particular PIP2 and 
PIP3, are important regulated membrane localisation signals (Czech, 2000, Leevers et aL,
1999). Of particular relevance to membrane targeting is the pleckstrin homology (PH) 
domain which mediates both protein:protein and proteindipid interactions. Indeed, 
several PH domain containing proteins have been shown to selectively bind PIP2 and/or 
PIP3, including small G-protein exchange factors Sos and Vav (section 1.2.5.2), the 
Akt/PKB Ser/Thr kinase (section 1.2.3.3), PLCy isoforms (Falasca et aL, 1998) and the 
Tec family of tyrosine kinases (section 1.2.3.4). However, other domains, including SH2 
and protein tyrosine binding (PTB) domains have also been shown to bind to PIP2 and/or 
PIP3 indicating a further level of complexity (Figure 1.4) (Toker & Cantley, 1997).
1.2.3.3, Akt/PKB
The serine/threonine protein kinase Akt, also known as protein kinase B (PKB) has 
emerged as a major target of PI 3-kinase signalling (Franlce et aL, 1995, Bui'gering & 
Coffer, 1995). Akt has a PH domain that binds both PIP2 and PIP3. Some evidence 
suggests that binding of phosphoinositides to the PH domain not only recruits PKB to 
the plasma membrane, but also plays a role in its activation by inducing conformational 
changes (Franke et aL, 1997). For activation, Akt requires phosphorylation on both 
Thr308 and Ser473. The kinase responsible for phosphorylating Thr308, termed PDKl 
(phosphoinositide dependent kinase 1), also contains a PH domain. PIP3 has also been 
shown to be required to recruit PDKl to the plasma membrane for activation (Alessi et 
aL, 1997). The kinase responsible for Akt phosphorylation on Ser473 (termed PDK2) 
remains to be identified.
21
DAG + InsP.
±  PI(4)P
PI(3)P
PI(4)P 
5-kinase 
5 = = ±  P I(4 ,5 )P 2
>I A
hÿ
HH w
w & (L
K E E
p S3 p
p P p%
o ft> fft
r yr Ir
P I (3 ,4 )P 2
t
Akt/PKB?
SHIP
I
PI(3,4,5)P3
PLD
Tec kinase-PLC 
Akt/PKB 
PDK l/2  
Exchange Factors
Figure 1.4. An overview o f phosphoinositide signalling. Selected enzymes 
synthesising various phosphoinositides are indicated. Effector pathways are also 
indicated where pertinent to this thesis.
Chapter 1
Akt has been implicated in the prevention of apoptosis by phosphorylating a range of 
proteins including Bad and caspase-9. A role for Akt in promoting cell cycle progression 
has also been proposed. Interestingly, Akt also phosphorylates glycogen synthase 
kinase-3 (GSK-3) which has been proposed to regulate the subcellular localisation of the 
ealcium dependent transcription factor, NF-ATc- (Gold et aL, 1999, Cross et aL, 1995). 
GSK-3 is constitutively active in cells and phosphorylates NF-ATc, resulting in its rapid 
export from the nucleus. By inhibiting GSK-3, Akt may allow NF-ATc to accumulate in 
the nucleus in response to calcium influx and thus promote transcription. In addition, 
recent studies have shown that PKB can positively regulate the transcription factor 
NFkB (Scheid & Woodgett, 2000, Ozes et aL, 1999, Romashkova & Makarov, 1999). 
Here, PKB appears to promote activation of IKK, the upstream kinase which 
phosphorylates the inhibitory component of the NFkB complex, IkB (Scheid & 
Woodgett, 2000). Once phosphorylated, IkB is degraded, freeing NFkB which can then 
translocate to the nucleus. These transcription factors, NF-ATc and NFkB are of 
particular interest as they are thought to play important roles in the regulation of 
cytokine gene transcription. Recent reports have indicated that PKB is activated by Fey 
receptors and G-protein coupled receptors in macrophages and by the BCR in B-cells 
(Tilton et aL, 1997). Further, Akt is a target of FcyRIIb/SHIP mediated inhibition (Jacob 
et aL, 1999) (discussed in section 1.2.8.12).
I.2.3.4. Tec family tyrosine kinases
The Tec family of protein tyrosine kinases, which includes Btk, Tec, Bmx and Itk, have 
emerged as an important group of non-receptor pro^in tyrosine kinases (Schaeffer & 
Schwartzherg, 2000, Bolen, 1995). All four kinase have closely homologous structures 
which include an N-terminal PH domain followed SH2, SH3 and kinase domains. In the 
case of Btk, the prototype Tec kinase, interaetion of its PH domain with PIP3 is 
sufficient to induce its recruitment and activation through autophosphorylation and 
phosphorylation by Src and/or Syk kinase family members. The importance o f the Btk 
PH domain is clear, as inactivating mutations in the Btk PH domain have been found to 
confer the phenotype of Bruton’s disease or X-linked agammaglobulinaemia (XLA), a
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severe immune deficiency disease of humans. There is a naturally oecuring mutant in the 
mouse, X-linlced immunodefficiency (Xid), that generates a phenotype similar to 
Bruton’s diease in man. The mutation in the Xid mouse is in the PH domain of Btk. The 
dependence of these kinases on PIP3 places them as important downstream effectors of 
PI 3-kinase activation. The downstream targets of Tec family kinases include apoptotic 
pathways, INK (c-jun N-terminal kinase) and PLCy.
I.2.3.5. Tec family kinases are required for PLCy activation
Of particular importance. Tec family kinase activation appears to be essential for PLCy 
activation (discussed in section 1.2.4.3) by antigen receptors (Fluckiger et aL, 1998). 
Studies in B-cells have demonstrated that participation in PLCy activation is a property 
of all Tec family members and that their role is independent from that of Src and Syk 
family kinases. Further, this PI 3-kinase/Tec/PLCy pathway has been shown to be a 
central target for FcyRIIb/SHIP mediated inliibition (Schai'enberg et aL, 1998, Bolland et 
aL, 1998) (section 1.2.8.9).
1.2.4. Signalling pathways leading to the mobilisation of calcium
Changes in cytosolic calcium is a major component of signalling by many immune 
receptors. Calcium levels can be elevated following release from intracellular stores and 
by calciiun entry. The central event leading to calcium store release in response to 
receptor stimulation is the activation of PLCy to generate inositol 1,4,5-trisphosphate 
(InsP3) (Berridge, 1993, Tsien & Tsien, 1990, Putney, 1986). InsP3 induces the rapid 
release of calcium from internal stores through the binding of InsPs to the InsP3 receptor 
(Figure 1.5). This, in turn induces store-operated calcium influx tlirough the cytoplasmic 
membrane calcium channels termed I c r a c  (calcium release activated current) (Floth & 
Penner, 1992).
1.2.4.1. Calcium is a key regulator of cell activatiou
Elevated intracellular calcium is a constant feature of cell activation triggered by ITAM 
beai’ing receptors in a number of cell types. Receptor induced calcium oscillations
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regulates a number of key signalling events, including PKC activation (see section 1,2.4.4) 
and gene transcription (Figure 1.5). Increases in calcium also regulate calmodulin 
dependent events including the activation of Ca"^/calmodulin dependent kinase (De 
Koninck & Schulman, 1998) and the calmodulin dependent serine tlireonine phosphatase, 
calcineurin. Elegant studies have demonstrated that ealcium osedations regulatç the 
nuclear localisation and activity of the transcription factors NEAT (regulated by 
calcineurin) and NFkB, which play a central role in antigen and Fc receptor mediated gene 
transcription (Figui'e 1.5) (Dolmetsch, Xu & Lewis, 1998, Hu et aL, 1999, Li et aL, 1998)
1.2.4.2. PLC
The phosphoinositide phospholipase C (PLC) family are enzymes which specifically 
hydrolyse phosphatidylinositol-4,5-bisphosphate PI(4,5)Pi to generate the second 
messengers inositol trisphosphate (InsP]) and diacylglycerol (DAG) (Lee & Rhee, 1995). 
There are three homologous groups of PLC (|3, y and Ô), all of which contain PH domains. 
PLCy also contains tandem SH2 domains and an SH3 domain. In tyrosine kinase 
dependent signalling, including most immune receptors, it is the PLCy isoforms (PLCyl or 
PLCy2) which are activated.
1.2.4.3. The mechanism of PLCy activation - the role of adapter protein complexes
The molecular mechanisms underlying PLCy activation in response to ligation of the TCR 
and the BCR have been largely defined. In the case of the TCR, the adapter proteins, 
LAT (Linker for the Activation of T-cells) and SLP-76 (SH2 domain containing leukocyte 
protein of 76 kDa), have been shown to play a key role in this process (Finco et aL, 1998, 
Yablonski e/'a/., 1998, Myung, Boerthe & Koretzky, 2000). These proteins are heavily 
tyrosine phosphorylated in response to TCR ligation. Here, activation of the Src family 
kinase, Lek, and the Syk analogue, ZAP-70, induces phosphorylation of the membrane 
associated adapter LAT. LAT in turn recruits PLCyl to the plasma membrane. 
However, for activity, PLCy must be phosphorylated by both Syk and Tec family 
kinases ( ZAP-70 and Itk for the TCR). The Tec family kinase appears to require the 
second adapter protein, SLP-76, to facilitate PLCyl activation. SLP-76 is recruited to
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LAT via the Grb2 homologue, Gads (Liu et aL, 1999). Thus, SLP-76, is recruited to 
LAT-PLCyl complexes, where it plays an intermediary between Itk and PLCyl to allow 
activation. Interestingly, no equivalent to LAT has been identified in B-cells. However, 
the B-cell specific adapter protein, BLNK (also known as SLP-65), appears to play the 
role of intermediary between PLCy2 and the Tec family kinase, Btk, in an analagous role 
to SLP-76 in T-cells (Ishiai et aL, 1999, Wienands et aL, 1998, Wong et aL, 2000, 
Kurosaki & Tsukada, 2000). As discussed in section 1.2.3.4, the recruitment of Tec 
family kinases to the plasma membrane has an additional requirement for PH domain 
binding to PIP3 (Fluckiger et aL, 1998). Likewise, the PH domain of PLCy isoforms, 
which also binds PIP3, is essential for activity (Falasca et aL, 1998). Similar mechanisms 
are likely to govern Fey receptor mediated PLCy activation. Indeed, both Fey receptors in 
monocytes have heen reported to induce the tyrosine phosphorylation of the SLP-76 
adapter protein and its association with other tyrosine kinase substrates (Chu et aL,
1998).
1.2.4.4. Calcium and DAG regulate PKC activation
The protein kinase C (PKC) family of serine/threonine kinase can be divided into three 
subgroups on the basis of their co-factor regulation (Nishizuka, 1988, Nishizuka, 
1992, Pareldi, Ziegler & Parker, 2000, Deklcer & Parker, 1994). Thus, conventional PKC 
isoforms (PKCa, p i, p2 and y) are dependent on calcium and DAG for activation. Novel 
PKC isoforms (ô, £, T|, 0,and fi) require DAG but not calcium, while the atypical PKC 
isoforms (Q require neither calcium or DAG. PLCy activation regulates PKC isoform 
activation by generating DAG and mobilising calcium. It is important to point out that 
phospholipase D (PLD) provides an alternative pathway to DAG (see section 1.2.7) 
though it is unclear whether PLD derived DAG is capable of regulating PKC activity. 
Activation of PKC is well established as being essential for phagocytosis in myeloid cells 
(Zheleznyak & Brown, 1992). PKC activation also plays a role in the regulation of the 
MAP kinase cascades (section 1.2.6.3). The role of different PKC isoforms in FcyRI 
signalling is discussed in section 1.4.5.
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1.2.4.5. PLCy/InsPs independent calcium signalling
An alternative I11SP3 independent pathway to calcium store release has also been 
described by us and others (Melendez et al., 1998b, Choi, Kim & Kinet, 1996). Here, 
tyrosine kinase activation leads to the PI 3-kinase dependent activation of phospholipase 
D and sphingosine kinase (Melendez et al., 1998b). Calcium store release here is thought 
to be mediated by the sphingolipid-gated calcium channel situated in the endoplasmic 
reticulum, termed the SCaMPER (Sphingolipid Ca^^ release Mediating Protein of 
Endoplasmic Reticulum) receptor (Mao et ah, 1996). Due to the particular relevance of 
this pathway to FcyRI signalling, it is covered in more detail in section 1.4.3.
1.2.5. Small GTPase coupled pathways
The mammalian superfamily of small GTPases includes in excess of 80 members of which 
the Ras proteins are the prototypes. Small GTPases cycle between inactive GDP bound 
and active GTP bound states and, thus, function as signal relays linking membrane 
receptors to signal transduction pathways (Rommel & Hafen, 1998, Hemiing & Cantrell, 
1998, Scita et aL, 2000, Genot & Cantrell, 2000). Activated GTPases bind to a wide 
variety of effector molecules to initiate multiple distinct signalling pathways. As many of 
these GTPases bind multiple distinct effector molecules, they act as versatile cellulai* 
switches. Here, discussion will be limited primarily to the Ras and Rho (ineluding Racl, 
cdc42 and Rho) families of small GTPases. Discussion will also be limited to the roles of 
these GTPases in mediating a subset of effector functions relevant to Fc receptor biology. 
Firstly, the role of Ras and Racl (a Rho family member) GTPases in mediating immune 
receptor activation of MAP kinase pathways will be covered. The involvement o f the 
Rho GTPases in mediating phagocytosis will also be discussed due to its particular 
relevance to Fc receptors. The involvement of the ARF family GTPases in the regulation 
of PLD and membrane trafficking will be discussed separately in section 1.2.7.1.
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1.2.5.1. Small GTPase activity is governed by GEFs, GAPs and GDIs
Guanine nucleotide binding by small GTPases is governed by the activity of guanine 
nucleotide exchange factors (GEFs) which promote the transition from a GDP bound 
inactive state, to the GTP bound active state. This effect is balanced by the activity of 
GTPase activating proteins (GAPs) which stimulate GTPase activity thereby promoting 
the hydrolysis of GTP and return these small GTPases to the GDP bound inactive state. 
A third class of proteins, the guanine nucleotide dissociation inhibitors (GDIs) regulate 
GTPase activity by inhibiting the release of GDP. Thus the activity of these GTPases is 
governed by the balanced activity of GEFs, GAPs and GDIs (Henning & Cantrell, 1998, 
Scita et al., 2000).
I.2.5.2. Ras and Racl activation by immune receptors: Adapter protein complexes 
recruit GEFs
Analagous to receptor tyrosine kinases, Fc receptor and antigen receptors induce 
recruitment of cytosolic exchange factors to the plasma membrane, where guanine 
nucleotide exchange can take place. Recruitment of these exchange factors involves the 
formation of adapter protein scaffolds. Thus, Ras activation appears to involve 
recruitment of the Ras exchange factor, Sos to the plasma membrane. Here, the adapter 
protein Grb-2 binds Sos via its SH3 domain. The SH2 domain of Grb-2 then allows 
recruitment of Sos to membrane proximal signalling complexes where activation of Ras 
tales place (Gale et al., 1993, Li et al., 1993, Rozakis-Adcock et al., 1993). In the cases of 
FceRI and the TCR, this recruitment involves Grb-2 binding to the membrane anchored 
adapter, EAT (Finco et al., 1998). In B-cells, which do not express LAT, the formation 
of Shc-Grb-2-Sos complexes appears to be important (Dambrosio, Hippen & Cambier, 
1996).
In a similar mechanism, the exchange factor Vav, links the T-cell receptor and FceRI to the 
Rho family members, Racl, cdc42 and Rho (Teramoto et al., 1997, Arudchandran et al.,
2000). In these systems, recruitment of Vav to the plasma membrane occurs through the 
SLP-76 adapter protein. The SH3 domain of SLP-76 binds to proline rich regions in Vav. 
Following receptor aggregation, SLP76 is recruited to the plasma membrane via indirect
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interactions with LAT. Both Sos and Vav also have PH domains which bind the products 
of PI 3-kinase though the relative contributions of PH domain targeting and adapter 
protein interactions in the recruitment of these exchange factors is not clear.
1.2.5.3. Ras effector pathways in immune receptor signalling
Ras plays a central role in the proliferation, growth, differentiation and death of all 
mammalian cells. Ras also mediates cell specific functions by linking receptors to specific 
effector pathways (Rommel & Hafen, 1998, Genot & Cantrell, 2000). Its actions are 
mediated through binding to effector molecules. The two best known effectors of Ras are 
the protein kinase, Raf-1, and PI 3-kinase. The primary target of Raf-1 is the MEK/ERK 
pathway which is discussed in section 1.2.6.2. Activated Ras directly associates with 
and activates the p i 10 catalytic subunit of p85 dependent PI 3-kinase. This provides a 
second potential mechanism for linking immune receptors to PI 3-kinase dependent 
pathways. PI 3-kinase signalling by immune receptors is discussed in section 1.2.3.
A further critical target for Ras mediated signals are the NEAT (nuclear factor of activated 
T-cells) family o f transcription factors. These transcription factors ai*e important for 
receptor induced transcription of multiple cytokines. NFAT is activated by antigen 
receptors in B and T-cells as well as by FceRI in mast cells and FcyRIII in NK cells. 
NFAT activation requires the co-ordinated interaction of receptor induced Ras activation 
and receptor activated calcium/calcineurin. The mechanism linking Ras to NFAT is not 
clear though an intermediary role for Rac has been proposed (Henning & Cantrell, 1998).
1.2.5.4. Effector pathways of Rho family GTPase
Like Ras, Rac mediates its effects through diverse signalling pathways (Aspenstrom, 
1999). One key set of effectors activated in the Racl and cdc42 dependent pathways are 
the p38 and JNK families of MAP kinases (Zhang et al., 1995, Coso et al., 1995). A role 
for p21 activated kinase (PAR) in the regulation of kinase easeades leading to JNK and 
p38 MAP kinase pathways has been proposed. Both Rac and cdc42 interact with a
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number of other Idnases capable of activating MAP kinase cascades such as MEKK and 
MEKK4 (Aspenstrom, 1999).
Members o f the Rho family of small GTPases co-ordinate cytoskeletal reorganisation 
induced by diverse stimuli. As phagocytosis, hy definition, requires reorganisation of the 
actin based cytoskelleton (section 1.1.8.1), the involvement of Rho family GTPases has 
been investigated. Essential roles for the Rho family members, Racl, cdc42 and Rlio in 
phagocytosis have been established (Cox et al., 1997, Hackam et al., 1997). 
Interestingly, the use of C3 toxin to inhibit Fey receptor mediated Rho activation in 
macrophages was found to block not only phagocytosis, but also tyrosine 
phosphorylation and calcium signalling. This effect on tyrosine phosphorylation and 
calcium signalling is thought to result from a disruption of receptor-cytoskeleton 
interactions required for efficient receptor clustering (Hackam et al., 1997).
Among the other targets for Rho family members are p67pHox, (phagocyte ^ idase) 
PI(4)P 5-kinase and phospholipase D (PLD) (Aspenstrom, 1999). P67phox is a 
component of the NADPH oxidase complex, critical for the respiratory burst (section 
1.1.8.4). P67pHox is a potential substrate for phosphorylation by PAR, an effector for 
Rac and cdc42. PI(4)P 5-kinase is responsible for catalysing the production of PI(4,5)P2, 
which is the substrate of PLCy. PI(4,5)P2 is also essential for receptor mediated 
activation of PLD. Regulation of PLD is discussed separately in section 1.2.7.1. Finally, 
a critical role for Rac In FceRI mediated NFAT nucleai* import has been demonstrated, 
though the mechanism for this action is not known (Turner et al., 1998).
1.2.6. MAP kinases - background
The MAP kinases are a growing family of proline directed serine-threonine protein 
kinases which are activated by a wide variety of extiacellular stimuli (Garrington & 
Johnson, 1999, Su & Karin, 1996). The MAPKs can be divided into a number of 
subgroups, which include the extracellular regulated kinases (ERKs), c-Jun N-terminal 
kinase (JNK) and the p38 group of kinases. The ERK family are the most widely studied 
of the MAP kinases due to their central role in mediating cell proliferation and
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transformation (cancer). The p38 and JNK MAP kinases fall under the subgroup of 
stress activated protein kinases as they are rapidly activated in response to environmental 
stresses such as osmotic shock and ultra-violet irradiation. These kinases play key roles 
in stress response, apoptosis and inflammation (Paul et a l, 1997, Herlaar & Brown,
1999). Among the substrates of the MAP kinases are a wide variety of transcription 
factors. Thus, the kinases provide a link between extracellular stimuli and transcription. 
Numerous other cellular effector functions are also targets of MAP kinase regulation and 
those pertinent to Fc receptor function are discussed below.
I.2.6.I. Regulation of the MAP Idnase pathways
The MAP kinase pathways are regulated by protein kinase cascades that are 
evolutionarily conserved from yeast to man (Garrington & Johnson, 1999). At the core 
of these cascades lies a three kinase module. The MAP kinases are all activated by dual 
phosphorylation of a common threonine-X-tyrosine motif (Table 1.3). This 
phosphorylation is mediated by distinct dual specificity MAP kinase kinases (MKKs). 
These kinases are in turn activated by serine /threonine phosphorylation by MAP kinase 
kinase kinases (MKKK, also known as MEKKs). This MEKK-MKK-MAPK model for 
activation is typified by the Raf-MEK-ERK cascade. The MKKs and MEKKs for the 
p38 and JNK pathways are indicated in figure 1.6.
In mammalian cells, MAP kinases form parallel signalling pathways often activated in 
response to the same stimulus. Thus, in immune receptor signalling, a wide variety of 
receptors, which include the BCR, FceRI and FcyRs, have been reported to activate ERK, 
p38 and JNK (Hashimoto et al., 1998, Ishizuka et al., 1997, Ishizuka et al., 1999, Rose et 
al., 1997). The focus of the following section lies on the activation of MAP kinase 
cascades by tyrosine kinase linlced receptors and, in particular, on their activation by 
antigen and Fc receptors.
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Table 1.3 Dual phosphorylation sites within the MAP kinase sequences
MAP kinase Dual Phosphorylation Site
ERK -TEY--
p38 --TGY-
JNK -TPY--
1.2.6.2. ERK is a downstream effector of Ras
The most documented MAPK activation pathway is the Ras-Raf-MEK-ERK pathway. 
Here, activated Ras recruits the serine/threonine kinase Raf-1 to the plasma membrane. 
Raf-1 then phosphorylates and stimulates the MAP kinase kinase, MEK (MEKl or 
MEK2), which is responsible for the dual phosphorylation of ERK. This pathway is 
utilised by the TCR. Thus, TCR-mediated ERK activation can be inhibited by expression 
of dominant negative Ras and specific inhibitors of MEK (Izquierdo et al., 1993). 
Likewise, the BCR induces Ras dependent ERK activation although an additional 
pathway dependent on PKC also appears to be involved (Gold et al., 1992).
1.2.6.3. Ras independent ERK activation - a role for PKC
A number of stimuli have been shown to activate the ERK pathway independent of Ras 
activation. Thus, phorbol ester stimulation of fibroblasts, which activates PKC, induces 
ERK activation independent of Ras but dependent on Raf-1 (Ueda et al., 1996). Further, 
MEK dependent but Raf-1 independent activation of ERK has also been reported in 
fibroblasts implying that PKCs exert regulatory control on ERK activation at multiple 
levels (Schonwasser et ah, 1998). Raf-1 has also been identified as a target of PLD
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mediated signalling (Rizzo et aL, 1999). Here, phosphatidic acid (PA), a product of PLD, 
appears to be important for the translocation of Raf-1 to the plasma membrane. These 
Ras independent pathways are of particular interest as a recent report has suggested that 
Fey receptors in monocytes activate ERK independent of both Raf-1 and Ras (Sanchez- 
Mejorada & Rosales, 1998). Sanchez-Mejorada et al found that ERK activation by 
immune complex in both THP-1 and U937 cells was unaffected by dominant negative 
isoforms of Ras and Raf-1. They further demonstrate that Ras and Raf-1 independent 
activation of ERK by Fey receptors is coupled to NFkB transcription of cytokine genes. 
The mechanism linking FcyR to ERK activation is yet to be determined.
1.2.6.4, Regulation of JNK and p38
As described in section 1.2.6.1, p38 and JNK are also regulated by a central three 
eomponent kinase cascade. The regulation of these cascades is, however, less well defined 
than for the ERK pathway. In mechanisms analogous to the Ras activation of ERK, the 
JNK and p38 MAP kinases have been shown to be downstream effectors of the Racl and 
cdc42 GTPases (Zhang et al., 1995, Coso et al., 1995, Hashimoto et al., 1999). Here, 
activated GTPases initiate kinase cascades leading to the activation of p38 and JNK. p 2 1 
activated kinase (PAK) is a candidate effector of Rac 1 leading to the activation of p3 8 and 
JNK. PAK is thought to phosphorylate JNK and p38 MEKK family members (Figure 
1.6).
The BCR has been shown to mediate Racl-dependent activation of hoth p38 and JNK. 
p38 appears to require PKC activation indicating that further levels of regulation exist 
(Hashimoto et al., 1998). BCR induced JNK aetivation also appears to have additional 
dependence on calcium release; this activation may occur through a calcineurin dependent 
mechanism. Little is known concerning the mechanisms governing Fey receptor mediated 
activation of p38 and JNK.
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Figure 1.6. An overview of the MAP kinase cascades. These pathways 
are described in more detail in section 1.2.6.
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1.2.6.5. MAP kinases regulate transcription factors
The MAP kinase cascades play a pivotal role in linking signal transduction pathways to 
transcriptional responses by phosphorylating, and thus modulating the activity of, 
transcription factors (Su & Karin, 1996, Garrington & Johnson, 1999). Each family of 
MAP kinases exhibits specificity for different subsets of transcription factors. Figure 1.6 
shows some of the transcription factor targets of the different MAP kinases. The A P 1 
transcription factor is the prototype of transcription factors regulated by the MAP 
kinases. API is composed of stable c-Jun and c-Fos dimers. C-Jun and c-Fos are early 
activation genes. Their expression is characteristically low in resting cells and is induced 
by extracellular signals. Thus, c-Jun transcription can be initiated by phosphorylation of 
the constitutively expressed MEF2C or c-Jun-ATF2 dimers. SimilaiJy, phosphorylation 
of Elkl can initiate c-Fos transcription. Further, phosphorylation of c-Jun by JNK M AP 
kinases greatly enhances its ability to activate transcription. As MEF2C, Elkl, ATF2 
and c-Jun are targets for various MAP kinases, MAP kinase activation can induce API 
transcription (Su & Karin, 1996).
The relevance of MAP kinase induced transcription in Fc receptor signalling has been 
firmly established. In murine macrophages. Fey receptor ligation induces increased AP-1 
binding (Cote-Velez, Ortega & Ortega, 1999). Further, in human monocytes and NK 
cells. Fey receptors are coupled through ERK activation to the transcription of c-Fos and 
TN F-a (Trotta, Kanakaraj & Perussia, 1996). Studies using specific inhibitors of ERK 
have also indicated a role in mediating Fey receptor induced NFkB activation in 
monocytes (Sanchez-Mejorada & Rosales, 1998).
1.2.6 6 . MAP Idnases synergise with other signals to induce transcription.
Interestingly, API transcription factors act in concert with NFAT transcription factors in 
the nucleus to induce transcription (Genot & Cantrell, 2000, Turner et al., 1998). This 
indicates crosstalk between the MAPK pathways and calcium:calcineurin signalling at the 
transcriptional level. Other studies have placed ERK upstream of NFkB in Fey receptor
36
Chapter 1
signalling, though the mechanism for this regulation remains unclear (Sanchez-Mejorada & 
Rosales, 1998). Other factors including calcium mobilisation and PKB activation play 
important roles in NFkB activation indicating that multiple signalling pathways converge 
at the level of transcription.
MAP kinase are also coupled to transcription independent effector functions. For 
example, ERK and p38 have also been implicated in Fey receptor stimulation of cytosolic 
phospholipase A (PLA) and the activation of the NADPH oxidase system (Herlaar & 
Brown, 1999, Hazan-Halevy & Levy, 2000, Hazan-Halevy, Seger & Levy, 2000).
1.2.7. PLD
The phospholipase D (PLD) family catalyse the hydrolysis of membrane phospholipids, 
in a substrate specific manner (Exton, 1994, Exton, 1999). Phosphatidylcholine PLD 
(PC-PLD) hydolyses PC to generate phosphatidic acid (PA) and choline. The 
downstream targets of phosphatidic acid ai-e not well defined. However, PA has been 
implicated as a lipid second messenger, regulating diverse signalling molecules, including 
Raf-1 (Rizzo et al., 1999). Alternatively, phosphatidic acid can be converted by PA 
phosphohydrolase to diacylglycerol (DAG) which may also act as a second messenger to 
activate, for example, novel PKCs (see section 1.2.4.4). PLD appears to play a central 
role in mediating membrane trafficking in a wide variety of cells (Melendez et al., 1998b, 
Roth et al., 1999). Recently, a role for PLD in the regulation of Fey receptor 
phagocytosis has been demonstrated, although the mechanism for this regulation remains 
unresolved (Kusner, Hall & Schlesinger, 1996, Kusner, Hall & Jackson, 1999, Lennartz, 
1999). In monocytes and neutrophils, a role for PLD in mediating the respiratory burst 
has also been reported (Exton, 1997).
1.2.71. Regulation of PLD
PLD is activated by a wide variety of stimuli including tyrosine kinase and heterotrimeric 
G-protein coupled receptors. Two are two loiown PLD isoforms, PLDl and PLD2. 
These two enzymes are regulated diffferently. Both are activated by PI(4,5)P2 (Pertile et
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a i, 1995). PLDl is regulated through various additional mechanisms, though the small 
GTPases, Rho and Arf, and PKC appear to play dominant roles (Exton, 1997, Exton, 
1999, Hammond et al., 1995). The regulation of PC-PLD activation by FcyRI activity is 
discussed further in section 1.4.3.
1.2.8. Inhibitory Signalling
As knowledge of the pathways activated by IT AM bearing immune receptors has 
increased it has also become apparent that the activating signals sent by one receptor can 
be countered by signals sent from another ‘inhibitory’ receptor. Studies on the low 
affinity IgG receptor, FcyRIIb, long known for its inhibitory effects on B cell activation, 
led to the recognition of the ITIM motif (Amigorena et al., 1992a, Muta et al., 1994a). 
The subsequent identification of the same motif within the cytoplasmic tails of many 
immune receptors, including the NK cell killer inhibitory receptors (KIRs), the T-cell ‘off 
switch’ CTLA-4 and the BCR associated CD22 has led to an explosion in the field of 
inhibitory signalling (Daeron, 1996, Unkeless & Jin, 1997). The current consensus 
sequence for the ITIM is, (lAZ')XYXXL, where X is any amino acid. This is reminiscent 
of the IT AM sequence, (D/E)XXYXX(L/I)XyYXX(I/L), although the characteristic 
double YXXL motif found in the IT AM is replaced by a single YXXL motif. Two 
fundamentally distinct inhibitory mechanisms governing ITIM mediated inhibition have 
now emerged (Gupta et al., 1997, Scharenberg & Kinet, 1996). The first, typified by the 
KIRs, involves recruitment of protein tyrosine phosphatases to counter tyrosine kinase 
induced protein phosphorylation and activation (Long et a l, 1997, Burshtyn & Long, 
1997). The second mechanism involves the recruitment of the inositol 5’phosphatase, 
SHIP, to FcyRIIb (Ono et al., 1996). Here, KIR inhibition of NK cell activity and 
FcyRIIb inhibition of B-cell and mast cell activation will be described as prototypical 
inhibitory receptors.
1.2.8.1. Killer inhibitory receptors recruit SHP-1 to inhibit NK cell activity.
A number of NK cell surface receptors, including FcyRIII, are able to mediate targte cell 
Idling tlnough cell lysis. When an NK cell encounters a target cell, it recognises and kills it
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if it does not express MHC (major histocompatability complex) class I molecules. For 
example, NK cells target IgG bound cells for lysis via FcyRIII (See ADCC - section 
1.1.8.3). If, however, the cells also express MHC class I molecules, which are the ligands 
for KIRs, cells are recognised as ‘self and are protected from lysis (Burshtyn & Long, 
1997, Long et al., 1997, Vely et al., 1996). Here, FcyRIII mediates the cell killing by 
activating tyrosine Idnase dependent signalling cascades through the IT AM bearing y- 
chain. Co-activation of KIRs induces the tyrosine phosphorylation of the ITIM tyrosine 
in the KIR cytoplasmic tail. The phosphorylated ITIM acts as a docking site for the 
tyrosine phosphatase, SHP-1, which blocks proximal tyrosine kinase dependent 
activation. A whole host of receptors appear to utilize this or similar mechanisms, 
including CD22 and CD72 in B-cells, CTLA-4 in T-cells, and the family of Leukocyte 
Inhibitory Receptors (LIRs) (Daeron, 1996, Unkeless & Jin, 1997, Vely et al., 1997).
1.2.8.2. SHPl and SHP-2
The SH2 containing phosphatases, SHP-1 and SHP-2, comprise tandem SH2 domains, 
responsible for ITIM binding, and a phosphatase domain (Frearson & Alexander, 1997). 
SHP-2 is ubiquitously expressed, while SHP-1 is lai’gely limited in expression to 
haematopoietic cells. An inhibitory role for SHP-1 is supported by the discovery that 
motheaten (me/me) mice, which show severe immunodefficiency, possess an inactivating 
mutation in the SHP-1 gene. The pathology of these mice results from marked 
overexpansion and overactivation of multiple haematopoietic cells. SHP-1 is now widely 
accepted as a negative regulator of many immune reeeptors, including antigen and Fc 
receptors (Frearson & Alexander, 1997). SHP-2 is documented as having both positive 
and negative effects on signalling. The inhibitory properties of SHP-2 are exemplified by 
its recruitment to the phosphorylated ITIM of CTLA-4 to negatively regulate T-cells 
(Burshtyn & Long, 1997).
1.2.8.3. FcyRIIb recruits SHIP to inhibit BCR and antigen receptor signalling
FcyRIIb is now widely accepted to inhibit the responses of a number of immune 
receptors, including the BCR on B-cells and FceRI and FcyRIII on murine mast cells
39
Chapter 1
(Ono et al., 1996, Ujike et al., 1999). Unlike the KIRs discussed above (section 1.2.8.2), 
FcyRIIb does not appear to recruit protein tyrosine phosphatase, but rather recruits the 
5’inositol phosphatase SHIP (Seharenberg & Kinet, 1996, Ono et al., 1996, Nadler et a l, 
1997). The generation of mice deficient in FcyRIIb has highlighted the central role of this 
receptor in modulating immune responses and also in the prevention of auto immunity 
(section 1.2.8.13) (Nakamura et al., 2000, Clynes, Dumitru & Ravetch, 1998, Yuasa et al., 
1999).
1.2.8.4. FcyRIIb negatively regulates B-cell receptor activation
The BCR comprises suiTace Ig (sig), and IT AM bearing signalling chains (a  and p 
chains). The binding of antigen to the BCR via sIg is a critical step in B-cell activation, 
ultimately resulting in antigen specific B-cell proliferation and antibody production. 
Physiologically, the BCR and FcyRIIb are co-aggregated when the B-cell encounters 
immune complexes of its cognate antigen. Here, the BCR and FcyRIIb simultaneously 
bind these immune complexes, thiough the antigenic determinants and Fc region of IgG 
respectively. This ‘co-ligation’ results in a downregulation of the B-cell response, 
thereby providing a negative feedback loop to regulate antibody secretion (Scharenberg & 
Kinet, 1996),
1.2.8.5. FcyRIIb inhibits FceRI induced degranulation of murine mast cells
A substantial body of work has implicated FcyRIIb as a negative regulator of murine mast 
cell degranulation induced by IgE. Aggregation of FceRI on mast cells by IgE:allergen 
complexes leads to the rapid release of inflammatory mediators, such as histamine 
(degranulation). This response is mediated by the ITAM bearing y-chain and p-chain 
subunits of FceRI. Co-aggregation of FcyRIIb with FceRI attenuates these responses 
(Ono et al., 1996, Fong et al., 1996). SHIP appears to be the inhibitory enzyme involved 
in this process as mast cells derived from SHIP knockout mice are hyper-responsive to 
IgE complexes (Huber et al., 1998). Interestingly, FcyRIIb has been reported to show low 
affinity binding for IgE and this provides a physiological mechanism for the recruitment 
of FcyRIIb to IgE:antigen complexes (Choi et al., 1996). Mast cell degranulation induced
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by aggregation of the low affinity IgG receptor FcyRIII is also attenuated by FcyRIIb 
coaggregation.
1.2.8.6. The mechanism of FcyRIIb mediated inhibition
The molecular mechanisms governing FcyRIIb mediated inhibition have been lai'gely 
defined using the B-cell model. Following co-aggregation of the BCR with FcyRIIb, the 
ITIM motif within the tail of FcyRIIb undergoes tyrosine phosphorylation. This 
phosphorylation creates a docking site for the SH2 domains o f thi'ee phosphatases, SHP- 
1, SHP-2 and the inositol phosphatase, SHIP (SH2 containing Inositol Phosphatase) 
(Ono et al., 1996, Dambrosio et al., 1995, Dambrosio, Fong & Cambier, 1996a). In 
contrast to the KIR ITIM hearing receptors, use of the motheaten (me/me) mice (section 
1.2.8.2) demonstrated that SHP-1 was not involved in mediating the actions of FcyRIIb 
(Ono et al., 1996, Gupta et al., 1997, Nadler et al., 1997). A role for SHIP was proposed 
as phosphorylated FcyRIIb in both B-cells and mast cells has been reported to recruit 
SHIP. In addition, studies with dominant negative mutants of SHIP and SHIP Icnockout 
mice (section 1.2.8.14) has confirmed the eritical role of this phosphatase in mediating the 
FcyRIIb inhibitory signal (Gupta et al., 1997, Liu et al., 1998).
1.2.8.7. SHIP is an inositol polyphsphate 5’phosphatase
SHIP was initially cloned as a 145kDa phosphoprotein found to associate with the 
adapter protein, She, in response to multiple cytokines (Ware et al., 1996, Damen et al., 
1996). This protein consists of an N-terminal SH2 domain, a highly conserved inositol 
polyphosphate 5’ phosphatase motif, two consensus sequence targets for PTB 
(phospho-tyrosine binding) domains and a proline rich region. SHIP selectively 
hydrolyses the 5’ phosphate from phosphatidyl inositol 3,4,5-trisphosphate (PIP3) and 
inositol 1,3,4,5-tetrakisphosphate (InsP^). Multiple forms of SHIP have been reported 
which are thought to be generated by post-translational C-terminal truncation (Damen et 
al., 1998), however, the physiological relevance of these truncated forms is not yet 
known.
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I.2.8.8. SHIP uncouples receptors from PI 3-kinase / PIP3 dependent signalling 
pathways
The major in vivo substrate of SHIP is believed to be PIP3, which is a major product of PI 
3-kinase activation (section 1.2.3). PIP3 has emerged as a key translocation signal for 
multiple intracellular signalling components (section 1.2.3.2). Dephosphorylation of PIP3 
by SHIP generates PI(3,4)P2. Through this process, the PIP3 signal is attenuated and, 
therefore, SHIP is able to uncouple receptors (such as the BCR) from a number of key 
signalling pathways. Interestingly, following co-aggregation of the BCR with FcyRIIb, 
SHIP has been reported to directly associate with the p85 subunit of PI 3-kinase (Gupta 
et aL, 1999). The role of this interaction is not entirely clear, though it could imply that 
SHIP directly inhibits PI 3-kinase activity as well as hydrolysing its products.
I.2.8.9. SHIP inhibits calcium signalling by blocldng Tec kinase dependent PLCy 
activation
Elevation of cytosolic calcium through both mobilisation of intracellular stores and influx 
from the extracellular space, is a critical component of both antigen and Fc receptor 
signalling. As previously described (section 1.2.3.5), mobilisation of calcium is dependent 
on Tec kinase activation of PLCy to generate InsP3. Further, Tec kinase activation of 
PLCy is dependent on the generation of PIP3 by PI 3-kinase. Thus, by recruiting SHIP to 
the plasma membrane, FcyRIIb is able to direct the hydrolysis of PIP3 and inhibit Tec 
kinase translocation and subsequent PLCy activation and calcium influx (Bolland et al., 
1998, Scharenberg etal., 1998).
1.2.8.10. FcyRIIb inhibits BCR induced Ras activation
FcyRIIb co-aggregation also inhibits BCR induced Ras activation. The meehanism 
governing this inhibition is still controversial. There are currently tliree proposed models. 
Firstly, the GTPase exchange factors (GEFs), Sos and Vav, contain PH domains capable 
of interacting with PIP3 (section 1.2.3.2). By hydrolysing PIP3, SHIP may inhibit Ras 
activation by preventing translocation of exchange factors to the plasma membrane. 
Secondly, a well-documented interaction has been demonstrated between SHIP and the
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adapter proteins, She and Grb-2. These adapter proteins have been implicated in BCR 
mediated Ras activation where they serve to recruit Sos to the plasma membrane through 
the formation of Shc:Grb-2:Sos complexes (see section 1.2.5.2). It has therefore been 
proposed that SHIP may thus indirectly inhibit Ras activation by competing with Sos for 
binding to She and/or Grb-2 (Tridandapani et a l, 1998, Tridandapani et a l, 1997). 
Thirdly, a role for the Ras GTPase activating protein, RasGAP, in mediating FcyRIIb 
inhibition has been demonstrated (Tamir et a l, 2000). Here, RasGAP is recruited by the 
adapter protein, p62 DOK, in response to FcyRIIb co-aggregation with the BCR. This 
interaction is dependent on SHIP recruitment to the ITIM of FcyRIIb. By activating 
RasGAP, FcyRIIb could enhance the conversion of active Ras-GTP to inactive Ras-GDP.
1.2.8.11. The role of SHIP:She interactions
Multiple stimuli, including BCR aggregation, Fc receptor aggregation and cytokine 
activation, induce the association of SHIP with the adapter protein. She (Damen et a l, 
1996, Cameron & Allen, 1999). This SHIP-She interaction is thought to involve the 
binding of the PTB domain of She to phosphorylated SHIP (Lamkin et a l, 1997). 
Defining the role of this interaction, however, has proved difficult. The recent generation 
of a SHIP deficient B-cell line has led to the surprising finding that She phosphorylation 
is dependent on the expression of SHIP (Ingham et a l, 1999). This result suggests that 
SHIP is upstream of She phosphorylation and, thus potentially, upstream of the 
Ras/MAP kinase pathway. As SHIP-Shc interactions can be induced in the absence of 
FcyRIIb CO-aggregation, it seems likely that this novel role for SHIP is independent of its 
inhibitory actions.
1.2.8.12. FcyRIIb inhibits BCR induced Akt/PKB activation
In B-cells, FcyRIIb co-aggregation partially inhibits Akt activation (Jacob et a l, 1999, 
Aman et a l, 1998). As Akt activation depends on PIP3, this inhibition is likely to be a 
result o f SHIP mediated PIP3 hydrolysis. Interestingly, PI(3,4)P2, the product o f PIP3 
hydrolysis by SHIP has been proposed to positively regulate Akt activity. Thus, SHIP
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induced PIP3 hydrolysis might act by inhibiting the kinases upstream of Akt activation 
(i.e. PDKl and PDK2 - see section 1.2.3.3) rather than directly on Akt itself.
1.2.8.13. Targeted disruption of FcyRIIb
The importance of FcyRIIb in modulating B-cell proliferation and antibody secretion in 
vivo has been demonstrated by the generation of FcyRIIb deficient mice (Ono et ah, 
1996). Mice which lack FcyRIIb show greatly enhanced antibody responses when 
challenged with antigen (Ravetch & Clynes, 1998). An additional role for FcyRIIb in the 
modulation o f macrophage activation by Fey receptors in murine systems has been 
revealed using the FcyRIIh knockout mice (Clynes et ah, 1999). Interestingly, these 
studies have demonstrated a role for FcyRIIb in the control and prevention of auto­
immune and inflammatory diseases (Nakamura et ah, 2000, Yuasa et ah, 1999, Clynes et 
ah, 1999). Thus, mice which lack FcyRIIb show greater susceptibility to, and severity of, 
disease in a number of auto-immune and inflammatory models. Clearly these studies 
reveal as central role for FcyRIIb in setting the thresholds for antigen and immune complex 
mediated activation.
1.2.8.14. Targeted disruption of SHIP
The role of SHIP as a crucial negative regulator of the immune system has been confirmed 
by generation of SHIP knockout mice. As expected, FcyRIIb mediated inhibition of B-cell 
and mast cell activation is disrupted in these animals, confirming the role of SHIP as the 
primary effector of FcyRIIb in these cells (Liu et ah, 1998, Huber et ah, 1998). 
Interestingly, BCR responses are enhanced in SHIP deficient B-cells even in the absence 
o f FcyRIIb coaggregation. Further, these studies have revealed a role for SHIP in the 
downregulation of cytokine and chemokine signalling (Helgason et ah, 2000, Helgason et 
ah, 1998, Kim et ah, 1999). Important roles for SHIP in both T-cell and B-cell 
development have also been reported.
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1.3. Monocytes and Macrophages
Macrophages participate in the production, activation and regulation of all Immune 
effector cells. These cells belong to the mononuclear phagocyte lineage, being derived 
from blood monocytes which terminally differentiate to give rise to tissue macrophages. 
Probably the most significant role of these cells is to engulf and destroy foreign and 
abeiTant material, including infectious agents, immune complexes, virus infected cells and 
cancer cells. These cells also play a key role in tissue homeostasis. Due to the differing 
roles of macrophages throughout the body, macrophages are highly hetergeneous.
1.3.1 The role of monocytes and macrophages in innate and adaptive 
immunity
Monocytes and macrophages have eentral roles in innate and adaptive immunity (Gordon, 
1999). Receptors on the surface of these cells directly bind to pathogens and result in 
internalisation and disposal. These cells also express receptors for the complement 
system and C-reactive protein (GRP) which mediate internalisation of complement and 
GRP opsonised pathogens. These innate functions of the immune system serve as a first 
line of defence against pathogens. In the adaptive response, production of antigen 
specific antibodies by B-cells results in either the formation of antibody:antigen 
complexes, known as immune complexes, or the opsonisation of pathogens tlirough 
antibody binding to surfaee antigens. The antibodies are then recognised by Fc receptors 
and the resultant aggregation of these receptors by immune complex or opsonised particle 
leads to their internalisation through the process of endocytosis for immune complexes or 
phagocytosis for opsonised particles. The focus of this section will deal primarily with 
the response of monocytes and macrophages to challenge with immune complexes.
1.3.2. Monocytes and macrophages orchestrate the inflammatory 
response
Inflammation islhe physiological process which occurs in response to damage induced by 
multiple agents, including pathogens, foreign bodies, complement opsonised particles, and
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immune complexes, as well as by physical injury (Rosenberg & Gallin, 1999). In the 
inflammatory response, soluble mediators and cellular components act in concert to 
eliminate the cause of damage. While this response is key to host defence, it is also clear 
that inflammation can result in tissue destruction associated with some disease processes. 
In inflammation, soluble inflammatory mediators are released which recruit and activate 
the cellular components of inflammation, including neutrophils, monocytes and 
lymphocytes. Many of these proinflammatory mediators are synthesised and released 
by macrophages and monocytes. These include the cytokines TN F-a, IL-1 (a  and p), 
IL-6 and IL-8 together with other inflammatory mediators such as prostaglandins and 
eicosanoids. Further, in the resolution of inflammation, macrophages are responsible for 
clearing recruited leukocytes, such as neutrophils and for the release of anti-inflammatory 
mediators such as transforming growth factor p (TGF-p) and lL-10. Thus, monocytes 
and macrophages play a key role in the initiation, coordination and resolution of the 
inflammatory response.
Other cells also play key roles in the inflammatory response (Rosenberg & Gallin, 1999). 
Release of IFN-y by NK cells and T-cells is important in the priming and activation of 
monocytes and macrophages. Neutrophils are phagocytic cells, which are rapidly 
recruited in response to inflammatory stimuli. These cells play a key role in the clearance 
of foreign materials and cellular debris. They, therefore, express high levels of phagocytic 
receptors, including Fc receptors and complement receptors. Eosinophils and mast cells 
play a central role in inflammation associated with allergy. Central to this response ai'e 
IgE and its receptors (e.g. FceRI and CD23) expressed on these cells.
1.3.3. Monocytes and macrophages contribute to lymphocyte regulation
Alongside their central roles in immune complex clearance and inflammation, monocytes 
and macrophages, also interact and coordinate lymphocyte responses. Monocytes and 
macrophages aie also a major source of the immune regulatory cytokines IL-10 and IL-12 
which regulate the type of lymphocyte response. In addition, macrophages are able to 
present internalised antigen to T-cells via MHC class II. This receptor is the most 
effective method of stimulating T-cell activation (Gordon, 1999).
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1.3.4. Monocytes and Macrophages are highly heterogeneous
Mononuclear cells such as monocytes and macrophages are highly heterogeneous, 
attributable to differences in their maturation status and also tissue specific variation. 
This heterogeneity makes in vitro study of these primary cells very difficult. Several 
murine models for studying primary mononuclear cells are widely used for the study of 
these cells. Here, the use of inbred mouse strains and tissue specific cell populations 
allows heterogeneity to be minimised. Further, the availability of transgenic technology in 
mouse systems has proved invaluable. A number of murine macrophage cell lines (i.e. 
J774) have also proved useful as they are easy to culture and relatively homogenous. 
Primary human mononuclear cells provide more difficulty due to genetic variation and 
disease status differences between donors. To overcome this difficulty, a number of 
human monocyte-like cell lines have been established, including U937, HL60 and THP-1 
(Harris & Ralph, 1985, Auwerx, 1991). These cells are widely used as models for 
studying human mononuclear cells, their functional properties and the changes they 
undergo during maturation.
1.4. The use of the U937 cell line in the study of Fey receptor biology
The U937 cell line was established from the pleural exudate of a patient with diffuse 
histocytic lymphoma (Sundstrom & Nilsson, 1976). U937 cells share many
characteristics of immature monocytes. These cells constitutively express FcyRI and 
FcyRIIa, but not FcyRIII. Many of the effector functions mediated by these cells require 
stimulation of U937 cells with agents such as IFNy, dibutyryl cyclicAMP (dbcAMP), 
phorbol esthers and vitamin D (Harris & Ralph, 1985). Thus, treatment of U937 cells 
with IFN-y induces the rapid upregulation of the high affinity receptor FcyRI. Further, 
IFNy increases expression of MHC class II, and enliances Fey receptor mediated 
phagocytosis and reactive oxygen metabolism. IFN-y primed U937 cells, therefore, 
provide a model for studying activated monocytes. Alternatively, U937 cells can be 
induced to terminally differentiate to become more macrophage-like cells with agents such 
as dbcAMP and PMA (Sheth et al., 1988). Treatment of cells with dbcAMP induces
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upregulation of the low affinity receptor FcyRIIa with a concomitant downregulation of 
FcyRI.
In our laboratory, we use the U937 cell line to study signalling events activated by 
immune complexes. As U937 cells undergo controlled differentiation when treated with 
agents such as IFN-y and dbcAMP, we are able to investigate the molecular mechanisms 
which link immune complexes to the activation of specific signalling pathways and 
cellular responses.
1.4.1. Signalling pathways activated by FcyRI in U937 cells
The human high affinity receptor for IgG, FcyRI has no known signalling motif within its 
cytoplasmic tail (Allen & Seed, 1989). In myeloid cells, including U937 cells, FcyRI non- 
covalently associates with y-chain homodimers which bear cytoplasmic ITAM motifs for 
the activation of soluble tyrosine kinases (see section 1.2.2).
1.4.2. Differentiation of U937 cells alters the signalling pathway activated 
by FcyRI to mobilize calcium
Previous work in our laboratoiy has demonstrated that differentiation of cells with either 
IFN-y or dbcAMP, changes the nature of the calcium responses activated by FcyRI 
(Davis, Sage & Allen, 1994, Davis etal., 1995a, Melendez et al., 1998a). Thus, in IFN-y 
primed U937 cells, aggi’egation of FcyRI induces a single calcium spike resulting solely 
from the release of calcium from intracellulai* stores. In these cells, FcyRI aggregation 
results in virtually no calcium influx. Conversely, in U937 cells differentiated to more 
macrophage like cells with dbcAMP, FcyRI aggregation results in both store release of 
calcium and calcium influx (Davis et a l, 1995a).
Melendez et al have demonstrated that the switch in the nature of calcium transients 
results from a fundamental switch in the signalling pathway activated by FcyRI under the 
different conditions of differentiation (Melendez et al., 1998a). Thus, in dbcAMP treated 
cells, FcyRI couples to the classical calcium mobilisation pathway described in section
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1.2.4. Here, receptor aggregation results in PLCy activation, production of InsP] and 
release of calcium from internal stores (Melendez, Harnett & Allen, 1999b). This calcium 
store release results in the opening of the plasma membrane calcium channel, Icrac> to 
generate calcium oscillations. Conversely, in IFN-y primed U937 cells, FcyRI couples to 
a novel pathway, involving the sequential activation of PI 3-kinase, PC-PLD and 
sphingosine kinase. The resultant cytosolic calcium response results from store release, 
apparently independent of PLCy activation and InsPg production. Here, no calcium influx 
is observed in response to FcyRI aggregation.
1.4.3. FcyRI activates a novel PLD/Sphingosine Kinase pathway to mobilize 
calcium in IFNy primed U937 cells.
In IFN-y primed U937 cells, FcyRI aggregation results in release of calcium from 
intracellular stores. However, this release of calcium stores is not accompanied by 
activation of PLCy to generate InsP]. Rather, FcyRI couples to the activation of PC-PLD 
and downstream activation of sphingosine kinase (Melendez et al., 1998b). The cloning 
of the SCaMPER receptor provides a pathway whereby sphingoid derivatives could 
effect calcium release from the endoplasmic reticulum (Mao et al., 1996). This novel, 
InsP] independent pathway to calcium release remains the subject o f some controversy.
1.4.4. The differentiation dependent switch in signalling pathway activated 
by FcyRI appears to depend on a switch in the accessory molecule 
recruited by FcyRI.
As discussed above, FcyRI couples to PLCy in dbcAMP differentiated U937 cells to 
mobilise calcium whereas in IFN-y primed cells FcyRI couples to PC-PLD to mobilize 
calcium. Interestingly, the use of mAbs to activate the low affinity receptor, FcyRIIa, 
demonstrated that this receptor is coupled to the activation of the PLCy pathway, but not 
PC-PLD, regardless of the differentiation state of the cell (Melendez et al., 1998a). Thus, 
in both IFN-y primed and dbcAMP differentiated cells, FcyRIIa activates PLCy and 
elevates InsP]. Furthermore, activation of PLCy by FcyRIIa in either cell type was 
associated with both calcium store release and calcium influx. Taken together, this raised
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the hypothesis that FcyRI might recruit FcyRIIa in dbcAMP treated cells to activate 
PLCy. Alternatively, FcyRI might couple to PC-PLD through the y-chain in IFN-y 
primed cells. To test this theory antisense oligonucleotides against FcyRIIa and y-chain 
were employed to specifically reduce levels of these proteins. Consistent with the above 
theory, anti-sense oligonucleotides to FcyRIIa reduced levels of PLCy activated by FcyRI 
in dbcAMP differentiated cells, but had no effect on PLD activation in IFN-y primed 
cells. Conversely, anti-sense oligonucleotides to the y-chain decreased PLD activation in 
IFN-y primed cells but had no effect on FcyRI mediated PLCy activation in dbcAMP 
differentiated cells. The data from these experiments implied that in dbcAMP 
differentiated cells, FcyRI is coupled to the activation of PLCy through recruitment of 
FcyRIIa, whereas in IFN-y primed cells, FcyRI is coupled to the activation of PC-PLD 
through recruitment of the y-chain (Melendez et ah, 1998a) (see Chapter 6).
1.4.5. Differentiation dependent switch in PKC isoform activation by FcyRI 
in U937 cells
As discussed in section 1.2.4.4, activation of specific PKC isoforms is dependent on 
second messengers such as calcium and DAG. As FcyRI induces differing calcium 
transients in IFN-y and dbcAMP differentiated U937 cells, it seemed likely that different 
PKC isofoims would be activated by FcyRI. Consistent with the short calcium signal in 
IFN-y primed cells, FcyRI is coupled to calcium independent PKC isoforms (5, e, Q. In 
dbcAMP differentiated cells, where FcyRI aggi'egation induces prolonged calcium 
oscillations, the receptor is coupled to the activation of calcium dependent PKC isoforms 
(a, P, y). Thus, differentiation of U937 cells results not only in a switch in the nature of 
the activated phospholipase pathway activated, but also in a switch in the activation of 
PKC isoforms (Melendez, Harnett & Allen, 1999a).
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1.5. Objectives of this study
The signalling pathway activated by FcyRI in U937 cells depends strictly on the 
differentiation state of the cell. Thus, in IFN-y primed cells, FcyRI is coupled to the 
activation of PC-PLD and sphingosine kinase resulting in the release o f calcium from 
intracellular stores but no calcium influx. In cells induced to differentiate to a more 
macrophage-like phenotype with dbcAMP, FcyRI is coupled to PLCy, calcium release 
from stores and calcium influx.
The aim of this project was to examine the mechanisms governing this differentiation 
dependent switch in signalling pathways activated by FcyRI in U937 cells. Two parallel 
approaches were taken:
1) To examine the potential of FcyRI to activate inhibitory pathways in either IFN- 
y or dbcAMP differentiated cells. In IFN-y primed U937 cells, FcyRI couples to PLD 
activation with no activation of PLCy. However, the PLCy pathway is intact in these 
cells as aggregation of FcyRIIa in identical cells results in the activation of PLCy. This 
raises the possibility that FcyRI might activate inliibitory signals to block the activation 
of PLCy. As the 5’ inositol phosphatase, SHIP, has been shown to block PLCy 
activation downstream of a number of immune receptors, the possible involvement of this 
pathway was of particular interest.
2) To elucidate the molecular basis for the switch in FcyRI coupling to different 
phospholipase pathways Activation of PLCy or PC-PLD by FcyRI appears to depend 
on the recruitment of different accessory molecules to transduce signals. Thus, in IFNy 
treated cells, FcyRI appears to couple to PC-PLD activation via the y-chain. Conversely, 
in dbcAMP cells FcyRI appears to couple to PLCy via FcyRIIa. This raises the 
possibility that the switch in signalling pathways results from fundamental differences in 
the signalling motifs of the y-chain and FcyRIIa. Here, the coupling of FcyRI to either y- 
chain or FcyRIIa was addressed. Further, the potential involvement of specific molecular 
components implicated in the activation of distinct phospholipase pathways were 
examined under different signalling conditions.
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Chapter 2 
Materials and Methods 
2.1. Materials
2.1.1. Biochemicals
Unless otherwise stated, all chemicals were purchased from Sigma.
2.1.2. Immunochemicals
The commercial antibodies used in this study are listed in tahle 2.1.
2.2. Cell biology techniques
2.2.1. Cell culture
2.2.1.1. U937 cell line
U937 cells (Sundstrom & Nilsson, 1976) were routinely cultured in RPMI 1640 medium 
(Imperial Laboratories) supplemented with foetal calf serum (10% v/v), glutamine (2 
mM), penicillin (10 U/ml) and streptomycin (10 pg/ml) at 37°C, 6.8% carbon dioxide. 
Cells were maintained at a density of between 5 x 10  ^ and 2 x 1 0 ^  cells/ml, as measured 
using a Neubauer haemocytometer, and were routinely sub-passaged twice weekly. To 
sub-passage, cells were harvested by centrifugation for 5 min at 400 g and resuspended in 
fresh complete medium. Typically cells were maintained in 75 cm^ tissue culture flasks in 
a volume of 10 mis.
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2.2.I.2. U937:Ap85 cell line
The U937:Ap85 cell line was provided as a kind gift by L. Stephens (Babraham Institute, 
Cambridge, UK). Cells were maintained as for normal U937 cells with the addition of 0.1 
mg/ml Hygromycin B and 0.6 mg/ml G418 (both from Calbiochem). Ap85 expression was 
induced with 15 mM isopropyl p-D thiogalactoside (IPTG), 5 nM phorbol 12-myristate 
13-acetate (PMA), and 100 pM  zinc chloride for 10 hours. Control cells were treated 
with the same levels of PMA and zinc chloride in the absence of IPTG.
2.2.I.3. Differentiation of U937 cells with IFN-yand dbcAMP
U937 cells were primed in fresh medium with IFN-y (200 ng/ml) where indicated for 24 
hours prior to experiments. Alternatively, cells were induced to differentiate by culturing 
in 1 mM dibutyryl cyclicAMP (dbcAMP) for 48 hours prior to experiments.
2.2.2. Flow cytometry
2.2.2.1. Analysis of surface receptor expression with monoclonal antibodies
Typically 1x10^ cells were washed with ice cold PBS (0.07 M Sodium Chloride, 75 mM 
disodium hydrogen orthophosphate, 5 mM sodium dihydrogen orthophosphate) and 
resuspended in lOOpl PBS with Ipg of relevant monoclonal antibody (mAb). Where 
appropriate, 3 pM monomeric human IgG was added to block non-specific interactions of 
monoclonal antibodies with Fc receptors. Following 45 mins incubation on ice cells, were 
washed twice and incubated for a further 45 mins with a fluorescein isothiocyanate 
(FITC) conjugated goat anti-mouse IgG secondary antibody (1:100 dilution). Irrelevant 
isotype control antibodies were used to control for non-specific labeling. Cells were 
analysed using a Becton Dickinson FAC Scan.
2.2.2.2. IgGrFITC binding and receptor blocking
For IgG binding, 10  ^ cells were incubated with 1 gg of FITC conjugated human IgG 
(IgGiFITC, Sigma) in 100 gl for 30 min on ice. In chapter 6, specific mAbs ai*e used to
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block the ligand binding pockets of specific receptors to assess the effect on IgG binding. 
To block the ligand binding pocket of FcyRI or FcyRIIa, cells were pre-incubated with 
mAb 10.1 (20 gg/ml) or mAb IV3 (20 gg/ml) respectively for 20 min prior to the addition 
of IgG:FITC. Cells with no IgGiFITC were used to control for autofluorescence. Cells 
were analysed using a Becton Dickinson FAC Scan.
2.3. Biochemical assays and methods
2.3.1. Fc receptor aggregation
2.3.1.1. FcyRI aggregation with human IgG
Cells were harvested by centrifugation (5 min, 400 g), washed and resuspended in ice cold 
RPMI / 25 mM HEPES, and incubated with IpM  monomeric IgG (Serotec) for 45 mins 
at 4°C to occupy surface FcyRI. Cells were then washed twice with RPMI to remove 
unbound ligand. Following this cells were resuspended in RPMI, 25 mM HEPES, 1% 
FCS and a 1:50 dilution of goat anti-human IgG (Serotec) was added to crosslink FcyRI 
bound IgG. Cells were then warmed to 37°C for the times specified. To block the ligand 
binding pocket of FcyRIIa (see chapter 6), cells were pre-incubated mAb ÏV3 (20 gg/ml) 
respectively for 20 min prior to the addition of goat anti-human IgG.
2.3.1.2. Fc receptor aggregation with monoclonal antibodies
To aggregate specific receptors, cells were washed and incubated with specific mAbs for 
45 min at 4°C. Cell were washed to remove unbound mAbs and the receptors were cross- 
linked by the addition of goat anti-mouse IgG (1:50 dilution; Sigma). Cells were then 
warmed to 37°C for the times specified.
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2.3.2. Determination of protein concentration
Protein concentrations were routinely determined for all cell lysates and membrane 
preparations. Protein concentrations were estimated using the Bio-Rad protein assay 
system which is based on the Bradford Coomassie brilliant blue dye binding system. A 
range of bovine serum albumin (BSA) standards was used to construct a standard curve 
and protein samples were suitably diluted to fall within the linear range of this cui've. 
Protein concentrations of all samples were routinely measured in duplicate.
2.3.3. Cell lysate preparation
For general lysate preparations, cells in suspension were lysed by the addition of ice-cold 
lysis buffer (1% (v/v) Triton X-100, 50 mM Tris-HCl, pH 7.5, 0.25% (w/v) sodium- 
deoxycholate , 150 mM NaCl, 1 mM EDTA, 1 mM vanadate and 1 mM NaF) containing 
protease inhibitors (1 mM phenylmethylsulfonyl flouride and 1 pg/ml each chy mo statin, 
leupeptin, antipain and pep statin). Alternatively, where the interactions between 
membrane associated proteins needed to be preserved (such as the interaction between 
FcyRI and y-chain) a digitonin based lysis buffer was used (1% (v/v) Digitonin, 0.12% 
(v/v) Triton X-100, 20 mM Tris-HCl, pH 7.5), 150 mM NaCl) also containing the above 
listed protease inhibitors. Following 30 min tumbling at 4°C lysates were clarified at 15 
000 g for 15 mins to remove insoluble cell debris. Lysates were either used immediately 
for immune precipitations or stored at -70 °C prior to electrophoresis.
2.3.4. Immune precipitation
A  large number of immune precipitations were carried out during the course of my PhD 
studies and protocols varied considerably. Outlined below aie typical protocols only. 
For the specific method used for any given immune precipitation, please refer to the 
relevant results chapters.
2.3.4.I. Protein G agarose protocol
Typically 500 pg of cell lysate for each sample was precleared with 20 pg protein G 
agarose (Santa Cruz Biotechnology) for 1 hour at 4°C to reduce non-specific binding. For
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Standard immune precipitations, 2 pg of specific antibody pre-conjugated to 10 fxg 
protein G agarose was added to each sample and incubated by tumbling overnight at 4°C. 
Precipitates were collected by centrifugation (400 g, 5 min) and washed four times with 1 
ml of lysis buffer (see section 2.3.3). Immune precipitates were subjected to Western 
blot analysis (sections 2.3.5 and 2.3.6) or inositol phosphatase assays (section 2.4.2).
2.3.4.2. Direct immobilisation of antibodies to agarose
To overcome high levels of background binding experienced using protein G agarose, 
antibodies for many immune precipitations were directly conjugated to agarose beads 
using the Pierce Amino Link Plus Immobilisation system. The agarose provided with this 
system has been activated to form aldehyde functional groups which react with primary 
amines present on proteins. Reduction of the resulting Schiff bases with sodium 
cyanoborohydride allows stable covalent coupling of antibodies to the agarose beads. In 
this kit, 4% beaded agarose is supplied as a 50% sluriy in columns. For the purposes of 
immobilising antibodies for immune precipitations, the agarose was removed from the 
columns and aliquoted into 1.5 ml eppendorfs. All immobilisations were carried out at pH 
7.2 in PBS according to the manufacturers protocol. As the agai’ose was no longer in 
columns, all wasliing steps were carried out by repeated dilution and centrifugation. 
Following immobilisation, agarose conjugated antibodies were stored at 4°C in PBS with 
0.05% (w/v) sodium azide as a preservative. In many cases secondary precipitating 
antibodies were immobilised to reduce cost and the number of immobilisations required. 
For example, large batches of polyclonal anti-mouse IgG were immobilised to allow the 
precipitation of any primary mouse monoclonal antibody.
Typically 500 jLtg of cell lysate was precipitated with 2 jug of specific antibody at 4°C 
overnight. In cases where immobilized secondary antibodies were used to precipitate 
specific antibodies, the secondary antibodies were added in excess. Immune precipitates 
were washed four times with lysis buffer prior to analysis.
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2.3.5. Sodium dodecyl sulphate- polyacrylamide electrophoresis (SDS- 
PAGE)
Through the course of my PhD studies a number of different gel systems were used in 
analysis of protein by SDS-PAGE. Below are outlined the two systems used for general 
procedures.
2.3.5.1. Laemmli protocol
SDS-PAGE was carried out according to the procedures described by (Laemmli, 1970). 
All acrylamide used here had an acrylamide to bis-acrylamide ratio of 29:1 (w/w). 
Resolving gels contained 375 mM Tris-HCl, pH 8.8, 0.1% (w/v) SDS, 0.06 % (w/v) 
ammonium persulphate and 0.08% (v/v) N,N,N’,N’-tertramethylethylenediamine
(TEMED). Acrylamide concentrations were varied from 6% to 12.5% (w/v) according to 
the required separation range. All resolving gels were overlaid with a 5% (w/v) acrylamide 
stacking gel containing 125 niM Tris-HCl, pH 6.8, 0.1% (w/v) SDS, 0.06 % (w/v) 
ammonium persulphate and 0.1% (v/v) TEMED. Protein samples were denatured by 
boiling for 5 minutes in Ix SDS-PAGE sample buffer (50 mM Tris-HCl, pH 7.5, 1% 
(w/v) SDS, 5% (v/v) (3-mercaptoethanol, 10 mM EDTA, 10% (v/v) glycerol and 0.01% 
(w/v) bromophenol blue). Proteins were electrophoresed in an Hoeffer SE 600 series 
vertical slab gel unit at a constant voltage (50 - 200V) until the bromophenol blue tracldng 
dye reached the bottom of the gel. For Western blotting, proteins were transferred to 
nitrocellulose as described below (section 2.3.6.).
2.3.5.2. Novex precast gel protoeol
The novex NuPAGE precast gel system (Invitrogen-Novex) offers a number of 
advantages, over standard SDS-PAGE systems in terms of speed, resolution and transfer 
efficiency. The NuPAGE system works with bis-tris buffered (pH 6.4) polyacrylamide 
gels, available at 3 different acrylamide concentrations (10% (w/v), 12% and 4-12% 
gradient gels) allowing different separation ranges to be selected. Further, by varying the 
running buffer used, the separation range can be varied further. Samples are denatured in 
NuPAGE LDS (Lithium Dodecyl Sulphate) sample buffer by heating to 70°C for 10 min.
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The decreased denaturing temperature prevents sample degradation and precipitation 
prior to electrophoresis. For reduced proteins, 50 mM dithiothreitol was added prior to 
sample denaturing. For a detailed protocol, including gel separation ranges, please refer to 
the manufacturers instructions.
2.3.6. IVestern blot analysis
For Western blot analysis, proteins were transferred to nitrocellulose (Schleicher and 
Schuel GmbH) using a Hoeffer TS series, Transphor Electrophoresis Unit. Transfer was 
carried out in 190 mM glycine, 25 mM Tris base, containning 20% (v/v) methanol at 300 
niA for 4 hours. Alternatively, where Novex precast gels were used, transfer was caiTied 
out according to the manufacturers instructions using the Novex XCell II blotting 
apparatus. Transfer efficiency was ascertained by stainning with Ponceau S solution for 
5 minutes followed by washing with double distilled H2O. Ponceau S was removed by 
wasliing with TBS (20 mM Tris.HCl, pH 7.6, 136 mM NaCl) containing 0.1% 
(v/v)Tween 20 (TBST). Nitrocellulose blots were blocked in TBST with 4% (w/v) non­
fat powdered milk (Marvel) for a minimum of 1 hour at room temperature. Typically, 
blots were incubated with primary antibodies at a final concentration of 0.1-1 pg/ml 
(Table 2.1) in TBS overnight at 4°C, Blots were then washed tliree times for 5 minutes 
with TBST. Blots were incubated with an appropriate secondary antibody (1:1000 to 
1:5000 dilution - see table 2.1) for 1-4 hours in TBST at room temperature. Blots were 
washed extensively with large volumes of TBST (typically 5x5 min washes) followed by 
a final wash in TBS prior to developing. Blots were developed using the Amersham 
enhanced chemiluminescence (ECL) system. To strip blots for reprobing, blots were 
washed in acid strip buffer (100 mM glycine, 150 mM NaCl, pH 2.6) for 45 minutes.
2.3.6.I. Detection of phosphotyrosine containing proteins by Western blot
Proteins phosphorylated on tyrosine residues can be detected by Western blot using the 
monoclonal antibody, 4G10 (Upstate Biotechnology). This antibody gives a veiy poor 
signal and high background using the standard blotting protocol outlined above (section 
2.3.6) so the following modified protocol was developed. Following membrane blocking
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with TBST 4% milk, blots were incubated with a 1:1000 dilution of 4G10 (Upstate 
Biotechnology) overnight at 4°C in TBS with 0.05 % (v/v) Tween 20 and 0,5 % (w/v) 
milk. Membranes were washed 3x5 minutes with TBST and incubated for 2 hours with 
donkey anti-mouse IgG: HRP (1:4000, Amersham) in TBST with 4% (w/v) mille. 
Membranes were then rinsed four times with large quantities of ddH20, washed 5x5 min 
with TBST with vigorous agitation followed by four further rinses with ddH20. Blots 
were developed as described above (section 2.3.6).
2.3.6.2. Detection of activated MAPK by Western blot (ERK, p38 and JNK)
To detect activated forms of the MAPKs, lysates were prepared as described in section
2.3.3. Typically, 10 pg of total cell lysate was electrophoresed and blotted for each 
sample using Novex precast gels as described in sections 2.3.5.2 and 2.3.6. Activated 
forms of ERK, p38 and JNK were detected by Western blot (section 2.3.6.) using rabbit 
polyclonal antibodies raised against peptides coiTesponding to the dual phosphorylated 
active sites of the different MAP kinases. All blots for activated MAPKs were stripped 
and reprobed with polyclonal antibodies which recognise all forms of the MAPK being 
assayed to ensure comparable loading of cell lysates between samples. For antibody 
specificities see table 2.1.
2.3.6.3. Detection of activated Akt/PKB by Western blot
Activated Akt/PKB is phosphorylated on a number of sites, including Serine 473 
(Ser473). Activated PKB can be detected by Western blot as described for the MAPKs 
(section 2.3.6.2) using rabbit polyclonal antibodies which recognise PKB phosphorylated 
on Ser473 (phospho-PKB - see Table 2.1). All blots for activated phospho-PKB were 
stripped and reprobed with sheep polyclonal antibodies which recognise all forms of 
PKB to ensure comparable loading of cell lysates between samples.
2.3.7. Ras and Rac assays
The Ras and R ad  small GTPases were assayed using Ras and Rac activation assay kits 
(Upstate Biotechnology). These kits comprise glutathione agarose bound GST fusion
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proteins of the Ras binding domain (RBD) of Raf-1 (which binds Ras:GTP) or the p21 
binding domain of PAK-1 (which binds Racl:GTP). Briefly, cells were stimulated and 
then lysed with Mg^ "^  lysis buffer (MLB - Upstate Biotechnology). Typically, 500 |ig 
cell lysate at a concentration of 1 mg/ml was used for each assay sample. Active Ras was 
precipitated with 5 |xl Raf-1 RBD agarose for 30 minutes. Active Rac I was precipitated 
with 5 |il PAK-1 PBD agarose for 60 minutes. Precipitates were washed with 3x500 p,l 
MLB followed by SDS-PAGE (section 2.3.5.2) and Western blotting (section 2.3.6). Ras 
and Rac 1 were detected with specific mAbs
2.3.8. Membrane preparation
Cells were washed twice in cold nuclear preparation buffer (10 mM Tris-HCl, pH 7.4, 2 
mM magnesium chloride, 140 mM sodium chloride). Cells were then lysed by three 
liquid nitrogen freeze-thaw cycles in nuclear preparation buffer containing 2% (v/v) 
Tween 40, protease inhibitors (1 mM phenylmethylsulfonyl flouride and Ipg/ml each 
chymostatin, leupeptin, antipain and pepstatin) and phosphatase inhibitors (IniM  
vanadate and ImM NaF). Cell debris and nuclei were removed by centrifugation (15 000 
g, 5 min) and membranes were precipitated by ultracentrifugation (Beckman Instruments) 
of the supernatant at 100 000 g, 4°C for 1 hour (Bunce et aL, 1988, Divecha, Banfic & 
Irvine, 1991). Following ultracentrifugation, the supernatant represents the cytosolic 
fraction. Membrane pellets were resuspended in cold nuclear preparation buffer.
2.4. Biochemical assays
2.4.1. Measurement of of phosphatidyl choline Phospholipase D (PC-PLD) 
activity
PC-PLD activity was measured by the transphosphatidylation assay (Briscoe, Plevin & 
Wakelam, 1994). Briefly U937 cells were labeled (10^ cells/ml) with [^H] palmitic acid (5 
gCi/ml) in RPMI 1640 containing FCS (10%) for 16 h. Following labeling, the cells were 
washed in ice-cold RPMI 1640 containing 10 mM HEPES and 0.1% (v/v) FCS (RHB 
medium) before being incubated (at a final concentration of 2 x 10  ^ cells/ml) in RHB
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medium containing 0.3% (v/v) butan-l-ol at 37 °C for 15 min. Specific Fc receptors were 
cross-linlced for 30 min as described above (section 2.3.1.), and the cells were extracted by 
Bligh-Dyer phase separation. An aliquot of the lower organic phase was removed and 
dried down under vacuum and the samples were redissolved in 25 ml chlorofonn/methanol 
(19:1 v/v), containing 40 jig unlabeled phosphatidyl-butanol (Lipid Products, South 
Nutfield, Surrey, UK) as standard, and applied to pre-run, heat activated TLC plated (20 
X 20 cm). Silica gel 150A groved plates (Whatman). The plates were developed in the 
organic phase of the solvent, ethyl acetate/1,2,4-trimethylpentane/acetic acid/water 
(11:5:2:10), for approximately 90 min, and the position of the phosphatidyl-butanol 
(PtdBut) product was detected using iodine vapour. [^H] PtdBut-containing silica, as 
indicated by the standard, was then scraped into scintillation vials and counted. Results 
were calculated as a percentage of the total radioactivity incorporated in the lipids.
2.4.2. In vitro inositoiphosphatase assay
Hydrolysis of [^H]lns(l,3,4,5)P4 (NEN) by immune precipitates was measured in 25 jil 
containing 16 | l lM  pH ]Ins(l,3,4,5)P4, 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2. 
Reaction mixtures were incubated, with shaking, for 10 min at 37 ^C, stopped with 500 
jil ice cold water, and immediately applied to 0.5 ml dowex-formate columns. [^H] 
lns(l,3,4)P3 product was eluted with 6 ml 0.7 M ammonium formate, 0.1 M formic acid 
and non-hydrolysed [^H]Ins(l,3,4,5)P4 was eluted with 6 ml 2.0 M ammonium formate, 
0.1 M formic acid (Damen et aL, 1996, Mitchell, Connolly & Majerus, 1989). Both 
eluted fractions were counted in a Beckman Instuments scintilation counter.
2.5. Molecular Biology
2.5.1. RNA preparation
Total cellular RNA was isolated by acid phenol extraction. Briefly, cells were lysed by 
resuspending cell pellets in GTC lysis buffer (4 M guanidinium isothicyanate, 25 mM 
sodium citrate pH 7, 0.5 % (w/v) lauroylsarcosine, 100 mM (3-mercaptoethanol). 
Samples were acidified with 0.2 M sodium acetate (pH 4), followed by the addition of an
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equal volume of acidified phenol (pH 4). To ensure good phase separation chloroform : 
isoamylalcohol (24:1, 100 ul added/ml total volume) was added. Following vigorous 
vortexing cells were incubated on ice for 15 minutes and spun (1 500 g) at 4°C for 20 
minutes to separate phases. The aqueous layer, which contains the RNA, was then 
removed to a fresh tube and the RNA precipitated with an equal volume of isopropanol 
followed by centrifugation (15 000 g, 20 min). RNA pellets were washed with 80% 
ethanol, re suspended in an appropriate volume of diethylpyrocarbonate (DEPC) treated 
water and stored at -70°C. RNA concentration was determined by measuring absorbance 
at 260 mn and purity was estimated by checking the 260 nm:280 nm absorbance ratio 
(RNA has a ratio of roughly 2:1).
2.5.2. Northern Blotting
For Northern blotting, equal quantities of total RNA (typically 20 jig) from each sample 
were denatured by heating to 60°C for 20 mins in the presence of 10% (v/v) formamide 
and 4% (w/v) formaldehyde. The RNA was then separated by electrophresis through a 
1% agarose gel containing 0.02 M MOPS (pH 7), 1 mM EDTA and 0.6 (w/v) 
formaldehyde. 10 mM iodoacetamide was also added to the gel as an RNAse inhibitor. 
To visualise RNA the gel was stained with 0.5 jig/ml ethidium bromide for 30 mins. 
RNA was transferred to nitrocellulose (Amersham) overnight by capillaiy elution with 
20xSSC (3 M NaCl, 0.3 M Sodium Citrate, pH 7) as transfer buffer. RNA was fixed to 
the nitrocellulose membrane by irradiating with ultraviolet light. The positions of 28S and 
18S ribosomal RNAs were marked on the blots to allow size estimation of specific 
mRNA bands. Blots were typically hybridized overnight at 55°C with a ^^P labeled 
double stranded DNA probe in 0.5 M sodium phosphate (pH 7.2), 6.6% (w/v) SDS, 4 
mM EDTA and 6.7 mg/ml polyA.
2.5.3 labeling of DNA
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2.53.1. random primer labeling of double stranded DNA
To generate radiolabeled probes for hybridising to blots, double stranded DNA templates 
were labeled using the High Prime (Boeliringer Mannheim) random primer labeling 
system. Specific template DNA was excised from the appropriate cDNA clone by 
restriction digestion (section 2.5.4.). Following electrophoresis, the correct DNA 
fragment was excised from the gel and purified using a Qiagen gel extraction kit. 
Alternatively, restriction digests were electrophoresed in low melting point agarose to 
allow labeling directly from the excised gel slice. Template DNA was denatured by 
heating to 100°C for 10 minutes prior to labeling. Approximately 10 ng DNA was 
labeled in 20 |Lil containing 4 ql Highprime reaction mix (contains buffers, Klenow 
fragment of DNA polymerase I, dATP, dGTP and dTTP), and 5jil [a-^^P] dCTP 
(1.85MBq at approx. 110 TBq/mmol -Amersham). Reactions were caiTied out at 37°C 
for 10 minutes. If low melting point agarose was used incubation time was increased to 1 
hour. Labeled probe was separated from unincorporated label using Clontech size 
exclusion spin columns (Chi'oma Spin-30). Labeled probes were boiled for 10 minutes 
prior to hybridization to Northern blots (section 2.5.2.) or Southern blots (section
2.5.8.1.).
2.5.3.2. 5’ end labeling of oligonucleotide probes with polynucleotide kinase
T4 polynucleotide kinase (T4-PNK) catalyses the transfer of the y-phosphate from ATP 
to the 5 ’-hydroxyl terminus of DNA. 10 pmolel of specific oligonucleotide was mixed 
with 15 jil [y-32P] dATP (5.55 MBq at approx. 110 TBq/mmol -Amersham), 5 |il lOx 
kinase buffer (Promega), 10 units (1 |ll1) T4 PNK (Promega) in a total of 50 jil. Following 
a 10 minute incubation at 37°C, reactions were terminated by the addition of 2 pi 0.5 M 
EDTA. Labeled probes were hybridised to PGR Southern blots (2.5.8.1.)
2.5.4. Restriction enzyme digestion of plasmid DNA
Typically 1 pg plasmid DNA was digested in 25 pi containing 2.5 pi of an appropriate 
reaction buffer and 1 pi of enzyme. If two restriction enzymes were used then 0.7 pi of 
each enzyme was used to keep glycerol concentrations to a minimum. Reactions were
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incubated for 1 hour at 37°C. All restriction enzymes were purchased from Boehringer 
Mannheim and appropriate buffers were chosen using the supplied buffer compatibility 
chart. If  larger quantities of DNA needed to be digested then reaction times and/or 
volumes were increased accordingly.
2.5.5. Agarose gel electrophoresis of DNA
Restriction digested DNA and PCR products were typically electrophoresed at 60 V 
through 1-2% (w/v) agarose in TAB buffer (40mM Tris-acetate, ImM EDTA) containing 
0.5 pg/ml ethidium bromide. Bands were visualised on an ultraviolet transilluminator and 
photographed with a Polaroid instant camera.
2.5.6. Transformation of Escherichia Coli DH5-cx andJM109 for plasmid 
preparations
For general plasmid preparations, competent subcloning efficiency DH5-a (GibcoBRL) 
or JM109 (Promega) cells were used. Briefly, 50 pi competent cells were gently mixed 
with 1-10 ng DNA and incubated on ice for 30 minutes. Cells were then heat shocked at 
42°C for 30 seconds followed by a 2 minute incubation on ice. Following the addition of 
1 ml LB medium (Lennox L Broth - GibcoBRL), cells were allowed to recover for 1 hour 
at 37°C prior to plating an aliquot on to LB agar plates (GibcoBRL) containing 100 pg/ml 
ampicillin. Colonies were grown overnight at 37°C.
2.5.7. Purification of plasmid DNA
For each plasmid preparation a single colony was picked from a freshly streaked 
ampicillin selective plate and innoculated into a 5 ml LB culture containing 100 pg/ml 
ampicillin. For minipreparations of plasmid DNA, 5 ml cultures were grown up 
overnight at 37°C prior to plasmid purification as outlined below (section 2.5.7.1.). 
Alternatively, when larger quantities of DNA were required, 5ml 'started cultures were 
incubated at 37°C for 8 hours prior innoculation into lai'ger volumes. When using 
const^cts in the CDM vector, 500 ml cultures were typically grown overnight and 
plasmid DNA purified by the caesium chloride method outlined below (section 2.5.7.2.).
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For ali other plasmids, 100 ml cultures were grown and plasmid DNA purified using 
Qiagen maxi-prep column purification according to the manufacturers protocol. For 
procedures where endotoxin contamination was considered a problem, such as 
transfection of U937 cells, EndoFree plasmid kits were used.
2.5.71. Minipreparations
For purification of small quantities of plasmids (1-5 pg) ,5 ml cultures were grown 
(section 2.5.7). Briefly, 1.5 mis of the cell culture was precipitated at 12 000 g for 30 
seconds. The cell pellet was resuspended in 100 pi GTE buffer (50 mM glucose, 25 mM 
Tris.Cl and 10 mM EDTA) and lysed by the addition of 200 pi 0.2 M NaOH/1% (w/v) 
SDS. Protein and genomic DNA was precipitated by the addition of 3 M potassium 
acetate (pH 4.8) for 5 min on ice followed by centrifugation at 12 000 g for 2 min. The 
supernatant, containing plasmid DNA was removed to a fresh tube and precipitated with 
2 volumes of ethanol at room temperature. Plasmid DNA was pelleted at 12, OOOg for 5 
minutes at 4°C. Pellets were washed in 70% (v/v) ethanol and resuspended in TE buffer 
(10 mM Tris, 1 mM EDTA, pH 8.0).
2.5.7.2. Caesium chloride maxi-preparations
For purification of large quantities of CDM plasmid clones, 250 mis - 1 1 of culture was 
grown (section 2.5.7). This protocol is essentially a scaled up version of the 
minipreparation protocol (section 2.5.7.1.) with the addition of a caesium chloride (CsCl) 
density gradient purification step included to give transfection grade plasmid DNA. 
Pelleted cells were resuspended in 10 mis GTE buffer (see section 2.5.7.1), lysed with 20 
ml 0.2 M NaOH/1% (w/v) SDS and protein and genomic DNA precipitated with 3 M 
potassium acetate (pH 4.8) for 10 mins on ice. Following centrifugation (10 000 g, 15 
min) the supernatant was filtered through cheesecloth and DNA precipitated by the 
addition of 0.6 volumes of isopropanol for 10 minutes at room temperature. DNA was 
pelleted at 12 000 g for 15 minutes, washed with 70% (v/v) ethanol and resuspended in 3 
ml TE buffer (pH 8.0). CsCl gradients were used to purify DNA. Ig CsCl was dissolved 
in every 1 ml of resuspended DNA. Ethidium Bromide was added to a final eoncentration 
of 740 pg/ml. Following removal of precipitate by centrifugation, the solution was
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transferred to an ultracentrifuge tube and spun at 100 000 g for 16 hours. The lower of 
the two DNA bands in the centre of the density gradient consists of closed circular 
plasmid DNA, and this band was collected using a hypodermic needle. Ethidium bromide 
was removed by repeated extraction with NaCl saturated butan-l-ol and CsCl was 
removed by precipitation of the DNA with ethanol. The DNA was re suspended in TE 
buffer (pH 8).
2.5.8. Semi Quantitative RT-PCR
For reverse transcriptase PCR (RT-PCR) cDNA was prepared from total RNA using an 
Invitrogen cDNA cycle kit with oligo dT primers. Briefly, reactions were carried out in 
20 pi containing 1 pg total RNA, RNase inliibitor, 5 mM dNTPs, 4 mM sodium 
pyrophosphate, 4 pi Invitrogen 5xRT reaction buffer and 0.5 pi AMV reverse 
transcriptase (RT). Reactions were carried out at 42®C for 1 hour followed by phenol 
chloroform extraction and ethanol precipitation. cDNA was aliquoted and frozen at - 
70°C until used in PCR reactions. Aliquots of cDNA were amplified by PCR as follows. 
To amplify FcyRIIa and FcyRIIb mRNA, a single crossreactive forward primer was used 
(FcyRII-FOR) with reverse primers specific for either FcyRIIa (RIIa-REV - Table 2.2) or 
FcyRIIb (RIIb-REV - Table 2.2). For FcyRIIb these primers flank the alternative 
FcyRIIb2 splice site to allow identification of different splice variants by PCR product 
size. PCR reactions were carried out in 50pl containing 20 pmole of each primer, 2.5 mM 
MgCl% , 5 pi Promega Taq lOx reaction buffer and 2 units Promega Taq polymerase. PCR 
reactions were continued for 20 to 40 cycles with each cycle comprising 1 minute at 93°C 
(denaturing), 1 minute at 50°C (primer annealing) and 1 minute at 72°C (product 
extension). To confirm the specificity of PCR reactions, products were Southern blotted 
and hybridized with end labeled oligonuleotide probes (section 2.5.3.2.) specific for either 
FcyRIIa or FcyRIIb (Table 2.2). Further, PCR products were subcloned into the pGEM- 
EasyT vector (Promega) (section 2.5.8.2.) and sent for automatic sequencing. To 
quantify relative levels of mRNA from different samples, FcyRIIa and FcyRIIb were 
amplified together. At 20 cycles, formation of product was shown to be linear with levels 
of input cDNA (data not shown). Following 20 cycles of PCR, products were subjected 
to Southern blot analysis (section 2.5.8.1) and hybridized with a specific ^^P random
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primer labeled probes (section 2.5.3.1.), Levels of cDNA levels were normalised between 
samples using primers specific for cyclophilin (Table 2.2).
2.5.8.1. Southern blotting PCR products
PCR products were electrophoresed as described in section 2.5.5. Gels were then soaked 
for 30 minutes each in denaturing buffer (1.5M NaCl, 0.5 M NaOH, pH 13), neutralising 
buffer (1.5 M NaCl, IM Tris.HCl, pH7.5) and 20 x SSC. DNA was transferred to 
nitrocellulose (Amersham) overnight by capillary elution with 20 x SSC as transfer buffer. 
DNA was fixed to the nitrocellulose membrane by irradiating with ultraviolet light. Blots 
were hybridized with either random primer labeled double strand DNA probes (section
2.5.3.1.) or with end labeled oligonucleotide probes (section 2.5.3.2) specific for either 
FcyRIIa of FcyRIIb (table 2.2).
2.5.8.2. Subcloning PCR products into pGEM Easy-T cloning vector
The pGEM Easy-T cloning vector has 3’thymidine (T) overhangs to enhance the 
efficiency of PCR product ligation by taking advantage of the single 3’ adenosine (A) 
added to the ends of PCR products by Taq DNA polymerase. Following electrophoresis, 
the PCR products were excised from the gel and purified using a Qiagen gel extraction kit. 
Purified PCR products were ligated into the pGEM Easy-T (50 ng/reaction) using T4 
DNA ligase overnight at 4°C according to the manufacturers protocol. Ligated vector was 
transformed into JM109 competent cells as decribed in section 2.5.6. Transformed cells 
were plated onto LB plates containing, Ampicillin (lOOpg/ml), O.lmM IPTG, X-Gal 
(40jig/ml), to allow blue/white screening. Following incubation overnight at 37°C, white 
colonies were picked and minipreps carried out (section 2.5.7.1.). Purified plasmids were 
screened for the presence of inserted PCR products by digestion with EcoRI (section 
2.5.4.). Cloned PCR products were sequenced and used as probes for Southern blot 
hybridisations (2.5.8.1.).
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Specificity (cione/species^) Usage^ Source^
FcyRI mlgGl (10.1) IP, FACS Calbiochem
FcyRI mlgGl (22) IP, FACS, X-link Medarex
FcyRII mlgGl (KB6I) IP, FACS, X-linlc DAKO
FcyRII mlgGl, (IV3) IP, FACS, X-linlc Medarex
FcyRIII mlgGl (3G8) FACS Medarex
CD89 mlgGl (A3) IP, FACS, X-link Serotec
human IgG and subtypes IP, FACS, X-link Serotec
anti-mouse IgG (goat) X-linlc Sigma
Anti-human IgG (goat) X-link Sigma
SLP76 (sheep) Wn, IP Upstate
pTyr mIgG2b(4G 10) Wn Upstate
y-chain (rabbit) Wn NEB
JNK and pJNK (rabbit) Wn NEB
ERIC and pERK (rabbit) Wn NEB
p38 and pp38 (rabbit) Wn NEB
pAkt (rabbit) Wn Santa Cruz
Sos (rabbit) Wn Santa Cruz
Vav (rabbit) Wn Santa Cruz
Cbl (goat) Wn Santa Cruz
Grb2 (rabbit) Wn, IP Santa Cruz
SHIP (goat) Wn, IP Santa Cruz
Syk (rabbit) Wn Santa Cruz
Lyn (rabbit) Wn Santa Cruz
PEG (rabbit) Wn Santa Cruz
p85 (rabbit) Wn Santa Cruz
She (rabbit) Wn Santa Cruz
She (mouse) Wn, IP Santa Cruz
RasGAP (mouse) Wn Santa Cruz
anti-mouse: FITC FACS secondary Abs Sigma
anti-mouse: HRP Wn secondary Ab Amersham
anti-rabbit:HRP Wn secondary Ab Amersham
anti-sheep:HRP Wn secondary Ab Upstate
anti-goat: HRP Wn secondary Ab Sigma
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Key for Table 2.1 (see previous page)
1 clone number and/or species in which antibody was raised.
2 IP; immuneprecipitation. FACS; fluorescent activated cell scanning. X-link; crosslinking 
studies. Wn; western blotting.
3 manufacturer
Amersham, Amersham, UK 
Serotec, Oxford, UK 
Sigma, Poole, UK
Upstate, Upstate Biotechnology, Lake Placid, USA 
Santa Cruz, Santa Cruz Biotechnology, Sta Cruz, CA, USA 
Medarex, NJ, USA
NEB, New England Biolabs, MA, USA 
DAKO Ltd, Cambridgeshire, UK
Table 2.2. Oligonucleotide primers
Primer Description Sequence
II-FOR FcyRII forward primer GCACAGGAAACATAGGCTACACG
Ila-REV FcyRIIa reverse primer GGTATCTTCTTAGAAAGTCCC
Ilb-REV FcyRIIb reverse primer GGTGATTGTGTTCTCAGCCCC
Ila-probe FcyRIIa probe CCTCCCAACGACCATGTCAACAG
Ilb-probe FcyRIIb probe GATGAGGCTGATAAAGTTGGGGC
Cyc-FOR cyclophilin forward primer GGTGACTTCACACGCCATAATG
Cyc-REV cyclophilin reverse primer GAGTTGTCCACAGTCGGAGATG
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Chapter 3
FcyRI activates SH2 containing inositol phosphatase (SHIP)
3.1. Introduction
Receptors for immunoglobulins (Ig) play a pivotal role linking the humoral and cellular 
arms of the immune system and thereby regulating the immune response to antigen. Each 
immunoglobulin class is recognised by a family of low and liigh affinity receptors (Hulett 
& Hogarth, 1994, Ravetch & Kinet, 1991). Thus, IgG is recognised by Fey receptors and 
three different subclasses of receptors (FcyRI, FcyRII and FcyRIII) have been defined on 
the basis of their structure and affinities for IgG. These receptors (except FcyRIIIb) 
comprise integral type I membrane glycoproteins and all possess similar overall structure. 
However, the cytoplasmic tails of the various receptors are highly divergent and these 
specify recruitment of different signalling pathways.
In common with many immunoreceptors, FcyRs couple to the activation of signal 
cascades via clustering of cytoplasmic immunoreceptor tyrosine activation motifs 
(IT AM) (Cambier et aL, 1995, Gambler, 1995). These IT AM motifs are generally found 
on receptor associated accessory molecules such as the y-chain, which associates with 
FcyRI, FcyRIII and FceRI or with the a  and p chains of the BCR. Occasionally, as is the 
case for FcyRIIa, the IT AM motif can be found in the cytoplasmic tail of the receptor 
itself. Aggregation of Fc receptor associated IT AM motifs by immune complex 
stimulates the activity of associated Src family kinases which phosphorylate key tyrosine 
residues within the ITAM motif. These phosphorylated IT AMs comprise docking sites 
for SH2 domain containing signalling molecules, including the tyrosine kinase Syk, and 
adapter proteins, which propagate signals (Agarwal et aL, 1993, Cambier & Johnson, 
1995, Duchemin & Anderson, 1997).
The recruitment and activation of Syk to activated ITAMs is critical for the activation of 
multiple key signalling pathways activated by Fc receptors (Crowley et aL, 1997).
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Probably the most studied of these Syk dependent pathways is the activation of 
phospholipase C (PLC) to generate the second messengers, inositol trisphoaphate (InsPg) 
and diacylglycerol (DAG), and resultant caleium transients (Liao, Shin & Rhee, 1992, 
Rankin et aL, 1993). Following receptor aggregation, PLCy translocates to the plasma 
membrane where it becomes activated in a PI 3-kinase dependent mapner (discussed in 
section 1.2.3.5) (Falasca et aL, 1998, Fluckiger et aL, 1998). Following activation, PLCy 
catalyses the production of InsP] and DAG from its membrane associated lipid substrate, 
PIP2. Production of InsPg is responsible for calcium release from intiacellular stores and 
subsequent calcium influx through the store operated calcium channel termed I c r a c  (Hoth 
& Penner, 1992).
Alongside ITAM bearing receptors, responsible for cellular activation, a new family of 
inhibitory immuno-receptors has recently been described (Daeron, 1996). These 
inhibitory receptors become activated when co-clustered with activating receptors and 
serve to block, or modulate, cellular responses to the activating signal. The inhibitory 
properties of these receptors are mediated through a cytoplasmic immunoreceptor 
tyrosine based inhibitory motif (ITIM) (Muta et aL, 1994a, Amigorena et aL, 1992b) 
which is closely related to the ITAM motif. Following receptor clustering, the ITIM 
motif becomes phosphorylated on a key tyrosine residue, whieh then serves to recruit 
SH2 containing inhibitory signalling molecules. Two functionally distinct inhibitory 
pathways have thus far been described for ITIM bearing receptors. Initially, the 
phosphorylayed ITIM motif was described as binding and activating, in vitro, the SH2 
containing tyrosine phosphatases, SHP-I (Dambrosio et aL, 1995) and SHP-2 
(Marengere, 1996). By activating tyrosine phosphatases, inhibitory receptors are able to 
block tyrosine kinase dependent activation. Such a mechanism appears to account for the 
inhibitory properties of, among others, the ITIM bearing killer inhibitory receptors 
(KIRs) and CD22 (Unkeless & Jin, 1997). However, this mechanism does not seem to 
account for the inhibitory properties of the ITIM bearing Fey receptor, FcyRIIb. Here, 
inhibition appears to centre round the recruitment of the SH2-containing inositol 
5'phosphatase (SHIP) to the phosphorylated ITIM (Scharenberg & Kinet, 1996).
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The inliibitory properties of FcyRIIb have been extensively studied for the B-Cell 
receptor (BCR) in B lymphocytes and FceRI in Mast cells (section 1.2.8.4 and 1.2.8.5). 
Co-ligation of FcyRIIb with either the BCR or FceRI, results in the recruitment of SHIP 
to the plasma membrane where it dephosphorylates PIP3, the lipid product of PI 3- 
kinase. PIP3 acts to target specific signalling molecules, including PLCy (Falasca et aL, 
1998) and Tec family kinases (Scharenberg et aL, 1998), to the plasma membrane. Thus, 
by dephosphorylating PIP3, SHIP is able to uncouple receptors from a specific subset of 
activatory pathways (Bolland et aL, 1998, Scharenberg & Kinet, 1996). A major target of 
this inhibitory pathway is PLCy, which under inhibitory conditions fails to generate the 
sustained production of InsP3 required for calcium influx. Interestingly, FcyRIIb co­
ligation with the BCR (Muta et aL, 1994a) or FceRI (Ono et aL, 1996) does not block 
calcium release from intacellular stores and also leaves tyrosine phosphorylation largely 
unaffected . Thus, unlike SHP-1 and SHP-2 mediated inhibition, SHIP is able to 
modulate, rather than entirely block, the cellular response to an activating signal.
The human high affinity receptor, FcyRI, contains no Imown signalling motif or homology 
with other immune system receptors (Allen & Seed, 1989). In IFN-y primed U937 cells, 
FcyRI associates non-covalently with the y chain (Ernst et aL, 1993, Ra et aL, 1989, 
Scholl & Geha, 1993) which contains an ITAM motif (Cambier, 1995). Aggregation of 
FcyRI by surface immune complexes results in clustering of the associated y chain and 
activation of the nonreceptor tyrosine kinases, Lyn and Syk, to initiate signal 
transduction as evidenced by tyrosine phosphorylation events (Scholl, Ahern & Geha, 
1992, Rankin et aL, 1993) and tyrosine kinase dependent calcium transients (Davis et aL, 
1994). In these cells, FcyRI aggregation results in release of caleium from intracellular 
stores which is not coupled with calcium entry (Davis et aL, 1994). Further, FcyRI fails 
to activate PLCy and thus InsP3 production. As the pattern of calcium transients and 
failure to activate PLCy following FcyRI aggregation resembles the signalling phenotype 
observed when coligating FcyRIIb with the BCR or FceRI, I decided to examine the 
possible involvement of SHIP in regulating FcyRI signalling.
Here, I show that SHIP is present in the membrane fraction of IFN-y treated cells and, 
after FcyRI aggregation, SHIP is transiently tyrosine phosphorylated. Further, the SH2
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domain containing adapter protein, She, also became tyrosine phosphorylated, 
translocated to the membrane fraction and became tightly associated with SHIP. Finally, 
SHIP appeared to be recruited to immune complexes following FcyRI aggregation 
possibly through interactions with the SH2 containing adapter molecule, She.
3.2. Results
3.2.1. SHIP becomes tyrosine phosphorylated in response to FcyRI 
aggregation
To determine whether SHIP was expressed in IFN-y stimulated U937 eells, lysates were 
examined by Western blotting with anti-SHIP antibodies (section 2.3.6). The mouse 
macrophage cell line P388D1 was used as a positive control. SHIP was detectable as a 
145 kDa protein in both cell types (Figure 3.1 A). This antibody, but not goat IgG, was 
also found to immune precipitate SHIP from U937 cell lysates (Figure 3.IB). Further, 
SHIP immune precipitates contained readily detectable Ins(l,3,4 ,5)P4 5-phosphatase 
activity whereas no activity was detectable in control immune precipitates (Figui'e 3.1C). 
I conclude that SHIP is expressed in IFN-y stimulated U937 cells.
To examine whether SHIP was involved in FcyRI mediated signalling pathways, plasma 
membrane preparations of cells at various time points following receptor aggregation were 
analysed by Western blot. Probing with anti-phosphotyrosine antibodies (section 2.3.6.1) 
revealed that a protein of the con'ect size for SHIP, is transiently phosphorylated 
following FcyRI aggregation, with peak phosphorylation occurring after 1-2 minutes 
(Figure 3.2A). Analysis of blots with anti-SHIP antibodies indicates that levels of 
membrane bound SHIP remain unchanged in response to crosslinking, ruling out 
membrane translocation as a regulatory mechanism. To assess the effect of tyrosine 
phosphorylation on the enzymatic activity of SHIP, 5' phosphatase activity was assayed 
in SHIP immune precipitates both before and two minutes after receptor crosslinking. In 
agreement with the results of other groups (Damen et aL, 1996), tyrosine
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phosphorylation was not seen to significantly affect the activity of SHIP in vitro (Figui'e 
3.2B).
3.2.2. FcyRI aggregation induces the association of She with SHIP
SHIP appears to be constitutively associated with the plasma membrane; its site of action 
and activity is apparently independent of tyrosine phosphorylation. It was therefore 
decided to immune precipitate SHIP over a time course following FcyRI aggregation and 
blot for associated tyrosine phosphorylated proteins which might play a regulatory role. 
Following stimulation, SHIP was seen to transiently associate with two tyrosine 
phosphorylated proteins of around 52 and 60 kDa. I identified these bands to be two 
isoforms of the adapter protein. She (Figure 3.3). The comparable time course of tyrosine 
phosphorylation of both She and SHIP together with the time course of She association 
with SHIP suggests this interaction to be tyrosine phosphorylation dependent.
To assess the interaction between SHIP and She more accurately, I immune precipitated 
She over a more extensive time course following FcyRI aggregation. SHIP became 
detectable in She immune precipitates within 1 minute of receptor aggi'egation, remained 
until 5 minutes but had disappeared after 15 minutes (Figure 3.4A). Probing for 
phosphotyrosine revealed that SHIP was always tyrosine phosphorylated in She immune 
precipitates (Figure 3.4A). Close examination of these anti-phosphotyrosine blots of She 
immune precipitates revealed the presence of a second transiently tyrosine 
phosphorylated protein of around 70 kDa associated with She . This protein was 
identified to be the tyrosine kinase, Syk (Figure 3.4A). Unlike the association of She with 
SHIP, Syk appears to be pre-associated with She, and is rapidly tyrosine phosphorylated 
after receptor crosslinking. Peak phosphorylation was observed 1 minute after 
crosslinking which is faster than the observed association of She with SHIP. Further 
analysis of SHIP immune precipitation blots revealed the presence of a transiently 
tyrosine phosphorylated protein of the correct size for Syk associating with SHIP (Figure 
3.3 - indicated by arrow). This suggests that a trimolecular complex containing SHIP, She 
and Syk may form transiently in response to FcyRI aggregation.
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To confirm the interaction of SHIP with She, 5'phosphatase activity associated with She 
was assayed prior to FcyRI crosslinking and two minutes after crosslinking. No 
measurable 5' phosphatase activity was observed in She immune precipitates from 
uncrosslinked cells, whereas two minutes following crosslinking, activity was readily 
detectable (Figure 3.4B). This process occured independently o f the activation of PI 3- 
kinase or phospholipase D (Melendez et aL, 1998b) as wortmannin (100 nm), LY294002 
(250 (iM), butan-l-ol (0.3% v/v) and butan-2-ol (0.3% v/v) did not influence the 
association of SHIP with She (data not shown). Analysis of membrane fractions also 
revealed that She transiently translocates from the cytosol to the plasma membrane 
(Figure 3.5). Peak levels were seen two minutes after crosslinking, concomitant with peak 
levels of SHIP tyrosine phosphorylation, suggesting this translocation may be dependent 
on an interaction with SHIP. Levels of cytosolic She were seen to decrease following 
FcyRI crosslinldng, concomitant with the increase of She in the plasma membrane fraction 
(data not shown), indicating that She is translocating from the cytosol.
3.2.3. SHIP is detectable in immune complexes following receptor 
stimulation
To determine whether SHIP and She associate with FcyRI signalling complexes membrane 
bound immune complexes were precipitated with protein G agarose. Western blot 
analysis indicates that both SHIP and She are detectable 2 minutes after receptor 
aggregation (Figui'e 3.6A). Surprisingly, levels were seen to remain elevated 15 minutes 
post aggregation, when SHIP phosphorylation has returned to near basal levels. SHIP 
and She were not present in control immune precipitations where no sheep anti-human 
IgG was included. The coincident appearance of SHIP and She is consistent with a model 
in which SH2 domain interactions between SHIP and She are involved in recruitment to 
signalling complexes. The presence of SHIP in these immune complexes was confirmed by 
a substantial increase in 5'phosphatase activity in this fraction after FcyRI aggregation 
(Figure 3.6B).
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3.3. Discussion
I have shown that SHIP, a key inliibitory regulator of immune cells, is present in IFN-y 
primed U937 cells. Following aggregation of FcyRI by the formation of surface immune 
complexes, SHIP is transiently tyrosine phosphorylated and associates with the adapter 
protein, She.
Previous work from this group has shown that aggregation of FcyRI in these cells 
activates a novel pathway which involves the sequential activation of tyrosine kinases, 
PI3-kinases, phospholipase D and sphingosine kinase (Melendez et aL, 1998b). The 
resultant calcium transients are short lived being derived entirely by release from internal 
stores, with no element of calcium influx (Davis et aL, 1994). Interestingly, activation of 
phospholipase C (PLC) could not be observed following FcyRI aggregation (Melendez et 
aL, 1998a). The PLC pathway is intact in these cytokine primed cells as PLC can be 
activated by other receptors, including FcyRIIa. Under these circumstances, activation of 
PLC is associated with calcium transients where calcium influx is observed (Melendez et 
aL, 1998a).
My finding here that SHIP is activated following FcyRI aggregation provides an 
explanation for these observations. Increasing evidence supports a role for PIP3 as a 
positive regulator o f calcium influx. By hyrolysing PIP3, SHIP prevents the translocation 
of key signalling proteins to the plasma membrane. In particular, the Tec family kinases, 
which bind to PIP3 via their PH domains, have been identified as potential targets of a 
SHIP mediated inhibitory signal (Bolland et aL, 1998, Scharenberg et aL, 1998). By 
preventing the translocation of Tec family kinases SHIP might prevent activation of 
downstream targets, such as PLCyl, which is required for sustained calcium influx. 
Preventing the translocation and activation of PLCyl, prevents sustained production of 
InsP3 which is required to activate store mediated calcium influx (Fluckiger et aL, 1998). 
Such a mechanism has been proposed for the action of SHIP in B-cells and mast cells 
where SHIP is recruited by FcyRIIb (Scharenberg et aL, 1998).
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The mechanism by which FcyRI activates SHIP remains unclear as FcyRI has not been 
reported to associate with any ITIM bearing receptors. For signal transduction, FcyRI 
uses the y chain which only features an activation motif or ITAM. However, recent work 
has shown that the cytoplasmic tail of the Granulocyte Colony-Stimulating Factor 
Receptor can recruit SHIP independent of an ITIM tlirough a mechanism involving She 
and the formation of Shc/SHIP complexes (Hunter & Avalos, 1998). The finding that the 
adapter molecule She forms a tight association with SHIP following FcyRI aggregation 
provides a mechanism to link the FcyRI :y chain complex to SHIP. Formation of this 
complex was apparently tyrosine phosphorylation dependent and the tyrosine kinase 
Syk appeared to associate with She. This suggests that, consistent with previous reports 
(JabrilCuenod et aL, 1996, Crowley, Harmer & DeFranco, 1996), Syk is involved in the 
phosphorylation of She and SHIP.
SHIP itself was found in the plasma membrane and, when immunoprecipitated from the 
cell, SHIP was constitutively active. This implies that tyrosine phosphorylation itself 
does not regulate enzyme activity but rather may play a role to target the enzyme to the 
correct adapter molecule such as She through SH2 domain interactions. It also suggests 
that there may be negative regulators of the enzyme to prevent activation in the absence 
of SH2 domain interactions.
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Figure 3.1 SHIP 5’inositol phosphatase is expressed in monocytic U937 
cells.
(A) Protein extracts (100 jlg/lane) from IFN-y primed U937 cells and the 
mouse macrophage cell line, P338D1, were analysed by Western blot using 
anti-SHIP antibodies as described. (B) Lysates from IFN-y primed U937 cells 
were immimoprecipitated with either anti-SHIP conjugated protein-G agarose 
or control unconjugated protein-G agarose (control) as described in the 
materials and methods (section 2.3.4.1). Immune precipitates were then 
analysed by Western blot (section 2.3.6). (C) SHIP immune precipitates
(Anti-SHIP) and control immune precipitates (Control) were subjected to 
5'inositol phosphatase assays as described previously (section 2.4.2). 
Background control assays were carried out in the absence of any immune 
precipitate (Blank). Data are the mean ± standard deviation (SD) of triplicate 
measurements derived from four separate experiments.
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Figure 3.2 Membrane associated SHIP becomes tyrosine 
phosphoryiated following FcyRI cross linking.
(A) IFN-y primed U937 cells were loaded with monomeric hIgG at 4°C and 
IgG occupied FcyRI was aggregated with sheep anti-hIgG as described in the 
materials and methods (section 2.3.1.1). Cells were warmed to 37°C for the 
times specified. Membrane fractions (30 p.g/lane) were isolated (section 2.3.8) 
and analysed by Western blot. Phosphotyrosine-containing proteins were 
detected using anti-phosphotyrosine (4G10) antibody. Membranes were 
stripped and re-probed with anti-SHIP antibodies. Control lanes contain 
membrane fractions from cells incubated with either no antibodies (No Ab), or 
just hlgG (hlgG). (B) Cells were incubated with either hIgG alone (No XL) or 
crosslinked for 2 minutes at 37°C (XL). Lysates were immune precipitated 
with either anti-SHIP antibodies (SHIP) or control goat IgG (Control). 
Immune precipitates were subjected to 5'inositol phosphatase assays as 
described in section 2.4.2. Background control assays were carried out in the 
absence of any immune precipitate (Blank). Data are the mean ± SD of 
triplicate measurements derived from three separate experiments.
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Figure 3.3 SHIP associates with tyrosine phosphoryiated She following  
FcyRI cross linking.
(A) Western blot analysis of SHIP immunoprecipitates probed with 
antiphosphotyrosine (4010) antibody. FcyRI was aggregated for 30 sec, 2 min 
and 10 min as indicated. Cells loaded with hlgG but with no addition of sheep 
anti-hlgO are used as control. SHIP immune precipitates were analysed by 
Western blot using anti-phosphotyrosine mAb 4010 (upper), anti-SHIP 
antibody (middle), and anti-She antibody (lower).
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Figure 3.4 She associated SHIP has SMnositol phosphatase activity.
(A) Western blot analysis of She immunoprecipitates. FcyRI was aggregated 
for 0, 30 sec, 1 min, 2 min, 5 min and 15 min as indicated. Cells with no 
addition of liIgG or sheep anti-hIgG (No Ab) and cells loaded with hlgG but 
no sheep anti-liIgG (IgG) were included as controls. She immune precipitates 
were analysed by Western blot using anti-phosphotyrosine antibody (upper). 
Blots were stripped and reprobed with anti-SHIP, anti-Syk and anti-Shc 
antibodies (lower panels) as indicated. The position of the precipitating anti- 
Shc antibody (IgG) is indicated on anti-Shc and anti-phosphotyrosine blots. 
This antibody is detected by the HRP-conjugated secondary antibody alone.
(B) 5'-inositol phosphatase assay of She immune precipitates. She was 
immune precipitated from either uncrosslinked cells (She No XL) or FcyRI 
crosslinked cells (She XL). Lysates were also precipitated with non-reactive 
serum as control (Control No XL and Contiol XL). Background control assays 
were earned out in the absence of any immune precipitate (Blank). Data are 
the mean ± SD of triplicate measurements derived from three separate 
experiments.
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Figure 3.5 FcyRI aggregation induces the translocation of She to the  
plasma membrane
Western blot analysis of membrane fractions. FcyRI was aggregated for 30 
secs, 1 min, 2 min, 5 min and 15 min. Membrane fractions (30|ag/lane) were 
analysed by Western blot, probing with either anti-SHIP antibody (upper) or 
anti-Shc antibody (lower). Cells loaded with hlgG but no sheep anti-hlgO 
(IgG) was included as a control.
82
XL Fc yRI
SHIP
She
Chapter 3
Figure 3.6 SHIP and She are detectable in immune complexes following 
receptor stimulation.
(A) FcyRI was aggregated for 30 sec, 2 min and 15 min as indicated. FcyRI 
based immune complexes were precipitated from membrane preparations by 
the addition of protein-G agarose. SHIP and She were detected by Western 
blot using anti-SHIP (upper) and anti-Shc (lower) antibodies. Cells loaded 
with liIgG alone act as an immune precipitation control. (B) 5'-inositol 
phosphatase assay of immune complex precipitates. Immune complexes were 
precipitated with protein-G agarose from uncrosslinked cells (No XL) or 
FcyRI crosslinlced (XL) cells (37*^C for 2 min). Background control assays 
were earned out in the absence of any immune precipitate (Blank). Data are 
the mean ± SD of triplicate measurements representative of tliree separate 
experiments.
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Chapter 4
Differentiation of U937 cells with dbcAMP induces the expression of 
FcyRIIb
4.1. Introduction
Macrophages play a key role in the coordination of inflammation. These cells must be 
activated to combat infection and kill abnormal cells such as vims infected cells and cancer 
cells. However, activation must be tightly regulated as effector functions of these cells, 
such as degranulation, the respiratory burst and generation of reactive oxygen species, can 
lead to tissue destruction and disease processes. It is important therefore to balance 
activating and inhibitory signals to precisely control the state of macrophage activation.
Fey receptors play a key role in the regulation of macrophage activation and also in the 
coordination o f inflammation (section 1.3). Thus aggregation o f Fey receptors by immune 
complexes leads to antigen internalisation, activation of various cytotoxic effector 
functions and production of inflammatory cytokines such as T N F-a (section 1.1.8). 
While the specific signalling pathways linking Fey receptors to these effector functions 
are becoming clearer, less is known concerning potential inhibitory pathways which 
switch off, or prevent incorrect activation of these cells.
Recent studies using mouse knockout models have indicated the importance of Fey 
receptors in mediating tissue damage in auto-immune and inflammatory disease models 
(Clynes et a l, 1999, Clynes et a l, 1998, Yuasa et al., 1999, Ravetch & Clynes, 1998). 
Mice deficient for the IT AM containing y-chain are completely protected from immune 
complex mediated inflammatory injury. Conversely, mice lacking the inhibitory I TIM 
bearing receptor, FcyRIIb, show entranced susceptibility to, and severity of, disease in 
multiple model systems. Further, macrophages isolated from mice lacking FcyRIIb show 
enhanced Fey receptor mediated calcium signalling, phagocytosis and inflammatory
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cytokine synthesis (Yuasa et aL, 1999, Clynes et aL, 1999). These studies highlight the 
importance of both positive and negative signalling pathways in the correct regulation of 
murine macrophage activation by immune complexes.
Previous work in our laboratory has defined a model system using human U937 
monocyte cells for studying Fey receptor mediated signalling pathways. Here we have 
demonstrated that the signalling pathway used by FcyRI to mobilise calcium is dependent 
on the differentiation state of the cell (Melendez et aL, 1998a). Further, we have 
demonstrated that this switch is dependent on the accessory molecule recruited by FcyRI. 
Thus, in IFN-y primed U937 cells, FcyRI couples via the y-chain to PLD, sphingosine 
kinase and calcium store release (Chapter 6) (Melendez et aL, 1998a). Conversely, in 
dbcAMP cells FcyRI couples via FcyRIIa to phospholipase C, calcium store release and 
calcium influx (Chapter 6) (Melendez et aL, 1998a).
Differences in calcium signalling and the nature of phospholipase enzyme activation 
between the differentiation states prompted us to look for inhibitory signalling pathways 
activated by Fey receptors (see Chapter 3). As FcyRIIb has been shown to modulate 
calcium signalling and phospholipase C activation by ITAM receptors in B-cells and mast 
cells (Ono et aL, 1996, Fluckiger et aL, 1998, Bolland et aL, 1998), it seemed possible that 
similar mechanisms may regulate macrophages. As FcyRIIb expression has not been 
demonstrated previously in human macrophages or U937 cells, the first step was to 
determine whether this inhibitory receptor was expressed and under what conditions.
Here, although undifferentiated U937 cells do not express cell surface FcyRIIb, 
differentiation of these cells to a more macrophage phenotype with dbcAMP induces the 
expression of this inhibitory IgG receptor. In contrast, priming cells with IFN-y does not 
induce expression of FcyRIIb. Further, in dbcAMP differentiated cells, FcyRIIb is 
capable of recruiting SHIP in response to co-aggregation with the activating IgG receptor, 
FcyRIIa. This data suggests that this receptor may act by limiting, but not blocking, 
specific signalling pathways activated by FcyRIIa. These findings delineate a potential 
novel role for FcyRIIb in the modulation of immune complex mediated activation of 
human macrophages.
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4.2. Results
4.2.1. DbcAMP upregulates the expression of FcyRIIa and induces the 
expression of FcyRIIb
Changes in the expression of various subclasses of FcyRII by U937 cells in response to 
differentiation with either IFN-y or dbcAMP were determined using a combination of 
Northern blotting, RT-PCR, FACS and Western blot analysis.
Total RNA was extracted from U937 cells at various timepoints following treatment with 
either IFN-y or dbcAMP and Northern blots prepared as decribed in chapter 2 (sections 
2.5.1 and 2.5.2). Hybridisation of blots with an FcyRI I specific cDNA probe revealed a 
2.6 kb transcript and a 1.5 kb transcript detectable at all timepoints tested following both 
IFN-y and dbcAMP treatment (Figure 4.1). FcyRIIa is reported to give rise to both a 2.6 
kb transcript and a 1.5 kb transcript which arise from differential polyadenylation 
(Brooks et aL, 1989). The size of the FcyRIIb transcript is also 1.5 - 1.6 kb (Brooks et 
aL, 1989). The nucleotide sequences for FcyRIIa and FcyRIIb are very similar and the 
cDNA probe was unable, under the conditions used here, to distinguish between the two 
transcripts. IFN-y treatment lead to an increase in the 2.6 kb transcript specific for 
FcyRIIa but only a very small increase in the 1.5 kb transcript (FcyRIIa or FcyRIIb). 
Treatment with dbcAMP however leads to a dramatic rise in the levels of both the 2.6 kb 
and 1,5 kb transcripts within 6 hours and these remained substantially elevated even 48 
hrs after treatment. Equal levels of 18S and 28S ribosomal RNA confirmed equal loading 
of total RNA (Figure 4.1 - bottom panel).
RT-PCR was used to determine the nature of the transcripts induced after IFN-y or 
dbcAMP differentiation. cDNA was generated using oligo dT primers and AMV reverse 
transcriptase (section 2.5.8). For PGR, a single forward primer, crossreactive for both 
FcyRIIa and FcyRIIb was used in conjunction with reverse primers that were designed to 
be specific for either FcyRIIa or FcyRIIb (see Table 2.2). For FcyRIIa, these primers were
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designed to generate a 719 bp product. For FcyRIIb, the reverse primer was designed that 
was specific for FcyRIIb and which lay downstream of a splice site. Thus, the primers 
flank a splice site which gives rise to the splice variants FcyRIIb 1 or FcyRIIb2, which has 
a shorter C-terminal domain. Thus, the RT-PCR product for FcyRJIbl would be 289 bp 
in length whereas that for FcyRIIb2 would be 232 bp in length (Figure 4.2). To quantify 
relative changes in the expression of specific FcyRII transcripts by RT-PCR, it was 
necessary to optimize the PCR conditions and cycle number to ensure a lineai' 
relationship existed between the amount cDNA template added to the PCR reaction and 
the amount of PCR product produced. As linearity between template and product was 
only maintained at low cycle numbers, it was necessary to Southern blot PCR products 
and hybridise blots with a crossreactive ^^P labelled FcyRII cDNA probe (section
2.5.8.1). The bands could then be quantified by comparing the relative hybridisation 
intensity between samples, as measured by quantitative phosphorimaging.
Products for both FcyRIIa, at around 700 bp, and FcyRIIb at around 300 bp, were 
detectable in untreated U937 cells (Figure 4.3). Differentiation with IFN-y for 6 and 12 
hours induced no significant change in expression of either FcyRIIa or FcyRIIb. 
Differentiation with dbcAMP however induced a massive upregulation of both FcyRIIa 
and FcyRIIb. Thus, levels of the FcyRIIa PCR product were increased 10 fold 24 hours 
after dbcAMP addition and 20 fold after 48 hours. For FcyRIIb, levels of the PCR 
product was increased 20 fold after 24 hours and over 50 fold at 48 hours (Figure 4.3).
These PCR products were positively identified as fragments of FcyRIIa and FcyRIIb in 
two ways. Firstly, oligonucleotide primers were designed that lay internal to the 
amplified fragment and were specific for either FcyRIIa or FcyRIIb (Table 2.2). These 
were ^^P end labeled and hybridised to Southern blots of PCR products (data not shown). 
The FcyRIIa specific probe hybridised only to the 700 bp fr'agment. The FcyRIIb 
specific probe hybridised only to the 300 bp fragment. Secondly, both PCR fragments 
were subcloned into the pGEMeasyT plasmid (Promega) and sequenced. Sequence 
analysis positively identified the 700 bp product as the expected fragment of FcyRIIa 
cDNA. The 300 bp fragment was identified as a fragment of FcyRIIb 1 cDNA
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As FcyRIIa and FcyRIIb have almost identical extracellular domains (section 1.1.3.2) 
(Brooks et aL, 1989), all mAbs available for fluorescent labeling of cells, with the 
exception of IV3, crossreact with both isoforms. The mAh IV3 (Medarex) however has 
been reported to only recognise FcyRIIa (Maresco et aL, 1999), FACS analysis (section
2.2.2.1) was carried out using mAb IV3 to determine whether FcyRIIa surface expression 
was upregulated by dbcAMP differentiation in response to the observed increase in 
mRNA expression (Figure 4.4A). In agreement with Northern and RT-PCR data, cell 
surface expression of FcyRIIa was upregulated by differentiation with dbcAMP for 48 
hours (Figure 4.4A.). No change in cell surface expression of FcyRIIa was observed 
following IFN-y treatment. Two additional antibodies, KB61 (Pulford et aL, 1986, 
Greenman et aL, 1991) and AT 10, recognise both FcyRIIa and FcyRIIb. FACS analysis 
with either antibody revealed an identical pattern (Figure 4.4B and data not shown).
In addition, Western blot analysis was performed to identify FcyRIIb in cell lysates. The 
mAh clone IIAD2 (a gift from Professor Jurgen Frey, University of Bielefeld, Germany) 
recognises the intracellular tail of human FcyRIIb and shows no crossreactivity with 
FcyRIIa (Weinrich et aL, 1996). Western blots were prepared using cell lysates from 
untreated U937 cells or cells differentiated with either IFN-y (24 hours) or dbcAMP (48 
hours). Cell lysate from the human EDR B-cell line, known to express FcyRIIb, was 
included on blots as a positive control. Probing blots with IIAD2 revealed a band of the 
correct molecular size for FcyRIIb in all U937 cell lysates. This FcyRIIb immunoreactive 
band was specifically upregulated by dbcAMP (Figure 4.5 A). Levels of FcyRIIb detected 
in lysates of cells differentiated for 48 hours with dbcAMP were comparable to levels 
seen in the EDR B-cell line positive control.
To test whether FcyRIIb was expressed at the cell surface in either IFN-y or dbcAMP 
cells, total surface FcyRII was immune precipitated. To do this, intact cells were labeled 
with the pan-FcyRII mAh, KB61, followed by extensive washing to remove unbound 
antibody. Following cell lysis, KB61 bound FcyRII was immune precipitated and 
precipitates were subjected to Western blotting with mAh IIAD2. Figure 4.5B reveals 
that FcyRIIb is expressed at the cell surface only in dbcAMP differentiated cells. The 
bands marked IgG in Figure 4.5B represent the heavy and light chain of mAh KB61 which
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are detected by the secondary anti-mouse:HRP antibody. The increased intensity of 
these bands in the dbcAMP precipitation is due to the increased expression of FcyRII 
(and thus binding of KB61) in these cells. In IFN-y primed cells, although IIAD2 
recognised a band of the correct molecular size for FcyRIIb in cell lysates (Figure 4.5A), 
the immune precipitation experiment performed here failed to demonstrate FcyRIIb at the 
cell surface as IIAD2 did not recognise a band in KB61 immune precipitates. This means 
either IIAD2 crossreacts non-specifically with other proteins in cell lysates or that IFN-y 
cells express low levels of non-surface expressed FcyRIIb.
4.2.2. FcyRII transiently recruits SHIP following receptor aggregation
In B-cells and Mast cells, FcyRIIb plays a critical negative signalling role. In these cells, 
FcyRIIb inhibits sustained PLCy activation and prolonged InsP] production by recruiting 
the 5’inositol phosphatase, SHIP (Bolland et aL, 1998, Scharenberg et aL, 1998) (section 
1.2.8.9). Having identified FcyRIIb on the surface of dbcAMP differentiated cells, its role 
in regulating immune complex mediated signalling in these cells was investigated. In this 
regard, the potential for FcyRIIb to recruit SHIP was examined.
FcyRII was aggregated over a timecourse using mAb KB61 and goat anti-mouse IgG (Fab 
specific) as described in section 2.3.1.1. Following aggregation, cell lysates were prepared 
and FcyRII precipitated with immobilized goat anti-mouse IgG (Fc specific) (section
2.3.4.2.). By using crosslinldng antibodies (Fab specific) and precipitating antibodies (Fc 
specific) with different specificities for mouse IgG, steric problems can be avoided. 
Immune precipitations were subjected to Western blotting with anti-phosphotyrosine 
mAbs (clone 4G10) and anti-SHIP polyclonal antibodies (Figure 4.6A). Alternatively, 
immune precipitates were subjected to in vitro inositol phosphatase assays (section 
2.4.2) (Figui'e 4.6B). Following receptor aggregation, a number of tyrosine 
phosphoryiated proteins appear in the FcyRII immune precipitates including a I45kDa 
protein (Figui’e 4.6A-top panel). Probing a parallel blot with anti-SHIP polyclonal 
antibodies reveals the transient association of p i45 SHIP with the receptor, appearing 
within 30 seconds after receptor aggregation (Figure 4.6A-bottom panel). SHIP 
immunoreactivity is no longer detectable 15 minutes after receptor aggregation. The
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presence of SHIP in FcyRII precipitates is confirmed by a transient increase in inositol 
phosphatase activity associated with the receptor. This activity followed a similar time 
course to the appearance of SHIP on Western blots (Figure 4.6B). SHIP could not be 
detected, either by Western blot, or by inositol phosphatase assay in FcyRII immune 
precipitates following receptor aggregation in IFN-y treated cells (data not shown). As 
IFN-y treated cells express no cell surface FcyRIIb (Figui’e 4.5B) this data implies that 
SHIP is recruited by FcyRIIb.
4.2.3. FcyRII aggregation results in the transient association of SHIP with 
RasGAP and She
As well as inhibiting PLCy and calcium influx, FcyRIIb has been reported to block 
activation of Ras by recruiting RasGAP to SHIP via the adapter protein p62 Dok (Tamir 
et al., 2000). To determine if such a mechanism exists in dbcAMP differentiated U937 
cells, SHIP was immune precipitated following a timecoui’se of FcyRII aggregation. 
Following SDS-PAGE, these immune precipitates were subjected to Western blotting and 
probed for the presence of RasGAP. Figure 4.7 demonstrates that after aggregation of 
FcyRII, RasGAP appears in the SHIP immune precipitates, suggesting that RasGAP is 
recruited to SHIP. The adapter protein. She, was also seen to transiently associate with 
SHIP in response to FcyRII aggregation (Figure 4.7). This SHIP-Shc interaction has 
recently been implicated in mediating the correct phosphorylation of She (Ingham et al., 
1999).
As SHIP cannot concomitantly bind to She and FcyRIIb (Tridandapani et ah, 1999), one 
possibility was that expression of FcyRIIb might interfere with the correct 
phosphorylation of She and, thus, disrupt She dependent signalling. To test this. She was 
immune precipitated following FcyRII aggregation from IFN-y and dbcAMP treated U937 
cells and immune precipitates western blotted for the presence of associated 
phosphotyrosine containing proteins. Figure 4.8 demonstrates that the She complexes 
formed in response to FcyRII aggregation appear identical regardless of the expression of 
FcyRIIb. The composition and role of these She complexes is discussed in more detail in 
Chapter 5.
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4.2.4. dbcAMP differentiated U937 cells show enhanced FcyRII responses 
when compared to IFN-y primed cells
Differentiation with dbcAMP upregulates cell surface expression of both FcyRIIa and 
FcyRIIb. Conversely, IFN-y induces little or no change in FcyRII expression and in these 
cells only FcyRIIa is expressed at the cell surface. To test whether this upregulation of 
FcyRII expression was accompanied by enhanced signalling, a number of key signalling 
events activated by FcyRII were compared between IFN-y and dbcAMP treated U937 
cells.
FcyRII was aggregated for 2 minutes with mAh KB61, under identical conditions on both 
IFN-y and dbcAMP differentiated cells. Analysis of cell lysates by Western blot with 
anti-phosphotyrosine antibodies (section 2.3.6.1) demonstrates that dbcAMP 
differentiated cells show substantially enhanced phosphotyrosine responses when 
compared to IFN-y primed cells (Figure 4.9A). As SHIP was found to transiently 
associate with RasGAP following FcyRII aggregation, FcyRII induced Ras activation was 
also examined in both IFN-y and dbcAMP differentiated cells. Figui’e 4.9B clearly shows 
that dbcAMP cells show enhanced FcyRII mediated Ras activation. As PKB has been 
reported as a target for FcyRIIb mediated inhibition (Aman et aL, 1998, Jacob et a l,  1999) 
, the ability of FcyRII to couple to PKB was also examined. Activated PKB can be 
detected in cell lysates on Western blots using antibodies which recognise PKB only 
when it is phosphoryiated on Ser473 (section 2.3.6.3.). Cell lysates were prepared as 
described above for the phosphotyrosine analysis. Intriguingiy, levels of phospho-PKB 
(Ser473) following FcyRII aggregation were found to be higher in IFN-y than dbcAMP 
differentiated cells (Figui’e 4.90). No phospho-PKB immunoreactivity could be detected 
in resting cells.
Previous work from the laboratory has also demonstrated that, following differentiation 
with dbcAMP, aggregation of FcyRII with mAbs induces a higher proportion of cells to 
exhibit calcium oscillations than in cells primed with IFN-y ((Melendez et aL, 1998a). 
Taken together, these data demonstrate that multiple aspects of FcyRII signalling are
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enhanced by differentiation with dbcAMP, likely reflecting the increased expression of 
FcyRII on these cells. Interestingly, the Ras responses are enhanced despite expression 
o^/FcyRIIb and the apparent involvement of the Ras inhibitory enzyme, RasGAP. Only 
PKB was found to be decreased in correlation with FcyRIIb expression, identifying this 
pathway as a possible target for a SHIP mediated inhibitory signal. These data imply 
that induced FcyRIIb expression does not abrogate FcyRIIa induced signal transduction 
but rather modulates the signal generated.
4.2.5. FcyRIIb modulation of FcyRIIa signalling
To determine the role of FcyRIIb in dbcAMP treated cells, a system was developed to 
differentially aggregate FcyRII subtypes with mAbs. Here, Fab fragments of mAb IV3, 
along with F(ab’)2 fragments of goat anti-mouse IgG were used to specifically aggregate 
FcyRIIa. Alternatively, mAh KB61 was used with with Fab^ fragments of goat anti­
mouse IgG to co-aggregate FcyRIIa and FcyRIIb. By using F(ab’)2 fragments, non­
specific recruitment of Fc receptors thi'ough Fc interactions with crosslinking antibodies 
can be avoided.
Using this system of differential aggiegation, the ability of FcyRIIa alone or FcyRIIa and 
FcyRIIb together to activate Ras was assessed. Receptors were aggregated for either 1 
minute or 3 minutes and Ras activity measured as described in section 2.3.7. As well as 
assaying Ras activity, the levels of tyrosine phosphorylation induced in cell lysates was 
determined by Western blot (section 2.3.6.1) to control for differences in the efficiency of 
each mAh to aggregate receptors. Figure 4.10 indicates that both IV3 and KB61 induce 
identical levels of Ras activation following receptor aggregation at both 1 minute and 3 
minute timepoints (Figure 4.10 - top panel). A comparison of the tyrosine 
phosphoiylation levels induced by each antibody however indicates that KB61 induces a 
substantially higher level of tyrosine phosphorylation than IV3 (Figure 4.10 - bottom 
panel).
Protein kinase B, another target for FcyRIIb mediated inhibitory signalling was also 
assayed following differential crosslinking (Figure 4.11). FcyRIIa was aggregated alone
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(using mAb IV3) or with FcyRIIb (using mAb KB61) over a timecourse and cell lysates 
prepared. Activated PKB can be detected in cell lysates using antibodies which recognise 
phospho Ser473“PKB (phospho-PKB) (section 2.3.6.3.). Here, slightly higher levels of 
phospho-PKB were detectable when FcyRIIa was aggregated alone with mAh IV3 (Figure 
4.11 - top panel). Once more, comparison of the levels o f tyrosine phosphorylation 
induced by mAb IV3 aggregation were significantly lower than those induced by KB61 
(Figure 4.11 - bottom panel). Thus, as for Ras activation, aggregation of FcyRIIa with 
mAh IV3 induces comparable levels of phospho-PKB to mAh KB61, despite inducing 
significantly lower levels of phosphotyrosine.
4.3. Discussion
4.3.1. Expression of FcyRIIb and SHIP recruitment in dbcAMP differentiated 
U937 cells
The data presented here show that differentiation of the human monocyte cell line, U937, 
with dbcAMP induces the expression of the inhibitory low affinity IgG receptor FcyRIIb. 
RT-PCR analysis indicates that the FcyRIIb splice variant expressed is FcyRIIb 1 (see 
section 1.1.3.2). Hybridisation with specific oligonucleotide probes and sequence 
analysis further confirmed the identity of this FcyRIIb PCR product. To assess whether 
upregulation of the mRNA for FcyRIIb was reflected at the protein level. Western blot 
analysis with the FcyRIIb specific mAb, IIAD2 was employed (Weinrich et al., 1996). 
This confirmed that FcyRIIb was surface expressed solely in dbcAMP treated U937 cells 
and further that expression levels were comparable to those seen in the EDR B-cell line. 
Taken together, these data also rule out the possibility that this induced expression might 
result from crossreactivity with the third FcyRII gene FcyRIIc (see section 1.1.3.2). 
Concomitant with this induction of FcyRIIb, FcyRIIa was also upregulated in dbcAMP 
differentiated cells as assessed by RT-PCR, Northern blot and FACS analysis.
The role of FcyRIIb 1 has been extensively studied in B-cells and mast cells (section 
1.2.8). Here, co-ligation of FcyRIIb with the BCR in B-cells or FceRI in mast cells results
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in inhibition of prolonged PLC activation, InsPg production and calcium influx (Ono et aL, 
1996, Bolland et aL, 1998, Scharenberg & Kinet, 1996). The finding that FcyRIIb 
expression was induced in dbcAMP differentiated U937 cells was entirely unexpected as 
previous work from our laboratoiy has demonstrated that in these cells, immune complex 
stimulation results in activation of PLCyl and prolonged calcium transients (Davis et aL, 
1995a, Melendez c/fl/., 1999b, Melendez et aL, 1998a). Initially, therefore studies were 
undertaken to assess whether this FcyRIIb expressed in dbcAMP differentiated cells was 
capable of recmiting the inhibitoiy apparatus so well characterised in B-cells and mast 
cells.
In murine B-cells and mast cells, the inhibitory properties of FcyRIIb centre round the 
recruitment of the 5’inositol phosphatase, SHIP, to the phosphoryiated ITIM within the 
receptors cytoplasmic tail (Ono et aL, 1996, Fong et aL, 1996, Dambrosio et aL, 1996a). 
Similarly, I demonstrate that SHIP transiently associates with FcyRII, as assessed by 
both Western blot and associated 5’inositol phosphatase activity. Conversely, in U937 
cells primed with IFN-y (which only express FcyRIIa) no SHIP or 5’ inositol 
phosphatase activity could be detected in FcyRII precipitates. Taken together these data 
support FcyRIIb mediated recruitment of SHIP in dbcAMP U937 cells.
It is important to point out that previous work from our laboratory (Chapter 3) and 
others has suggested that the SFIIP pathway might be activated by FcyRs in the absence 
of an ITIM bearing receptor. Thus FcyRI and FcyRII aggregation induce the tyrosine 
phosphorylation of SHIP and its association with the adapter protein. She, in IFN-y 
primed U937 cells (Cameron & Allen, 1999), untreated U937 and THP-1 cells (Maresco 
et aL, 1999). Recent data from B-lymphocytes however demonstrates that BCR induced 
interactions between SHIP and She, rather than being inhibitory, play a cmcial role in 
directing the phosphorylation of She (Ingham et aL, 1999). Using SHIP deficient DT40 
chicken B-cells, Ingham et al demonstrate that, in the absence of SHIP, the BCR fails to 
induce significant She phosphorylation. In the light of this data, it seems likely that our 
observed interactions between SHIP and She induced by FcyRs in IFN-y primed U937 
cells ai’e independent of the inhibitory actions of SHIP and are more likely to be 
important in directing the correct phosphorylation of She (see Chapter 3).
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In dbcAMP differentiated U937 cells, FcyRIIb appears to recruit SHIP to the immune 
complex. I hypothesised that this recruitment might interfere with SHIP mediated She 
phosphorylation, consistent with previous reports that SHIP cannot concomitantly bind 
to FcyRIIb and She (Tridandapani et ah, 1999). To test this theory. She complexes 
induced by FcyRIIa alone in IFN-y treated cells and those induced by co-aggregation of 
FcyRIIa and FcyRIIb in dbcAMP differentiated cells were compared. Following FcyRII 
aggi’egation in either IFN-y or dbcAMP treated cells, She immune precipitates were 
probed for the presence of tyrosine phosphoryiated proteins, and also for SHIP. The 
equal levels of SHIP detected in association with She, and the near identical pattern of 
tyrosine phosphoryiated proteins associated with She (discussed further in Chapter 5) 
under these different conditions of differentiation suggests that this is not the case. This 
data implies two distinct roles for SHIP in these cells.
In summary, differentiation with dbcAMP induces the expression of FcyRIIb, which 
when CO-aggregated with FcyRIIa, transiently recruits SHIP. This recruitment of SHIP is 
specific to dbcAMP cells and appears independent of the previously reported, ITIM  
independent, SHIP-Shc interactions induced by Fey receptors (Cameron & Allen, 1999).
4.3.2. FcyRIIb modulation of Immune complex mediated signalling in 
dbcAMP differentiated U937 cells
Differentiation of U937 cells with dbcAMP both upregulates the ITAM bearing FcyRIIa 
and induces expression of the ITIM bearing FcyRIIb. Further, FcyRI expression in these 
dbcAMP differentiated cells is downregulated (Chapter 6 - Figure 6.5) and FcyRIII 
expression is not detectable (data not shown). Thus, the outcome of this differentiation is 
a U937 cell in which immune complex induced signalling is mediated primarily by FcyRII 
isoforms. Use of mAbs to aggregate specifically FcyRII in either dbcAMP differentiated 
cells or IFN-y primed cells indicates that upregulation of FcyRII expression by dbcAMP 
is accompanied by enhanced coupling of FcyRII to tyrosine phosphorylation events and 
Ras activation. In contrast, coupling of FcyRII to PKB activation was found to be more 
robust in IFN-y primed cells than in dbcAMP differentiated cells..
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DbcAMP differentiation of U937 cells results in upregulation of FcyRIIa and the 
appearance of FcyRIIb at the cell surface. The enhanced responses to FcyRII aggregation 
in these cells is likely to result from enhanced FcyRIIa expression. However, in other cell 
systems FcyRIIb has been shown to act as an inhibitory receptor. Therefore, the data 
presented here on Ras activation,together with the previous data on PLCyl activation and 
calcium transients (Davis et aL, 1995a, Melendez et aL, 1998a), raise questions concerning 
the role of FcyRIIb in the modulation of immune complex mediated signalling pathways in 
U937 cells. One possibility is that FcyRIIb is required to set a threshold or ceiling for 
FcyRIIa signalling. Such a mechanism may not be required at lower levels o f FcyRIIa 
expression, or under circumstances where other Fey receptors play a dominant role in 
immune complex signalling, such as FcyRI in IFN-y treated cells. Another possibility is 
that FcyRIIb, when co-expressed with FcyRIIa, does not play an inliibltory role, but 
rather forms part of an activating complex. As no data exist for the effect of FcyRIIb on 
FcyRIIa signalling, attempts were made to develop a system to differentially aggregate 
FcyRIIa and FcyRIIb with mAbs.
In murine B-cells, a number of pathways have been identified as targets for FcyRIIb 
mediated inhibition. These include the PLCy/InsPa/calcium pathway, the Ras/MAP 
kinase pathway and PKB (section 1.2.8). Two approaches were taken to assess the 
effects of FcyRIIb expression on signalling.
Firstly, the signalling profiles activated by FcyRII aggregation in IFN-y primed cells and 
dbcAMP differentiated cells were compared. Here, IFN-y primed cells express solely 
FcyRIIa at the cell surface, while dbcAMP differentiated cells express both FcyRIIa and 
FcyRIIb. Data here indicate that both tyrosine phosphorylation and Ras activation are 
enhanced in dbcAMP differentiated cells. As FcyRIIa is upregulated in dbcAMP 
differentiated cells, these enhanced responses are likely a result of increased expression of 
the activating receptor. PKB, conversely, was found to be phosphoryiated more robustly 
following FcyRII aggregation in IFN-y treated cells than in the dbcAMP differentiated 
cells. This identifies PKB, which is inhibited by FcyRIIb in B-cells (Jacob et aL, 1999, 
Aman et aL, 1998), as a potential target for FcyRIIb mediated inhibition in U937 cells.
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Secondly, to avoid complications associated with differentiation, mAbs were used in an 
effort to differentially aggregate FcyRIIa and FcyRlIb within the same, dbcAMP 
differentiated ceils. Here, using a mAh which recognises only FcyRIIa (IV3) or a mAh 
which recognises all FcyRII isoforms (ICB61) attempts were made to assess the effects of 
FcyRIIb co-aggregation on Ras and PKB activation. The experimental conditions used 
were designed to maximally aggregate surface FcyRII. Clearly, this is a non-physiological 
stimulus as, in vivo, immune complexes are variable both in size and Ig composition. 
However, the wide variety of receptors expressed on myeloid cells, with their varying 
affinities for different IgG subclasses (IgGl-4) and Ig classes (ie. IgA and IgE) results in 
highly variable ratios of receptor recruitment to any given immune complex. It is 
therefore necessary to use mAbs to trigger activation in a precise manner, to begin to 
understand the relative contributions of specific receptors.
Data generated using this system of differential crosslinldng has indicated some 
differences in the responses generated by the FcyRIIa specific mAb, IV3, and the pan- 
anti-FcyRII mAb KB61. Aggregation of FcyRII with either mAb results in equal levels of 
both PKB and Ras activation. However, KB61 was found to couple to consistently 
higher phosphotyrosine responses. Thus, the relative activation of Ras or PKB 
responses to phosphotyrosine responses is lower when aggi'egating both receptors 
together with mAh KB61. This is consistent with FcyRIIb playing a role tempering 
FcyRIIa responses. These data might also imply that co-aggregation of FcyRIIa with 
FcyRIIb results in enhanced coupling to tyrosine kinase activation.
Intriguingly, though FcyRIIa and FcyRIIb show more than 95% homology in their 
extracellular domains, their affinities for different IgG subtypes differ (section 1.1.3.4) 
(van de Winkel & Capel, 1993). This raises the possibility that the cellular response to 
immune complexes will depend dramatically on the proportions of different IgG subtypes 
within any given immune complex. For example, immune complexes with high levels of 
IgG2 might be expected to preferentially aggregate FcyRIIa whereas IgG4 complexes will 
aggregate a higher proportion of FcyRIIb. Such a system would allow the cell to integrate 
its response according to the composition of a given immune complex, and thus react
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appropriately. As different IgG isotypes are associated with different types of immune 
response, such a system could have broad implications in terms of immune regulation.
As well as modulating Fey receptor signal transduction, a number of other potential roles 
for FcyRIIb exist. It is quite possible, for example, that FcyRIIb might exert its inhibitory 
actions on other Fc receptors such as FceRI or FcaRI, which are also present in U937 
cells. Further, FcyRII has been shown to bind C-reactive protein (CRP) providing 
another potential target for modulation (Bharadwaj et aL, 1999). In addition to 
modulating signal transduction, FcyRIIb might play a role in the targeting of immune 
complexes to specific subcellular compartments. In B-cells, for example, FcyRIIb 1 has 
been reported to block BCR bound antigen presentation by inhibiting endocytosis 
(Amigorena et aL, 1992a, Minskoff, Matter & Mellman, 1998). A potential role for 
U937 expressed FcyRIIb in the regulation of immune complex bound antigen presentation 
has not been ruled out.
In summary, the modulating effects of FcyRIIb on macrophage signal transduction 
appears distinct from its role in B-cells, reflecting the differing physiological roles that 
FcyRs play in these different cell types. Thus, in B-cells, FcyRIIb acts as an inhibitory 
feedback mechanism to switch B-cells ‘o ff. In myeloid cells the role of FcyRIIb appears 
more flexible, with the nature of the signal transduced likely to depend more on the ratio 
of activating and inhibitory receptors aggregated. The overall upregulation of FcyRII in 
these cells is likely to reflect an enhanced role for dbcAMP differentiated macrophage lilce 
cells in the clearance of immune complexes. This is supported by the fact that FcyRII (as 
opposed to FcyRI) is a low affinity receptor which only recognises pre-formed immune 
complexes. By expressing different isoforms of FcyRII with differing affinities for IgG 
subtypes and differing signalling motifs within their cytoplasmic tails, cells will be able to 
respond according to the composition of the specific immune complexes they encounter. 
In conclusion, the data presented here indicate a novel role for human FcyRIIb in the 
modulation of macrophage activation.
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Figure 4.1 Northern blot analysis of FcyRII expression,
U937 cells were treated with either IFN-7 or dbcAMP and harvested at the 
times shown (hours). Total RNA (20 gg/sample) was subjected to Northern 
blot analysis. Blots were hybridised with ^^P-labeled cDNA probe specific 
for FcyRII. Bands were visualised by autoradiography (top panel). The 
bottom panel shows equal loading of total RNA as assessed by ethidium 
bromide staining of the RNA gel prior to blotting. The bands indicated are the 
18S and 28S ribosomal subunits as indicated.
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Figure 4.2 Plan for RT-PCR amplification of FcyRIIa and FcyRIIb 
cDNAs.
A single forward primer crossreactive for both FcyRIIa and FcyRIIb (FOR) 
was designed in conjunction with specific reverse primers for either FcyRIIa 
(REV2A) or FcyRIIb (REVB). The FcyRIIa primers predict a PCR product of 
719 bp. For FcyRIIb, the primers flank a splice site in the FcyRIIb sequence 
(marked i )  such that FcyRIIb 1 would give rise to a 289 bp fragment while 
FcyRlIb2 would give rise to a 232 bp fragment.
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Figure 4.3 Semi quantitative RT-PCR analysis of Fc^RIIa and FcyRIIb 
expression.
U937 cells were treated with either IFN-y or dbcAMP and harvested at the 
times shown (hours). Following preparation of cDNA by reverse 
transcription, PCR was used to amplify either FcyRIIa and FcyRIIb or 
cyclophilin as described in the materials and methods (section 2.4.8). PCR 
products were visualised by Southern blot hybridisation with a crossreactive 
cDNA probe for FcyRII (top panel). Cyclophilin was used as an internal 
standard to ensure equal loading of cDNA, as indicated. Bands were visualised 
by autoradiography.
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Figure 4.4 FACS analysis of FcyRIIa and total FcyRII surface 
expression.
Untreated U937 cells and cells treated with either IFN-y (24 hours) or 
dbcAMP (48 hours) were labeled with either the FcyRIIa specific mAb IV3 
(top panel), or total FcyRII specific mAb KB61 (bottom panel). Human IgG 
(3jaM) was also added to prevent non-specific binding of antibodies to Fc 
receptors. A goat anti-mouse IgGiFITC was used as a secondary antibody 
and cells were subjected to FACS analysis. Control cells with no primary 
antibody were also included (indicated by *).
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Figure 4.5 Western blot analysis of FcyRIIb expression.
(A) Cell lysates (20 pg/sample) fi'om untreated U937 cells (control) and cells 
treated with either IFN-y (24 hours) or dbcAMP (48 hours) were subjected 
SDS-PAGE and Western blot analysis with the FcyRIIb specific mAb IIAD2. 
Cell lysate (20 pg) from the EDR human B-cell line was also included as a 
positive control. An anti-mouse:HRP was used as a secondary antibody and 
bands were visualised using the ECL system (Amersham).
(B) Surface expressed FcyRII was immune precipitated using the pan-FcyRII 
mAb KB61 as described in the results section. Immune precipitates were 
subjected to Western blot analysis with the FcyRIIb specific mAb IIAD2 as 
described for (A). The heavy and light chains of the precipitating antibody 
KB61, which are detected by the secondary HRP conjugate, are indicate by 
IgG.
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Figure 4.6. Western blot analysis of FcyRII immune precipitates.
Cells were treated with dbcAMP for 48 hours prior to the experiment. FcyRII 
was aggregated for the times indicated. Cells where no crosslinking antibody 
was added were included as a control. FcyRII was precipitated via KB61 
using goat anti-mouse (Fc specific) IgG conjugated agaiose. Immune 
precipitates were subjected either to Western blot analysis (A) or in vitro 
inositol phosphatase assays (B). For Western blot analysis (A), membranes 
were probed with either anti-phosphotyrosine mAb 4G10 (top panel) or goat 
polyclonal anti-SHIP antibodies (bottom panel). For inositol phosphatase 
assays (B) data aie the mean ± standard deviation (error bars) of triplicate 
measurements and are representative of thi'ee separate experiments.
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Figure 4.7 SHIP interacts with RasGAP and She following FcyRII 
aggregation.
Cells were treated with dbcAMP for 48 hours prior to the experiment. FcyRII 
was aggi'egated using mAb KB 61 and goat anti-mouse IgG for the times 
indicated (min). Cells where no crosslinking antibody was added were 
included as a control. Following preparation of cell lysates, SHIP was immune 
precipitated with polyclonal goat anti-SHIP antibodies. Immune precipitates 
were subjected to Western blot analysis with anti-RasGAP mAbs (top panel), 
anti-She mAbs (middle panel) and goat anti-SHIP polyclonal antibodies 
(bottom panel).
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Figure 4.8 FcyRIIb expression does not effect the formation of She 
complexes.
U937 cells were treated with IFN-y or dbcAMP as indicated. FcyRII was 
aggregated for 2 minutes using mAb KB61 and goat anti-mouse IgG. Control 
cells were incubated with goat anti-mouse IgG alone. She was immune 
precipitated with rabbit polyclonal anti-Shc antibodies as previously 
described. Immune precipitates were analysed by Western blot with anti- 
phosphotyrosine mAb 4G10 (top panel), goat polyclonal anti-SHIP 
antibodies (middle panel) or anti-Shc mAb (bottom panel).
106
She IP: 
175 -  
83-  
62-
32 -
IFN-y dbcAMP
1 2 1 2
8 £
SHIP
♦- SHIP 
She
Chapter 4
Figure 4.9 dbcAMP differentiated cells show enhanced FcyRII induced 
signalling.
Ü937 cells were treated with dbcAMP for 48 hours prior to experiments. For 
(A) and (B) FcyRII was aggregated for 2 minutes using mAh KB61 and goat 
anti-mouse IgG. For (C) FcyRII was aggregated for 1 minute or 3 minutes as 
indicated. Control cells were incubated with goat anti-mouse IgG alone. (A) 
Cell lysates (20 |ig/sample) were subjected to Western blot analysis with anti- 
phosphotyrosine mAb 4G10. Numbers beneath blot indicate the relative 
intensity of phosphotyrosine in each lane as assessed by densitometry, with 
control arbitrarily set as 1. (B) Ras activity was assessed in cell lysates as 
described in section 2.3.7. Numbers beneath blot indicate the relative 
intensities of the Ras band as assessed by densitometry, with control 
arbitrarily set as 1. (C) PKB-Ser473 phosphorylation in cell lysates
(20|.ig/sample) was assessed by Western blot using polyclonal anti-phospho 
Ser473-PKB antibodies (top panel). Blots were reprobed with anti-PKB 
antibodies (bottom panel) to ensure comparable loading of cell lysates. 
Numbers beneath blot indicate the relative intensity of bands as assessed by 
densitometry, with control arbitrarily set as 1. These data are corrected for 
equal loading.
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Figure 4.10 Activation of Ras by FcyRIIa aggregation or FcyRIIa/FcyRIIb 
co-aggregation.
U937 cells were differentiated with dbcAMP for 48 hours. FcyRIIa was 
aggregated alone with inAb IV3 (as indicated) and goat anti-mouse IgG for 1 
minute or 3 minutes. Alternatively, FcyRIIa/FcyRIIb were co-aggregated with 
mAb KB61 (as indicated) and goat anti-mouse IgG for I minute or 3 minutes. 
Control cells were incubated with goat anti-mouse IgG alone. Ras activity was 
assessed in cell lysates (top panel) as described in section 2.3.7. Tyrosine 
phosphorylation of proteins in cell lysates was assessed by Western blotting 
with anti-phosphotyrosine mAb 4G10. Numbers beneath blots indicate the 
relative intensity of bands as assessed by densitometry with control arbitrarily 
set as 1. Data is normalised for equal loading.
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Figure 4.11 Activation of PKB by FcyRIIa aggregation or FcyRIIa/FcjRIlb 
co-aggregation.
U937 cells were differentiated with dbcAMP for 48 hours. FcyRIIa was 
aggregated alone with niAb IV3 (as indicated) and goat anti-mouse IgG for the 
times indicated. Alternatively, FcyRIIa/FcyRIIb were co-aggregated with mAb 
KB61 (as indicated) and goat anti-mouse IgG. Control cells were incubated 
with goat anti-mouse IgG alone. PKB phosphorylation in cell lysates 
(20|ig/sample) was assessed by Western blot using polyclonal anti- 
phosphoPKB (Ser473) antibodies (top panel) as described in section 2.3.6.3. 
Blots were reprobed with anti-PKB antibodies (middle panel) to ensure 
compaiable loading of cell lysates. Tyrosine phosphorylation of proteins in 
cell lysates was assessed by Western blotting with anti-phosphotyrosine mAb 
4G10. Numbers beneath blots indicate the relative intensity of bands as 
assessed by densitometry, with control arbitrarily set as 1. Data is normalised 
for equal loading.
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Chapter 5 
Differential coupling of FcyRI and FcyRII to adapter proteins, PLCyl, 
small G-proteins and the MAP kinase cascades
5.1. Introduction
Fey receptors (FcyR) play a critical role in the coordination of the immune response to 
antibody:antigen complexes by triggering the production of multiple cytokines, 
inflammatory mediators and cell surface molecules. The specific response to immune 
complexes depends on multiple factors including cell type, and differentiation state, and 
the Fey receptor subtypes involved. The signalling events which link FcyR engagement to 
the nucleus have not been well defined. It is clear, however, that activation of signalling 
pathways by FcyR as well as other immunoreceptors (including BCR, TCR and FceRI) 
involves the activation of Src and Syk family tyrosine kinases (Agarwal et al., 1993, 
Cambier, 1995). These kinases in turn phosphorylate multiple substrates essential for 
signal transduction (Liao et ah, 1992, Scholl et aU, 1992). Recently, progress has been 
made towards understanding the molecular mechanisms linking tyrosine kinase activation 
to specific effector pathways.
Among the many substrates of Src and Syk family tyrosine kinases are a number of 
adapter proteins which have no intrinsic activity. Rather, these adapter proteins contain 
multiple protein:protein and protein:lipid interaction domains. Studies of several of these 
adapter proteins have revealed their critical roles in coordinating specific biological 
responses. It appears that these adapter proteins act as complex molecular scaffolds, 
linking tyrosine kinase activation with specific effector pathways (Rudd, 1999, Myung et 
a l, 2000).
PLCy activation plays a central role linking Fc and antigen receptors to the generation of 
second messengers and the mobilisation of calcium (section 1.2.4) (Benidge, 1993, Tsien 
& Tsien, 1990, Putney, 1986). Following receptor engagement, PLCy is recruited to the
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plasma membrane where it catalyses the conversion of the membrane lipid, PtdIns(4,5)P2, 
into diacylglycerol (DAG) and InsPg. InsP3 in turn induces the release of calcium from 
intracellular stores, which is followed by store operated calcium influx through plasma 
membrane calcium channels (Hoth & Penner, 1992). This calcium mobilisation plays a 
role in the activation of a number of transcription factors (section 1.2,4.1) (Dolmetsch et 
ah, 1998, Hu et al., 1999, Li et a l, 1998). Further, the PLCy product DAG, along with 
calcium release, plays a key role in the activation of PKC isoforms (Nishizuka, 1992, 
Dekker & Parker, 1994). Recently, a number of adapter proteins have been identified, 
which linlc antigen receptors (the BCR and TCR) and FceRI to PLCy activation.
In the cases o f the TCR and FceRI, the adapter proteins, LAT, and SLP-76, are critical 
for PLCy activation (Finco et al,, 1998, Yablonski et al., 1998, Saitoh et al., 2000, Turner 
& Kinet, 1999). LAT is an integral membrane protein which contains multiple tyrosine 
residues within its cytoplasmic tail. Conversely, SLP-76 is a cytoplasmic adapter which 
bears a number of proteinrprotein interaction motifs, including an N-terminal acidic 
domain containing multiple tyrosine residues, a central pro line rich region (which interacts 
with SH3 domains) and a C-terminal SH2 domain for phosphotyrosine binding. 
Following aggregation LAT, which co-localises with activated receptors in lipid rafts, 
becomes rapidly tyrosine phosphorylated by Src and Syk family tyrosine kinases. 
Phosphorylated LAT recruits PLCy to the plasma membrane, which is necessary, but not 
sufficient for activation of PLCy (Zhang et a l, 1998). For activity, PLCy must be 
phosphorylated, not only by Syk family kinases, but also by Tec family kinases (Itk for 
the TCR, Btk for FceRI) (Scharenberg & Kinet, 1998). Thus, the adapter protein SLP- 
76, another Syk substrate, appears to link LAT and PLCy with Tec family kinases. SLP- 
76 can simultaneously interact with both LAT (via the adapter protein. Gads), and Tec 
family kinases. Further, SLP-76 can directly bind the SH3 domain of PLCy.
To complicate matters, SLP-76 and LAT, also play a critical role in linking the TCR and 
FceRI to the activation of Ras and Rac GTPases (Finco et al., 1998, Bubeck Wardenburg 
et al., 1998). Here, tyrosine kinase dependent activation of small GTPases appears to be 
governed by the recruitment of specific guanine nucleotide exchange factors (GEFs) to the 
plasma membrane. These GEFs promote the exchange of GDP for GTP bound to small
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G proteins and, thus, facilitate their activation (section 1.2.5.2). Recruitment of these 
exchange factors is facilitated by adapter protein scaffolds.
In the case o f Ras, activation appears to be governed by recruitment of the Ras GEF, Sos 
to the plasma membrane (Gale et al., 1993, Li et al., 1993). The critical adapter protein, 
Grb2, binds to Sos via its two SH3 domains. The single SH2 domain of Grb2 can bind to 
tyrosine phosphorylated LAT, thereby recmiting Sos to the plasma membrane where 
activation of Ras takes place (Kane et a l, 2000). It should be noted that the adapter 
proteins involved in the recruitment of Grb2:Sos differ according to receptors and cell 
types. Thus, in B-cells, which do not express LAT or SLP-76, the adapter protein She 
has been implicated in the recruitment of Grb2-Sos complexes to the BCR (Harmer & 
DeFranco, 1997).
The activation of Rac appears to follow a similar pattern to Ras. For the TCR and FceRI, 
the Rac GEF, Vav, is recruited to the membrane through SH3 domain interactions with 
the adapter protein, SLP-76. SLP-76 forms a poorly defined adapter protein complex, 
containing Grb2 or the related adapter, Gads, which binds to the membrane tethered LAT 
(Liu et al., 1999, Kane et al., 2000, Turner & Kinet, 1999).
Ras, Rac and Rho regulate a wide range of cellulai* processes from cytoskeletal 
reorganisation and endocytosis through to modulation of transcription. Many of the 
transcriptional responses initiated by these proteins are mediated thi'ough activation of 
the MAP kinases (MAPKs) (Genot & Cantrell, 2000, Aspenstrom, 1999, Su & Karin, 
1996).
The MAPKs are a growing family of serine-threonine protein kinases which are activated 
by a wide variety of extracellular stimuli (Garrington & Johnson, 1999, Su & Karin, 
1996). The MAPKs can be divided into a number of subgroups, including the 
extracellular regulated kinases (ERKs), c-Jun N-terminal or stress activated protein 
kinases (JNK/SAPK) and the p38 group of kinases. Among the substrates of these 
kinases are a wide variety of transcription factors and, thus, different activation patterns
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of the MAPKs (ERK, JNK, p38) are likely to lead to differential expression of genes 
(section 1.2.6).
ERK, p38 and JNK are activated by a many immunoreceptors, including the BCR, TCR, 
FceRI and FcyRs (Hashimoto et al., 1998, Turner & Kinet, 1999, Rose et al., 1997). 
However, the mechanisms and functional consequences of their activation varies greatly 
depending on the cell type and the receptors involved. The best understood pathway to 
MAPK activation is the Ras/Raf/MEK/ERK pathway. Here, activated Ras binds to and 
activates the serine/threonine kinase Raf-1. Raf-1 then phosphorylates and stimulates 
MEK which in turn activates ERK. Similar, but less well defined pathways exist for the 
JNK and p38 families of MAPK (Coso et al., 1995). For example, activated Rac binds 
to, and activates p21 activated kinase (PAK) which can initiate kinase cascades leading to 
the activation of p38 and JNK (Zhang et a l, 1995, Coso et al., 1995). It is clear, 
however, that regulation of the MAPK pathways is complex, with multiple distinct 
signalling events being integrated to give a specific response.
Previous work from our laboratory has demonstrated that FcyRl couples to a novel 
signalling pathway in IFN-y primed U937 cells. Here, FcyRl aggregation leads to the 
tyrosine kinase dependent activation of phospholipase D, sphingosine kinase and 
subsequent calcium mobilisation (Melendez et al., 1998b). Surprisingly, no PLCy activity 
can be detected. Conversely, aggregation of FcyRIl in the same cell type leads to a robust 
activation of PLCy and InsPs dependent calcium mobilisation (Melendez et al., 1998a). 
The mechanism responsible for this fundamental difference in signalling is not clear.
To investigate the mechanism governing PLCy activation in U937 cells, adapter proteins 
have been examined, which are known to be involved with PLCy activation in other cell 
types. Here, 1 demonstrate that SLP-76 forms distinct complexes in response to FcyRl 
and FcyRll activation, providing a potential mechanism for the differential activation of 
PLCy by the two receptors. Further, 1 demonstrate that SLP-76 differentially interacts 
with the adapters, Grb2 and She, which are implicated in the activation of Ras and Rac. 
Following on from these differences, the coupling of FcyRl and FcyRll to Ras, Rac and 
the downstream activation of the MAP kinase cascades is addressed.
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5.2. Results
5.2.1. Regulation of adapter protein complexes by FcyRl and FcyRll
Immune receptor activation of multiple signalling pathways, including the activation of 
PLCy, small GTPases, and MAPKs, involves the formation of adapter protein 
complexes. These adapter complexes are responsible for the subcellular localisation and 
activation of signalling molecules such as PLCy and small GTPases. Previous work in the 
laboratory (Melendez et al., 1998a) has demonstrated that FcyRl and FcyRll couple to 
distinct signalling pathways in IFN-y primed U937 cells. Thus, FcyRll couples to the 
activation of PLC-y, while FcyRl couples to PC-PLD activation. To elucidate the 
molecular mechanisms behind these differences, adapter protein complexes likely to be 
involved in Fey receptor signal transduction have been analysed.
5.2.1.1. SLP-76 and PLCyl associate with FcyRll following receptor aggregation
In FceRI and T-cell antigen receptor signalling, the adapter protein SLP-76 plays a central 
role in coupling receptor aggregation to PLCy activation. As SLP-76 is also expressed in 
monocytes and macrophages, this adapter protein is likely to play a role in Fey receptor 
mediated PLCy activation. Here, a role for SLP-76 in signal transduction by either FcyRl 
or FcyRll was investigated.
IFN-y primed U937 cells were activated by aggregation of either FcyRl or FcyRll with 
monoclonal antibodies (section 2.3.1.2) for 2 minutes. Following the preparation of cell 
lysates, SLP-76 was immune precipitated and analysed by Western blot (Figure 5.1). 
Figure 5.1 A demonstrates that aggregation of either FcyRl or FcyRll induces high levels of 
protein tyrosine phosphorylation in total cell lysates. Analysis of SLP-76 immune 
precipitates with anti-phosphotyrosine antibodies indicated that SLP-76 becomes 
phosphorylated following aggregation of either FcyRl or FcyRll (Figure 5. IB). However, 
the appearance of a broad phosphotyrosine band at around 40 kDa in SLP-76 precipitates 
following specific aggregation of FcyRll was intriguing. This band did not appear in SLP- 
76 immune precipitates following specific aggregation of FcyRl in the same cells. As
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FcyRll itself runs as a broad band at around 40kDa, this suggested that SLP-76 may 
interact directly with the receptor. As Western blotting antibodies against FcyRIla are 
not available, it was not possible to detect FcyRll directly. Instead, FcyRll immune 
complexes were immune precipitated via the crosslinking goat anti-mouse antibody, 
following FcyRll activation. These complexes contain phosphorylated FcyRIla and allow 
direct comparison with the 40 kDa band present in SLP-76 immune precipitates. Figure 
5.IB clearly demonstrates exact co-migration of phosphorylated FcyRIla in immune 
complex precipitates with the phosphorylated band found in SLP-76 immune 
precipitates. Further to this, reprobing the FcyRIla precipitates with SLP-76 antibodies, 
reveals the presence of SLP-76 in FcyRll immune complexes (Figure 5.1C). Western 
blots of the SLP-76 immune precipitates from control cells, and following aggregation of 
either FcyRl or FcyRll were reprobed for SLP-76, to ensure equal loading of immune 
precipitates (Figure 5.1C). To examine proteins associating with SLP-76 after receptor 
aggregation, SLP-76 immune precipitate blots were also reprobed for y-chain, PLCyl and 
Grb2 (Figure 5.1C). The y-chain was readily detectable in cell lysates but no y-chain was 
detectable in SLP-76 precipitates (Figure 5.1C). This indicates that the y-chain does not 
associate with SLP-76 following aggregation of either FcyRl or FcyRll in these cells.
SLP-76 can interact with the SH3 domains of effector proteins, such as PLCyl, via its 
central proline rich region (Kane et a l, 2000), Reprobing SLP-76 immune precipitates 
with anti-PLCyl antibodies reveals that PLCyl can be detected in immune precipitates 
even in unstimulated cells, indicating a constitutive interaction between PLCyl and SLP- 
76. This constitutive interaction remains unaffected by FcyRll aggregation (Figure 5.1C). 
Interestingly, aggregation of FcyRl appears to decrease the association of SLP-76 with 
PLCyl. This data is consistent with FcyRl failing to couple to PLCyl activation.
As the membrane associated adapter protein, LAT, has been shown in other systems to 
anchor SLP-76 and PLCyl at the plasma membrane to allow activation, blots were also 
probed with polyclonal anti-LAT antibodies. LAT was readily detectable in cell lysates 
but not in SLP-76 immune precipitates or FcyRll immune complexes (data not shown).
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Taken together, these data imply that FcyRll recruits both SLP-76 and PLCyl to immune 
complexes at the plasma membrane. The fact that SLP-76 and PLCyl are associated even 
in resting cells suggests that SLP-76 and PLCyl may be recruited as a preformed complex. 
Conversely, SLP-76 does not appear to associate with the y-chain signalling subunit of 
FcyRl. Further, FcyRl appears to decrease the association of SLP-76 with PLCyl. These 
data provide a mechanism for the previous observation that FcyRll, but not FcyRl, 
couples to PLCyl activation.
5.2.L2. FcyRl but not FcyRll induces the association of SLP-76 with Grb2
Further to PLCy activation, SLP-76 plays a central role in the activation of small G- 
protein coupled pathways. Central to this activation is the ubiquitous Grb2 adapter 
protein. As a tyrosine phosphorylated bands of around the correct size for Grb2 appear 
in SLP-76 immune precipitates, blots were reprobed with mouse anti-Grb2 monoclonals. 
Figure 5.1C (bottom panel) reveals that FcyRl, but not FcyRll, aggregation induces the 
association of Grb2 with SLP-76 (Figure 5.1C). The slightly larger 25 kDa band 
appearing in SLP-76 precipitates from FcyRll stimulated cells, is not Grb2 but rather 
corresponds to anti-FcyRII mAh light chain (this band is detected directly by the 
secondary anti-mouse :HRP). The intense band present in the FcyRll immune precipitate 
also corresponds to the anti-FcyRII mAh light chain. The appearance of Grb2 in SLP-76 
immune precipitates following FcyRl aggregation implies that SLP-76 mediates distinct 
responses for FcyRl and FcyRll.
5.2.I.3. FcyRl and FcyRll induce the formation of distinct She complexes
The adapter proteins, Grb2 and She, play a central role in the activation of the small 
GTPases, Ras and Rac, by localizing guanine nucleotide exchange factors at the plasma 
membrane. Flere, a role for these adapter proteins in FcyRl and FcyRll signal 
transduction was investigated. IFN-y primed U937 cells were stimulated via FcyRl or 
FcyRll for 2 minutes using mAbs, and cell lysates prepared as previously described 
(section 2.3.3). Attempts to precipitate Grb2 from cell lysates proved unsuccessful. 
However, She was successfully immune precipitated from cell lysates with a monoclonal
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anti-She antibody. Immune precipitates were then subjected to Western blot analysis 
(section 2.3.6 and sections therein). Anti-phosphotyrosine analysis of Western blots 
reveals the presence of multiple tyrosine phosphorylated proteins in She immune 
precipitates following aggregation of either FcyRl or FcyRll (Figure 5.2A). No tyrosine 
phosphorylated bands were detected in She precipitates from unstimulated cell lysates. 
Detecting the phosphorylation of She itself is hindered by crossreactivity of the 
secondary, anti-mouse:HRP conjugate with the mouse anti-Shc precipitating antibody 
(Fig 5.2A - indicated by IgG).
The She immune precipitates were reprobed with various specific antibodies to signalling 
proteins. This allowed the identification of the major phosphotyrosine containing 
proteins in these She immune precipitates. Thus, in cells following specific aggi'egation of 
FcyRl, She forms complexes with p i45 SHIP, p i20 Cbl, SLP-76 and Grb2 (Figui'e 5.2B), 
and these proteins are tyrosine phosphorylated (Figure 5.2A). In cells following the 
specific aggregation of FcyRll, the She complex also contains SHIP, Cbl and SLP-76 as 
tyrosine phosphorylated proteins (Figure 5.2B). However, no Grb2 could be detected 
(Figure 5.2B). As well as lacking Grb2, the stoichiometry of She complexes induced by 
FcyRll differ from those induced by FcyRl. Thus, FcyRl induced She complexes contain 
significantly higher levels of Cbl and SLP-76 than those induced by FcyRll. Levels of 
SHIP in She precipitates however are almost identical. None of these proteins were 
detectable in She immune precipitates from resting cells, indicating that these interactions 
are induced by receptor aggregation. Reprobing blots with rabbit polyclonal anti-Shc 
antibodies indicates equal loading of She in the immune precipitates (Figure 5.2 B).
5.2.1.4. FcyRl, but not FcyRll induces the formation of Shc-Grb2-Sos 
complexes
She has been implicated in the recruitment of the GEFs, Sos and Vav, to activate Ras and 
R ad  respectively. She immune precipitates were therefore probed for the presence of 
Sos (GEF for Ras) and Vav (GEF for R ad ). Figure 5.3 indicates the presence of both Sos 
and Vav in She immune precipitates from unstimulated cells. FcyRl aggregation induced 
an approximate four fold increase in Sos associated with She complexes. As FcyRl also
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induces the association of She with Grb2, this data supports a role for Shc-Grb2-Sos 
complexes in FcyRl signal transduction. No significant increase in Sos levels associated 
with She was observed in response to FcyRll aggregation, consistent with the absence of 
Grb2 in these complexes (Figure 5.3). Interestingly, both FcyRl and FcyRll aggregation 
induced an approximate two fold increase in Vav in She immune precipitates. These data 
together imply that FcyRl and FcyRll might couple to different patterns of small GTPase 
activation.
5.2.2. Regulation of Ras and Rac by FcyRl and FcyRIla
The finding that FcyRl and FcyRll induce the formation of distinct adapter protein 
complexes with the effectors, Sos and Vav, led to experiments to investigate the activation 
of the small GTPases, Ras and Racl. The ability of FcyRs to activate Ras and Rac was 
assessed using Ras and Rac assay kits (section 2.3.7). Here, agarose conjugated fusion 
proteins comprising either the Ras binding domain of Raf-1 or the Racl binding domain of 
PAK (a Racl effector) aie used to precipitate active Ras-GTP and active Racl-GTP, 
respectively. As these fusion proteins do not bind the inactive GDP bound forms of Ras 
or Racl, the quantity o f GTPase precipitated, as assessed by Western blot, is a measure 
of activity.
5.2.2.I. Both FcyRl and FcyRll activate Ras and Racl
The ability of FcyRl and FcyRll to activate Ras and Racl was assessed in IFN-y primed 
U937 cells by aggregating specific receptors with monoclonal antibodies (section 2.3.1.2). 
Following preparation of cell lysates, active Ras and Racl were precipitated as described 
above (Figure 5.4). Control lanes indicate that simply warming the cells to 37°C induces 
some activation of Ras and Racl. Aggregation of FcyRl led to a substantial increase in 
Ras-GTP above control within 1 minute which was increased further by 3 minutes 
(Figure 5.4A). FcyRl also induced a transient small increase in Racl activity with 
maximal activity observed at 1 minute. FcyRll aggregation also induced the activation of 
both Ras and Racl although the increase in Ras was much lower than that observed for 
FcyRl (Figure 5.4B). The apparently enhanced Ras activity in the 3 minute control lane
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(Figure 5.4B - control 3) is a result of longer exposure times required to detect Ras 
activity induced by FcyRll. Racl activation induced by FcyRll follows a similar pattern 
to that observed for FcyRl.
5.2.2.2. Activation of Ras and Rac by FcyRl and FcyRll is downstream of FI 3-Idnase 
activation
As activation of small GTPases often lies downstream of PI 3-kinase, the effect of PI 3- 
kinase inliibitors on Ras and Racl activation was investigated. Preincubation of cells with 
the PI 3 -kinase inhibitors LY294002 (250 | l l M )  and wortmannin (50 nM) inhibited the 
majority of Ras and Racl activation induced by FcyRl aggregation (Figure 5.5 A). FcyRll 
induced Ras activity was also inhibited by preincubation of cells with LY294002 (250 
|L iM )  and wortmannin (50 nM) (Figure 5.5B). FcyRll induced Racl activation was less 
sensitive to PI 3-kinase inhibitors although LY294002 (250|iM) substantially reduced 
activation. Preincubation of cells with wortmannin was found to only slightly decrease 
FcyRll mediated Racl activation.
5.2.2.3. Ras and Rac activation does not require activation of p85-dependent PI 3- 
kinase
Previous work in the laboratory has demonstrated that FcyRl couples to both tyrosine 
kinase dependent and G-protein coupled PI 3-kinase isoforms, to generate a prolonged 
PIP3 response (Melendez et ah, 1998c). Conversely, FcyRll couples solely to tyrosine 
kinase dependent PI 3-kinase to give a short PIP3 response (Melendez et ah, 1998c) 
(unpublished observations). Overexpression of a dominant negative isoform of the p85 
subunit (Ap85) of the tyrosine kinase dependent PI 3-kinase blocks activation by 
preventing recruitment of the catalytic p i 10 subunit to phosphorylated IT AMs (Hara et 
a l, 1994), Thus, overexpression of Ap85 in U937s abolished PIP3 production in 
response to FcyRll aggregation. As Ap85 has no effect on G-protein coupled PI 3-kinase, 
overexpression of Ap85 only delays the production of PIP3 (Melendez et a l,  1998c).
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Expression of dominant negative Ap85 in the U937;Ap85 cell line was induced with 
IPTG (described in section 2.2.1.2). Overexpression of the truncated Ap85 was 
confirmed by Western blot (Figure 5.6), which shows expression of the truncated Ap85 
only after induction with IPTG. Comparison of band intensity indicates that dominant 
negative Ap85 is expressed at approximately 20 fold higher levels than endogenous p85. 
As insulin is reported to activate only p85 dependent PI 3-kinase in U937 cells, insulin 
was used as a control (Hara et aL, 1994). Either FcyRl or FcyRll was aggiegated for 1 
minute in either control U937 cells or U937 cells induced to overexpress Ap85. 
Alternatively, cells were incubated for 1 minute with insulin (10 pg/ml). Expression of 
Ap85, rather than blocking FcyRl or FcyRll mediated activation o f Ras, resulted in a small 
enhancement of induced activity in all cases (Figure 5.7). Likewise, insulin induced Ras 
activation was slightly enhanced by overexpression of Ap85. Expression of Ap85 had 
little effect on Racl activation by either FcyRl or FcyRll. Insulin only induced very low 
levels of Racl activation at the time point examined making it difficult to assess the 
effects of Ap85 expression here. In order to assess whether overexpression of Ap85 
affected the ability of Fey receptors and insulin to induce tyrosine phosphorylation, 
levels of phosphotyrosine in cell lysates were assessed by Western blot (section 2.3.6.1). 
Comparison of phosphotyrosine responses in cell lysates indicates that Ap85 also 
slightly enhances Fey receptor and insulin induced tyrosine phosphorylation (Figure 5.7 - 
bottom panel). In addition, close examination of the phosphotyrosine blots indicates that 
a band of the correct size for Ap85, present only in the IPTG induced samples, is 
tyrosine phosphorylated in response to both FcyRl and FcyRll aggregation (Figure 5.7 - 
indicated Ap85). Taken together, these data imply that Ras and Rac activation do not 
depend on the activation of the tyrosine kinase dependent PI 3-kinase. Furthermore, as 
both Ras and Rac activation are inhibited by LY294002 and wortmannin, but not by 
Ap85 expression, these data also imply that other PI 3-kinase isoforms lie upstream of 
Ras and Rac.
5.2.3. Regulation of MAP Kinase activation by FcyRl and FcyRIla
Next, the coupling of FcyRl and FcyRll to the MAPK signalling cascades was examined. 
To investigate whether FcyRl and FcyRll couple to different MAPK pathways in IFN-y
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primed U937 ceils, specific receptors were aggregated and MAPK phosphorylation was 
measured by Western analysis (section 2.3.6.2). Cells were harvested at given time 
points after receptor aggregation and lysed. Western blots of cell lysates were probed 
with antibodies which specifically recognise dual phosphorylated active MAPKs as 
described in materials and methods (section 2.3.6.2). As Ras and Rac activation were 
found to be influenced by the inhibitors wortmannin and LY294002, their effect on 
activation was also examined.
5.2.3.I. FcyRl and FcyRll activate ERKl and ERK2 downstream of PI 3-kinase
Aggregation of FcyRl induced the rapid transient phosphorylation of both p42 and p44 
ERK within 3 minutes of receptor aggregation (Figure 5.8A - top panel). Levels of 
phosphoERK decreased partially 30 minutes after receptor aggregation. ERK activation 
by FcyRl was almost entirely abolished by preincubation with the PI 3-kinase inhibitor 
LY294002 (250 |iM). Wortmannin (50 nM), a structurally distinct PI 3-kinase inliibitor, 
also inhibited ERK activation but to a lesser extent than LY294002. Blots were striped 
and reprobed with antibodies recognizing all forms of ERK to ensure equivalent loading 
between lanes (Figure 5.8A - bottom panel).
Aggregation of FcyRll with mAbs (clone IV3) also induced the phosphorylation of both 
p42 and p44 ERK though the response appeared slower than that observed for FcyRl 
(Figure 5.8B - top panel). Peak phosphorylation was observed 10 minutes following 
aggregation. By 30 minutes, phosphorylation had returned to near basal levels. ERK 
activition was completely abolished by preincubation with LY294002 (250jiM). 
Wortmannin (50nM) was also found to inhibit ERK phosphorylation, though to a lesser 
extent than LY294002. Blots were stripped and reprobed with antibodies recognizing all 
forms of ERK to ensure comparable levels were present in each sample (Figure 5.8B 
bottom panel).
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5.2.3.2. FcyRl and FcyRll activate p38 MAPK
Dual phosphorylation of p38 in response to FcyRl and FcyRll aggregation was assessed 
as for ERK (section 2.3.6.2). Levels of phospho-p38 were substantially elevated at 3 
minutes and 10 minutes after FcyRl aggregation (Figure 5.9A). After 30 minutes levels of 
phospho-p38 had returned to basal levels. The PI 3-kinase inhibitor, LY294002, reduced 
FcyRl induced p38 phosphorylation at earlier time points (3 minutes and 10 minutes). 
However, 30 minutes following FcyRl aggregation, inhibition o f PI 3-kinase with 
LY294002 appeared to enhance the levels of phospho-p38 above untreated cells. 
Inhibition of PI 3-kinase with wortmannin had little effect on phosphorylation of p38 and 
a reduction was only observed at 10 minutes post receptor aggregation.
FcyRll aggregation also induced phosphorylation of p38 though to a lesser extent than 
FcyRl (Figure 5.9B). Also, phosphorylation of p38 in response to FcyRll showed slower 
kinetics than FcyRl, with levels of phospho-p38 remaining above basal levels 30 minutes 
after FcyRll aggregation. Surprisingly, treatment of cells with LY294002, rather than 
inliibiting p38 activation, caused a substantial increase in phosphorylation of p38, 
particularly 30 minutes after receptor aggregation. Wortmannin, as with FcyRl had little 
effect on p38 activation except at the 10 minute timepoint where inhibition of p38 
phosphorylation was almost complete.
5.2.3.3. ERK and p38 activation do not require p85-dependent PI 3-kinase 
activation
As described earlier, FcyRl and FcyRll couple to distinct patterns of PI 3-kinase 
activation. Thus, FcyRl couples to both tyrosine kinase dependent PI 3-kinase and G- 
protein coupled PI 3-kinase, whereas FcyRll couples solely to tyrosine kinase dependent 
PI 3-kinase isoform. To investigate whether differences in the sensitivity of ERK and 
p38 activation by FcyRl and FcyRll to PI 3-kinase inhibitors was a result of these 
differences in PI 3-kinase isoform activation, the effect of Ap85 overexpression on 
MAPK activation was assessed. Figure 5.10 shows the activation profiles of ERK and 
p38 in response to FcyRJ aggregation in uninduced U937:Ap85 and induced U937:Ap85. 
These data demonstrate that overexpression of Ap85 does not block either ERK or p38
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activation by either FcyRl (Figure 5.10) or FcyRll. In fact ERK and p38 phosphorylation 
appeared to be enhanced by overexpression of Ap85 in all cases. Reprobing blots for 
total ERK and total p38 demonstrate comparable loading of cell lysates (Figure 5.10).
S.2.3.4. FcyRl activates JNK
As for ERK and p38, coupling of FcyRl and FcyRll to the JNK pathway was assessed 
with phosphorylation state specific antibodies (section 2.3.6.2). Figure 5.11A 
demonstrates that FcyRl aggregation induces JNK phosphorylation, peaking at 10 
minutes after aggi'egation and returning to near basal levels by 30 minutes. Conversely, 
FcyRll failed to induce detectable JNK phosphorylation over the timecourse examined 
(Figui'e 5.11 A). Figure 5.1 IB demonstrates that FcyRl stimulated JNK phosphorylation 
is inhibited to an equal degree by both LY294002 and wortmannin. Figure 5.11C 
indicates that overexpression of Ap85, also does not block FcyRl induced JNK activation. 
Rather, expression of Ap85 enhances levels of phospho-JNK induced by FcyRl, in line 
with data presented earlier.
In summary, both FcyRl and FcyRll are coupled to the ERK and p38 MAPK pathways. 
However, while both receptors coupled to comparative levels of ERK activation, only 
FcyRl induced an increase in Shc-Grb2-Sos complexes and substantial Ras activation. 
These data might suggest differences in the ERK activation pathway utilised by FcyRl 
and FcyRll. Interestingly, only FcyRl appears to couple to the activation of JNK.
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5.3. Discussion
The adapter proteins, SLP-76 and LAT, are essential for the activation of PLCy in T-cell 
antigen receptor signalling and FceRI signalling in mast cells (Revied in Kane et al., 2000, 
Turner & Kinet, 1999). Here, LAT recruits PLCyl to the plasma membrane while SLP- 
76 is essential for activation of PLCyl by Tec family kinases. The mechanism linking Fey 
receptors to PLCy activation, however, remains unclear. In IFN-y primed U937 cells, we 
have established that FcyRll is coupled to the activation of PLCyl. Conversely, 
aggregation of FcyRl fails to activate this pathway. Data presented here provides a 
potential explanation for these findings. In IFN-y primed U937 cells, SLP-76 and PLCyl 
were found to be constitutively associated. Following aggregation of FcyRll, SLP-76 is 
tyrosine phosphorylated and associates with a number of phosphotyrosine containing 
proteins. The most prominent of these tyrosine phosphorylated proteins is FcyRll itself. 
Further, both SLP-76 and PLCyl can be detected in FcyRll signalling complexes. LAT, 
which anchors PLCy to the plasma membrane in TCR and FceRI signalling, could not be 
detected in association with either FcyRll or SLP-76. These data provide evidence that 
FcyRll might directly recruit SLP-76-PLCyl complexes to the plasma membrane, where 
activation can take place. Interestingly, aggregation of FcyRl under identical conditions 
also results in the tyrosine phosphorylation of SLP-76 and its association with multiple 
tyrosine phosphorylated proteins. However, neither the y-chain (the signalling subunit 
for FcyRl and also FceRI) nor FcyRll could be found in SLP-76 complexes following 
FcyRl aggregation. These data are consistent with the previous finding that FcyRl does 
not couple to the activation of PLCy in IFN-y primed U937 cells. It is tempting to 
speculate that the ability of FcyRIla, but not y-chain, to recruit SLP-76-PLCyl complexes 
is a result o f the atypical IT AM motif of FcyRIla (section 1.2.1.1).
Interestingly, the constitutive association between SLP-76 and PLCy, observed in resting 
U937 cells appeared to be decreased following aggregation of FcyRl. Further, FcyRl 
aggregation was found to induce the association of SLP-76 with Grb2. As SLP-76 is 
reported to interact with the SH3 domain of Grb2 via its proline rich domain, this raises
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the possibility that the SH3 domains of Grb2 and PLCyl might compete for binding to 
the proline rich domain of SLP-76. This hypothesis is under active investigation.
Though FcyRJ fails to couple to PLCy, FcyRl aggregation was found to induce the 
tyrosine phosphorylation of SLP-76 and its association with the adapter proteins, She 
and Grb2. SLP-76, She and Grb2 have been implicated in the activation of the small 
GTPases, Ras and Racl (section 1.2.5.2). A potential role for these adapters was 
examined in the coupling of FcyRJ to the activation of Ras and Racl. Consistent with a 
role for these adapters in FcyRJ mediated Ras activation, levels of Sos associated with She 
complexes were substantially increased in response to FcyRJ aggregation. Further, 
previous data (Cameron & Allen, 1999) indicates that FcyRJ induces the translocation of 
She to the plasma membrane in response to receptor aggregation. In contrast to FcyRJ, 
aggregation of FcyRll, did not induce the association of Grb2 with either She or SLP-76. 
In addition, no increase in Sos levels associated with She was detected. Consistent with 
these findings, FcyRJ was found to couple more efficiently to Ras than FcyRll. Both 
FcyRl and FcyRll induced comparable increases in Vav association with adapter 
complexes. Patterns of Rac activation for FcyRJ and FcyRll were also similar.
A major response to Ras activation is the activation of Raf-1 and the subsequent coupling 
to MEK and ERK (section 1.2.6.2). Despite apparently significant differences in levels 
of Ras activation induced by FcyRJ and FcyRJI, both receptors were found to couple to 
comparable levels of ERK activation, as assessed by analysis o f phosphoERK levels. 
Recent reports have implicated Ras independent pathways in the activation of ERK by 
Fey receptors. Firstly, in human neutrophils, aggregation of either FcyRIla or FcyRIIIb 
(the latter not expressed by U937 cells) induces ERK activation, independent of the 
formation of Shc-Grb2-Sos complexes (Hazan-Halevy et al., 2000). Secondly, Sanchez- 
Mejorda et al show that Fey receptor mediated activation of ERK in THP-1 and U937 
cells is largely unaffected by expression of dominant negative Ras or Raf-1 (Sanchez- 
Mejorada & Rosales, 1998). The U937 cells used in this study were not primed with 
IFN-y and will thus express relatively low levels of FcyRJ in comparison to the cells used 
here. Further, FcyRJ is reported not to associate with the y-chain in undifferentiated 
U937 cells (van de Winkel & Capel, 1993). These reports are consistent with the findings
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here that FcyRIla is able to activate ERK in the absence of a robust Ras activation. Taken 
together with the finding that FcyRl induces the formation of Shc-Grb2-Sos complexes 
and robust Ras activation, these data imply that FcyRl and FcyRll may couple to the 
activation of ERK via distinct signalling pathways.
FcyRl and FcyRJI induced comparable increases in Vav associated with She adapter 
complexes. Patterns of Rac activation for FcyRl and FcyRll were also similar. As Racl 
has been found to lie upstream of p38 and JNK in other systems, the coupling of FcyRl 
and FcyRJI to p38 and JNK was assessed. FcyRJ was found to couple to both p38 and 
JNK phosphorylation, while FcyRJI was found to induce a comparably modest induction 
of p38 phosphorylation and little or no JNK response. The reasons for these differences 
are not clear.
Interestingly, Fey receptor aggregation on murine macrophages has been found to activate 
ERK, p38 and JNK (Rose et al., 1997). Further, FceRJ aggregation in mouse bone 
marrow derived mast cells also couples to all tluee MAP kinase cascades (Ishizuka et al., 
1997, Ishizuka et a l, 1999). As murine Fey receptors and FceRI couple to the activation 
o f signal transduction pathways via the y-chain, these data indicate that the y-chain 
IT AM is capable of activating all three MAPK cascades. Consistent with a conserved 
function for the y-chain in the regulation of human MAPK activation, FcyRJ in IFN-y 
primed U937 cells also activates ERK, p38 and JNK.
Also of interest, the activation patterns of the MAP kinases by FcyRIla closely follows 
those reported for the phagocytosis of IgG opsonised bacteria by neutrophils (McLeish 
et al., 1998). Here, Fey receptors couple to the activation of ERK and p38, but not JNK 
activation. Neutrophils express FcyRIla and FcyRIIIb, though as FcyRJIb is GPI 
anchored, and cannot associate with y-chain, signal transduction is thought to be governed 
primarily by FcyRIla (Hazan-Halevy et al., 2000). It seems likely, therefore, that the 
same pathway is used by FcyRIla in both neutrophils and monocytes. Thus, FcyRIla 
might provide a y-chain independent pathway for immune complexes to mediate a distinct 
MAP kinase response. This is particularly intriguing as FcyRIla is a human specific 
receptor.
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The significance of differences in the MAP kinase profiles activated by FcyRJ and FcyRll 
is not clear. P38 has been implicated in mediating activation of the respiratory burst 
(Herlaai- & Brown, 1999, Hazan-FIalevy et a l, 2000) and thus this pathway may be 
expected to lie downstream of both FcyRl and FcyRll. The differences in JNK activation 
will likely reflect differences in transcriptional regulation by FcyRl and FcyRll. ERK, 
p38 and JNK have been variously implicated in the regulation of inflammatory cytokine 
production though responses appear to vary greatly between different systems and cell 
types (Paul et a l, 1997, Ip & Davis, 1998, Herlaar & Brown, 1999). The transcriptional 
response mediated by FcyRl and FcyRJI remain to be determined.
The effects of the PI 3-kinase inhibitors wortmannin and LY294002 on activation of the 
MAP kinase cascades raises some intriguing points. ERK activation induced by either 
FcyRJ or FcyRJI was inhibited by LY294002 and to a lesser extent by wortmannin. The 
effects of PI 3-kinase inliibitors on p38 phosphorylation ai*e clearly complex. The data 
presented imply that PI 3-kinase may play important positive and negative regulatory 
roles in the regulation of p38 activity. Further work is required here to establish the role 
of PI 3-kinase in the regulation of this pathway. As MAP kinase pathways are also 
regulated by PKC, the effect of PKC inliibitors on Fey receptor mediated MAP kinase 
activation is also under investigation (Ueda a/., 1996, Cote-Velez et a l, 1999, McLeish 
et a l, 1998).
As inhibitors may have additional effects, the role of PI 3-kinase was examined using a 
dominant negative isoform of the p85 subunit of p85 dependent PI 3-kinase. 
Overexpression of this dominant negative subunit abolishes PIP3 production in response 
to insulin (Hara et ah, 1994) or FcyRJI aggregation and delays PIP3 production in 
response to FcyRl crosslinking (Melendez et a l, 1998c). Surprisingly however, 
overexpression of Ap85 did not inhibit, but rather slightly enhanced, Ras, Rac, MAPK 
and phospho-tyrosine responses induced by both FcyRJ and FcyRJI. In particular, the 
fact that FcyRJI induced ERK, Ras and Rac responses were inhibited by LY294002 and 
wortmannin, but not Ap85 expression, implies a dependence on an alternative PI 3-kinase 
isoform (section 1.2.3.1).
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We have previously demonstrated that in IFN-y primed U937 cells FcyRll, but not FcyRl 
couples to the activation of PLCyl (Melendez et al., 1998a). I show here that FcyRl and 
FcyRll couple to the assembly of different adapter protein scaffolds providing a potential 
mechanism for the differences in PLCy activation observed. Following on from 
differences in adapter protein complexes FcyRl and FcyRJI were shown to be coupled to 
distinct activation patterns of the MAPK cascades. Taken together, these data imply 
that FcyRJ and FcyRJI will induce distinct patterns of transcription. Future work will 
attempt to identify specific transcription factors and genes targeted by the two receptors 
with particular focus on the production of inflammatory cytokines.
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Figure 5.1 SLP-76 associates with FcyRll following FcyRll aggregation.
Cells were loaded with either anti-FcyRI mAh 22 or anti-FcyRII mAh KB61 at 
4°C and receptors aggregated by the addition of goat anti-mouse IgG. Control 
cells were stimulated with goat anti-mouse IgG alone. Cells were warmed to 
37°C for 2 minutes and cell lysates prepared. (A) cell lysates (10 pg/sample) 
were subjected to Western blot analysis with the antiphosphotyrosine mAh 
(4G10) (bottom panel). (B and C) SLP-76 was immune precipitated from 
cells lysates and precipitates were subjected to Western blot analysis. FcyRll 
immune complexes were also precipitated following FcyRll aggregation 
(indicated FcyRll IP on Western blots) via the goat anti-mouse crosslinker by 
the addition of anti-goat IgG conjugated agarose. 10 jig of cells lysate (lysate) 
was also included on Western blots. (B) Western blots were probed for 
phosphotyrosine with mAh 4G10. (C) Blots were stripped and reprobed for 
PLCy, SLP-76, y-chain and Grb2.
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Figure 5.2 FcyRl and FcyRll induce the formation of distinct She 
complexes.
Cells were loaded with either anti-FcyRI mAh 22 or anti-FcyRII mAh KB61 at 
4°C and receptors aggregated by the addition of goat anti-mouse IgG. Control 
cells were stimulated with goat anti-mouse IgG alone. Cells were warmed to 
37°C for 2 minutes and cell lysates prepared. She was immune precipitated 
from cell lysates and probed for the presence of tyrosine phosphorylated 
proteins with mAh 4G10 (A). Blots were stripped and reprobed (B) for 
SHIP, Cbl, SLP-76, She and Grb2 as indicated.
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Figure 5.3 Analysis of Shc-Sos and She-Vav complexes induced by 
aggregation of FcyRl and FcyRll.
Cells were loaded with either anti-FcyRI mAh 22 or anti-FcyRII mAh KB61 at 
4°C and receptors aggregated by the addition of goat anti-mouse IgG. Control 
cells were stimulated with goat anti-mouse IgG alone. Cells were warmed to 
37°C for 2 minutes and cell lysates prepared. She was immune precipitated 
from cells lysates and probed for the presence of Sos (top panel), Vav (middle 
panel) and She (bottom panel). The numbers beneath the Sos and Vav blots 
indicate relative intensity of bands (noimalised to control) as calculated by 
densitometry.
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Figure 5.4 FcyRl and FcyRll activate Ras and Rac.
Cells were primed with IFN-y for 24 hours prior to assays. Cells were loaded 
with either anti-FcyRI mAh 22 (A) or anti-FcyRII mAh KB61 (B) at 4°C and 
the receptors were aggregated by the addition of goat anti-mouse IgG. Control 
cells were stimulated with goat anti-mouse IgG alone. Cells were warmed to 
37°C for the times indicated and Ras and Rac activity were assessed. 
Numbers beneath blots indicate the relative intensity of bands as assessed by 
densitometry, with the 3 minute control point of each experiment arbitrarily 
set as 1. No values are given for the 1 minute control points as bands were too 
faint for accurate quantitation.
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Figure 5.5 FcyRI and FcyRII activate Ras and Rac.
Cells were primed with IFN-y for 24 hours prior to assays. Cells were loaded 
with either anti-FcyRI mAh 22 (A) or anti-FcyRII mAh KB61 (B) at 4°C and 
the receptors were aggregated by the addition of goat anti-mouse IgG. Control 
cells were stimulated with goat anti-mouse IgG alone. Cells were warmed to 
37°C for the times indicated. To inhibit PI 3-kinase cells were incubated for 
20 minutes prior to receptor aggregation with either 250 p,M LY294002 or 50 
nM wortmannin as indicated, Ras and Rac activity were assessed as described 
in section 2.3.7.
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Figure 5.6 Ap85 expression is induced in U937:Ap85 cells by IPTG
U937:Ap85 cells were cultured as described. Cells were primed with IFN-y 24 
hours prior to experiments. Ap85 expression was induced by 15 mM IPTG 
for 10 hours as described (section 2.2.1.2). Cells, with no addition of IPTG 
were used as a control. Cell lysates were prepared and 10 jag of each sample 
subjected to SDS-PAGE. Expression of Ap85 was assessed by Western blot 
analysis with anti-p85 PI 3-kinase rabbit polyclonal antibodies.
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Figure 5.7 FcyRI and FcyRIl induced Ras and Rac activation are not 
dependent on p85 dependent PI 3-ldnase.
U937:Ap85 cells were primed with IFN-y 24 hours prior to experiments. To 
induce Ap85 expression, 15mM IPTG was added 10 hours prior to 
experiments. Cells were loaded with either anti-FcyRI mAh 22 or anti-FcyRII 
mAh KB61 at 4°C and receptors aggregated by the addition of goat anti-mouse 
IgG. Control cells were stimulated with goat anti-mouse IgG alone. Cells 
were warmed to 37°C for 1 minutes. Alternatively, cells were stimulated with 
10 jLig/ml insulin for 1 minutes as indicated. Ras (top panel) and Rac (middle 
panel) activity were assessed as described in section 2.3.7. To assess the 
effects of Ap85 expression on the induction of tyrosine phosphorylation, cell 
lysates (10 pg/sample) from the above described stimulations were subjected 
to Western blot analysis with mAh 4G10 (bottom panel).
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Figure 5.8 FcyRI and FcyRIl activate ERK downstream of PI 3-kinase.
U937 cells were primed with IFN-y for 24 hours prior to experiments. Ceils 
were loaded with either anti-FcyRI mAh 22 (A) or anti-FcyRII mAh KB61 (B) 
at 4°C and receptors aggregated by the addition of goat anti-mouse IgG. 
Control cells were stimulated with goat anti-mouse IgG alone. Cells were 
warmed to 37°C for the times indicated. To inhibit PI 3-kinase, cells were 
pre-incubated with either LY294002 (indicated LY) or wortmannin (indicated 
by WM) for 20 minutes prior to receptor aggregation. Cells were warmed to 
37°C for the times indicated (minutes) and cell lysates prepared. ERK 
phosphorylation was assessed in cell lysates (10 jxg/sample) by Western blot 
analysis with polyclonal anti-phosphoERK antibodies (indicated pERK). 
Blots were stripped and reprobed with pan-ERK antibodies to control for 
equal loading (indicated ERK). Numbers beneath blots indicate the relative 
intensity of bands as assessed by densitometry, with the control point of each 
experiment arbitrarily set as 1. These data are conected for equal loading.
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Figure 5.9 FcyRI and FcyRIl activate p38 with different sensitivities to PI 
3-kinase inhibition.
U937 cells were primed with IFN-y for 24 hours prior to experiments. Cells 
were loaded with either anti-FcyRI mAh 22 (A) or anti-FcyRII mAh KB61 (B) 
at 4°C and receptors aggregated by the addition of goat anti-mouse IgG. 
Control cells were stimulated with goat anti-mouse IgG alone. Cells were 
wanned to 37°C for the times indicated. To inhibit PI 3-kinase, cells were 
pre-incubated with either LY294002 (indicated LY) or wortmannin (indicated 
by WM) for 20 minutes prior to receptor aggregation. Cells were warmed to 
37°C for the times indicated (minutes) and cell lysates prepared. P38 
phosphorylation was assessed in cell lysates (10 jig/sample) by Western blot 
analysis with polyclonal anti-phospho-p38 antibodies (indicated pp38). 
Blots were stripped and reprobed with pan-p38 antibodies to control for equal 
loading (indicated p38). Numbers beneath blots indicate the relative intensity 
of bands as assessed by densitometry, with the control point of each 
experiment arbitrarily set as 1. These data are corrected for equal loading.
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Figure 5.10 FcyRI induced ERK and p38 activation are not dependent on 
p85 dependent PI 3-Idnase.
U937:Ap85 ceils were primed with IFN-y 24 hours prior to experiments. To 
induce Ap85 expression, 15 mM IPTG was added 10 hours prior to 
experiments. To aggregate FcyRI, cells were loaded with mAh 22 at 4°C 
followed by goat anti-mouse crosslinking antibody. Control cells were 
stimulated with goat anti-mouse IgG alone. Cells were warmed to 37°C for 
the times indicated (minutes) and cell lysates prepared. Western blots of cell 
lysates (10 pg/sample) were prepared and probed with anti-phospho-ERK 
antibodies (pERK) or anti-phospho-p38 antibodies (pp38). Blots were 
stripped and reprobed with pan-ERK (ERK) or pan-p38 (p38) antibodies to 
ensure compai'able loading of cell lysates. Separate blots were also probed 
with anti-p85 antibodies to check for the expression of Ap85 following IPTG 
induction (bottom panel). The bands conesponding to endogenous p85 and 
induced Ap85 are indicated.
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Figure 5.11 FcyRI aggregation activates p46 and p52 JNK.
U937 cells were primed with IFN-y for 24 hours prior to experiments. (A) 
Cells were loaded with either anti-FcyRI mAh 22 or anti-FcyRII mAh KB61 at 
4°C and receptors aggregated by the addition of goat anti-mouse IgG. Control 
cells were stimulated with goat anti-mouse IgG alone. Cells were warmed to 
37°C for the times indicated. JNK phosphorylation was assessed in cell 
lysates (10 pg/sample) by Western blot analysis with polyclonal anti- 
phospho-JNK antibodies (indicated pJNK). Blots were stripped and 
reprobed with pan-JNK antibodies to control for equal loading (indicated 
JNK). (B) FcyRI induced JNK phosphorylation is downstream of PI 3- 
kinase. To inhibit PI 3-kinase cells were incubated for 20 minutes prior to 
receptor aggregation with either 250|aM LY294002 (indicated LY) or 100 nM  
wortmannin (indicated WM). FcyRI was aggregated as described above. 
Phospho-JNK and total JNK were detected by Western blot as described 
above. The numbers beneath these blots indicate the relative intensity of 
bands as assessed by densitometry, with the control arbitrarily set as 1. 
These data aie corrected for equal loading. (C) Ap85 expression enhances 
FcyRI induced JNK activation. U937:Ap85 cells were treated as for Figure 
5.10. FcyRI was aggiegated with mAh 22 for the times indicated and JNK 
phosphorylation assessed as described above.
39
A
U. f
] JNK
B
c
4 -  p54 
^  p46
] JNK
] pJNK
1 2 3 0  1807.6:140 51 10;130 34 6.9
Ap85
c co O O o o  o o r o ’—i m  o  m   ^ m
] pJNK
p46
Chapter 6
Chapter 6
Differential recruitment of accessory molecules by FcyRI during 
monocyte differentiation.
6.1. Introduction
Fc receptors play a pivotal role linking the cellular and humoral arms of the immune 
response. Each class of immunoglobulin is recognised by a set of receptors; thus, IgG is 
recognised by Fey receptors (FcyRs), IgA by FcaRs, IgE by FceRs and IgM by FcpRs 
(Ravetch & Kinet, 1991, Hulett & Hogarth, 1994). The precise distribution of these 
receptors on cells defines the nature of the cellular response to antigens. On leukocytes, 
aggregation of Fc receptors by immune complexes leads to a variety of responses such as 
endocytosis and phagocytosis, activation of the oxidative burst, cytokine release and 
degranulation. Activation of these receptors can ultimately lead to targeted cell killing 
tlirough the process of antibody mediated cell cytotoxicity (Fanger et al., 1989), which is 
critically important for cancer surveillance and the clearance of virus infected cells (Ely et 
al., 1996).
Three classes of FcyRs have been identified; FcyRI (CD64), FcyRIl (CD32) and FcyRIl I 
(CD 16) (section 1.1.3). FcyRI, the human high affinity IgG receptor, comprises an 
integral type I membrane glycoprotein and is confined in expression to myeloid cells. 
Aggregation of FcyRI on myeloid cells results in the initiation of tyrosine kinase 
dependent activation of signal transduction pathways as evidenced by tyrosine 
phosphorylation and tyrosine kinase dependent cytosolic calcium transients (Liao et a l, 
1992, Rankin et a l, 1993, Davis et al., 1994, Scholl et al., 1992). However, the 
cytoplasmic tail of FcyRI possesses no known signalling motif. In particular FcyRI lacks 
an Immunoreceptor Tyrosine Activation Motif (ITAM) (Allen & Seed, 1989). To recruit 
tyrosine kinases, FcyRI is required to recruit an accessory molecule and this receptor has 
been shown to associate with the y-chain (Ernst et al., 1993, Ra et al., 1989, Scholl &
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Geha, 1993). The y-chain, a 7 kDa protein, was first identified as a component of the 
multisubunit high affinity receptor for IgE, FceRI (Blank et aL, 1989) and belongs to a 
family of signal transducing molecules which include  ^and p chains (Gambler et al., 1995) 
of the T cell receptor. These proteins form homo- or hetero-dimers being characterised as 
integral type I membrane proteins with a short extracellular region, a single 
transmembrane spanning unit and a cytoplasmic tail containing one or more conserved 
ITAM motifs (Cambier et al., 1995). The essential role of the y-chain in linking Fc 
receptors to intracellular signalling cascades has been demonstrated by the y-chain knock­
out mouse (Clynes et al., 1999).
The FcyRIl subfamily of IgG receptors show low affinity for IgG and, thus, these 
receptors only recognise IgG that has been aggregated by multivalent antigens (section 
1.1.3.2). Unlike other IgSF family Fc receptors, FcyRIl iso forms contain cytoplasmic 
signalling motifs. Thus, the cytoplasmic tail of FcyRIIa contains an IT AM motif capable 
of recruiting tyrosine kinase dependent signalling pathways (Brooks et al., 1989).
U937 cells are a human monoblastic cell line that constitutively express FcyRI and FcyRIl 
but not FcyRIII. These cells also express the IgA receptor, FcaRI. FcocRI, lüce FcyRI 
and FceRI, requires the y-chain for signal transduction (Morton et al., 1995). These cells 
can be differentiated to a more macrophage phenotype by treatment with dibutyryl 
cAMP (dbcAMP) (Sheth et al., 1988). We have recently shown that the Irigh affinity 
receptor for IgG, FcyRI, exhibits a differentiation dependent molecular switch in the 
nature of the intracellular signalling cascades activated (Melendez et al., 1998a). Thus, in 
cells primed with IFN-y, FcyRI activates a novel signalling pathway in which the receptor 
is coupled to activation of phosphatidyl choline-specific phospholipase D (PC-PLD) 
(Melendez et al., 1998b). In cells differentiated to a more macrophage-like phenotype 
with dbcAMP, FcyRI is coupled to the activation of phospholipase C resulting in the 
generation of inositol 1,4,5 trisphosphate through the hydrolysis of phosphatidyl inositol 
4,5-bisphosphate (PIP2). The molecular mechanisms regulating this switch were unclear 
although the coupling appeared to depend on differential recruitment of the y-chain for 
signal transduction.
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Here, using blocking antibodies, I show that signal transduction in dbcAMP differentiated 
cells, following the formation of surface immune complexes through ligand binding to 
FcyRI in dbcAMP differentiated cells has an absolute requirement on recruitment of the 
low affinity receptor, FcyRIl and results in coupling of FcyRI to phospholipase C 
activation. In these cells, the y-chain no longer appears to be physically or functionally 
associated with FcyRI but rather associates with the IgA receptor, FcaRI. In contrast, in 
cytokine primed cells, signal transduction by FcyRI does not require recruitment of 
FcyRIl as blocking the ligand recognition site has no effect on the phosphotyrosine signal. 
In these cells, the y-chain associates with FcyRI not FcaRI. Of interest, recruitment of 
the y-chain in either cell type directs coupling of these receptors to PC-PLD activation. 
Thus, FcyRI in cytokine primed cells and FcaRI in dbcAMP differentiated cells activates 
PC-PLD.
6.2. Results
6.2.1. FcyR! physically and functionally associates with the y-chain in IFN-y 
primed cells but not in dbcAMP differentiated cells
Immunoprecipitates of FcyRI were Western blotted and probed for the presence of the y- 
chain. As expected, the y chain co-immunoprecipitated with FcyRI in cells primed with 
IFN-y (Figure 6.1 A). However, in cells differentiated with dbcAMP, the y-chain could 
not be deteeted in FcyRI immunoprecipitates (Figure 6.1 A). Following human IgG 
immune complex activation (section 2.3.1.1), the y-chain was rapidly tyrosine 
phosphorylated in IFN-y primed cells but not in dbcAMP differentiated cells (Figure 
6 .IB). Taken together, this data indicates that the y-chain associates physically and 
functionally with FcyRI in IFN-y primed cells but not in dbcAMP differentiated cells.
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6.2.2. Activation of signalling cascades by immune compiexes requires 
binding to both FcyRI and FcyRIl in dbcAMP differentiated celis but not in 
IFN-y treated cells
The ability of immune complexes to initiate intracellular signalling cascades was measured 
by Western blot analysis and detection of tyrosine phosphorylated proteins (section 
2.3.6.1). Formation of surface immune complexes resulted in the rapid phosphorylation 
of tyrosine residues on multiple proteins in both IFN-y primed and dbcAMP 
differentiated U937 cells (Figure 6.2A). Thus, surface immune complexes are able to 
initiate signalling cascades in dbcAMP differentiated cells which are independent of y- 
chain recruitment. To determine the potential role of FcyRIl in mediating the activation of 
signalling pathways, cells were loaded with the monoclonal antibody IV3 which blocks 
IgG binding to FcyRIl (Kavai et a l, 1991). The effect of the presence of mAh IV3 on 
phosphotyrosine patterns generated by the aggregation of human IgG by surface immune 
complexes was determined in both IFN-y primed cells and dbcAMP differentiated cells.
In IFN-y primed cells, the phosphotyrosine patterns were identical following formation 
of surface immune complexes in the presence or absence of the anti-FcyRII mAh, IV3. In 
contrast, loading dbcAMP differentiated cells with IV3 to block FcyRIl virtually 
abolished tyrosine phosphorylation resulting from ligation o f FcyRI by surface immune 
complexes (Figure 6.2A). This observed reduction in the phosphotyrosine profile in the 
presence of IV3 was not a result of this antibody preventing the binding of human IgG to 
dbcAMP differentiated U937 cells as FACS analysis demonstrated that binding of 
fluorescent IgG was unaffected by the presence of IV3 (Figure 6.2B).
Taken together, this data suggests that signal transduction following the formation of 
surface immune complexes in dbcAMP primed cells requires binding to both FcyRI and 
FcyRIl. In dbcAMP treated cells, binding to FcyRI alone is insufficient to initiate fiill 
signalling as evidenced by the deficient profiles of tyrosine phosphorylation observed in 
the presence of mAh IV3. Thus, this data implies that FcyRI requires FcyRIl for signal 
transduction in dbcAMP differentiated cells. In contrast, in IFN-y primed cells, FcyRI is 
able to fully initiate signalling independently of FcyRIl. Of interest, in IFN-y primed 
cells, the phosphotyrosine patterns obtained following the specific aggregation of FcyRIl
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using receptor specific monoclonal antibodies differed fiom that observed for surface 
immune complexes or anti-FcyRI antibodies (Figure 6.2A). This data together with the 
ability of FcyRI to associate with the y chain suggests that, in IFN-y primed cells, the y 
chain accounts for the signalling cascades initiated by FcyRI, following formation of 
surface immune complexes. In contrast, in dbcAMP differentiated cells, FcyRI no longer 
uses the y chain for signal transduction but rather surface immune complexes appear to 
require the recruitment of FcyRIIa for tyrosine kinase activation.
6.2.3. Expression of the y-chain is increased by both iFN~yand dbcAMP 
differentiation in U937 cells
Next, the reason for the failure of FcyRI to associate the y-chain was investigated. Firstly, 
the presence of the y-chain following differentiation was investigated by Northern and 
Western blot analysis. Cells were treated with either IFN-y (200 ng/ml) or dbcAMP (1 
mM) and the level o f expression of y chain mRNA was examined at various times. In 
undifferentiated cells (time 0), only very low levels of the mRNA for y-chain were 
detected (Figure 6.3A). Following treatment with IFN-y, the level of mRNA for the y- 
chain was increased above basal at the first time point (6 h) and remained elevated 24 h 
after treatment with IFN-y. Treatment of cells with dbcAMP resulted in an increase in the 
mRNA for the y-chain such that at 24 h the mRNA showed a 10 fold increase over basal 
levels.
Changes in y-chain mRNA expression were miiTored by changes in the protein level as 
detected by Western blot analysis. Equal amounts of protein (20 |xg) from resting cells or 
from cells treated either IFN-y or dbcAMP were probed for the presence of the y-chain 
(Figure 6.3B). Treatment with IFN-y for 24 h resulted in a two fold increase in the y- 
chain protein. Differentiation with dbcAMP resulted in a larger, 10 fold, increase in the y- 
chain expression. This data indicates that the y-chain is expressed in dbcAMP treated 
cells; indeed expression is upregulated by dbcAMP. Therefore, the failure of FcyRI to 
recruit the y-chain in dbcAMP differentiated cells is not a result of dovm-regulation of the 
y-chain.
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6.2.4. FcaRI expression is increased by dbcAMP and in these cells the y- 
chain preferentially associates with FcaRI
The y-chain is known to associate with Fc receptors other than FcyRI; notably, FcaRI, 
FceRI, FcyRIII (section 1.1.6). It was hypothesised that, in dbcAMP differentiated cells, 
the y chain preferentially associates with another Fc receptor, in particular FcaRI 
(CD89). Immunoprecipitates of FcaRI were probed for the presence of the y-chain. In 
dbcAMP differentiated cells, the y-chain co-immunoprecipitated with FcaRI. In 
contrast, in IFN-y primed cells, only low levels of the y-chain could be detected in 
immunoprecipitates of FcaRI (Figure 6.4A). These results contrast to those observed for 
FcyRI (Figure 6.1 A).
Tyrosine phosphorylation patterns were compared following specific aggregation of 
FcaRI using anti-CD89 monoclonal antibodies in IFN-y primed or dbcAMP 
differentiated cells. Aggregation of FcaRI in dbcAMP differentiated cells resulted in 
rapid tyrosine phosphorylation of multiple proteins whereas the signal was minimal 
following aggregation in IFN-y primed cells (Figure 6.4B). Specific tyrosine 
phosphorylation of the y-chain was investigated in the two cell states following 
aggregation of FcaRI. Thus, in dbcAMP differentiated cells, the y-chain was tyrosine 
phosphorylated following FcaRI aggregation using CD89 specific antibodies whereas, in 
IFN-y primed cells, a similar approach resulted in a very small phosphotyrosine signal 
despite equal loading of y-chain immunoprecipitates (Figure 6.4C).
The relative expressions of FcyRI and FcaRI in IFN-y and dbcAMP treated cells were 
measured using Northern blot (section 2.5.2) and FACS analysis (section 2.2.2.1). FcyRI 
is known to be tightly regulated by IFN-y in U937 cells and, consistent with this, IFN-y 
resulted in a large transient increase in the mRNA for FcyRI (Figure 6.5A) and this was 
matched by an increase in the mean fluorescent intensity of the cell surface receptor 
(Figure 6.5B). In contrast, the mRNA for FcaRI was reduced in cells treated with IFN-y 
although the mean fluorescent intensity of the cell surface FcaRI remained essentially 
unchanged by IFN-y treatment (Figures 6.5 A and 6.5B).
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In cells differentiated with dbcAMP, the opposite effects were observed. Thus, FcyRI 
expression was reduced whereas FcaRI expression was increased (Figure 6.5A). After 12 
h exposure to dbcAMP, the mRNA levels for FcaRI had increased 8 fold above basal and 
then gradually declined over time such that by 48 h levels had returned approximately to 
basal levels. For FcyRI, 24 h after dbcAMP differentiation, the mRNA was no longer 
visible by Northern blot analysis (Figure 6.5A). A significant increase in mean surface 
fluorescence for FcaRI was observed after 48 h differentiation with dbcAMP (Figure 
6.5B).
Thus, differentiation with dbcAMP results in the upregulation of expression of both 
FcaRI and y-chain and in these cells, the y-chain co-immunoprecipitates with FcaRI but 
not FcyRI. Furthermore, specific aggregation of FcaRI results in enhanced tyrosine 
phosphorylation of the y-chain in dbcAMP differentiated cells when compared to IFN-y 
primed cells. Taken together, this data indicates that in IFN-y treated cells, the y-chain is 
predominantly associated with FcyRI whereas in dbcAMP differentiated cells, the y-chain 
is associated with FcaRI.
6.2.5. FcaRI is coupied to Phospholipase D activation in dbcAMP 
differentiated ceils
In IFN-y treated cells, FcyRI couples to the activation of PC-PLD via the y-chain (16). 
Conversely, in cells differentiated with dbcAMP, FcyRI no longer associates with the y 
chain or couples to the activation of PC-PLD. This data implies that receptor coupling to 
PC-PLD requires the y-chain. As FcaRI associates with the y-chain in dbcAMP treated 
cells, the ability of this receptor to activate PC-PLD was investigated.
The coupling of y-chain to PC-PLD activation was confinned (section 2.4.1) (Figure 6.6). 
In IFN-y treated cells, specific aggregation of FcaRI did not lead to a significant increase 
in PC-PLD activity (Figure 6.6). However, in dbcAMP differentiated cells, specific 
aggregation of FcaRI resulted in an increase in PC-PLD activity (Figure 6.6). Thus, in 
dbcAMP differentiated cells, FcaRI is coupled to the activation of PC-PLD in a y-chain 
dependent manner.
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6.3. Discussion
Here I have demonstrated that differentiation of U937 cells alters the nature o f the Fc 
receptor that associates with the y-chain and changes the activation mechanism of cells by 
IgG immune complexes. Both IFN-y and dbcAMP increase expression of the y-chain. 
However, the y-chain associates physically and functionally with FcyRI only in IFN-y 
primed cells. In dbcAMP differentiated cells, the y-chain no longer associates with FcyRI 
but rather functionally couples FcaRI to intracellular signalling cascades. In both IFN-y 
and dbcAMP differentiated cells, y-chain recruitment results specifically in activation of 
PC-PLD. In the absence of functional coupling of FcyRI with the y-chain in dbcAMP 
differentiated cells, IgG containing immune complexes initiate an alternative signalling 
pathway tlirough the recruitment of FcyRIl to FcyRI.
The cytoplasmic tail o f FcyRI contains no known signalling motif (Allen & Seed, 1989) 
and a functional association with the y chain is well-recognised (Ernst et a l, 1993, Ra et 
a l, 1989, Scholl & Geha, 1993). Here, I show that the y-chain associates with FcyRI only 
in IFN-y primed cells. Using identical immunoprécipitation conditions, the y-chain in 
dbcAMP differentiated cells did not associate with FcyRI. We have previously shown 
that dbcAMP differentiation results in a switch in the nature of the signalling pathways 
activated by surface immune complexes (Melendez et al., 1998a). Differential recruitment 
of the y-chain was proposed as the mechanism underlying this switch although the 
mechanism regulating this switch was unclear. The failure of FcyRI to recruit the y-chain 
cannot be explained by its absence in dbcAMP differentiated cells as here we have shown 
that expression of the y-chain is upregulated following differentiation. It appears rather 
that following differentiation, the y-chain preferentially associates with FcaRI.
Two possible reasons may account for the switch in Fc receptor association of the y- 
chain. The first lies in the predicted nature of the interaction of the two chains as this 
appears to be more robust for interactions between FcaRI and the y-chain than for the
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Other receptors. Thus, association of y-chain with FcaRI can be observed in cell 
membranes solubilised with 1% Nonidet P-40 whereas the same detergent disrupts the 
association of y-chain with FcyRI (Launay et al., 1999). The association between y-chain 
and FcyRI can only be observed in the presence of mild detergents such as 1% digitonin 
(Launay et al., 1999). Recruitment of the y-chain is dependent on the transmembrane 
domains of FcaRI and FcyRI (Lang, Shen & Wade, 1999, Launay et al., 1998). FcaRI 
possesses an ai'ginine residue in its transmembrane domain and this residue is essential for 
the recruitment of the y-chain presumably through the formation of an ion pair interaction 
with the aspartate of the y-chain. Mutation o f the arginine to leucine resulted in failure to 
recruit the y-chain and thereby trigger the signalling cascades (Lang et al., 1999, 
Pfefferkorn & Yeaman, 1994). In contrast, the mechanism of interaction of the y-chain 
with FcyRI is unknown. Although the transmembrane domain of FcyRI is necessary and 
sufficient for the functional recruitment of the y-chain (Launay et al., 1999, Morton et al., 
1995), there is no positively charged amino acid in the predicted transmembrane domain 
of FcyRI (Allen & Seed, 1989). A similar ion pair interaction between the juxtamembrane 
histidine residue of FcyRI with the aspartate of the y-chain has been proposed (Lang et 
al., 1999) but shown not required for functional y-chain recruitment (Davis et al., 1995b).
The second possible explanation for the differential Fc receptor association with the y- 
chain following differentiation is that the two proteins associate during their synthesis 
and passage through the endoplasmic reticulum. Both IFN-y and dbcAMP treatment 
increase mRNA and protein expression of the y-chain. However, IFN-y differentially 
increased expression of FcyRI but downregulated FcaRI. In these cells the y-chain is 
predominantly associated with FcyRI. In contrast, dbcAMP upregulated expression of 
FcaRI and downregulated FcyRI and, in these cells, the y-chain appears to be 
predominantly associated with the FcaRI. A possible explanation for the findings here 
are that, during nascent synthesis, the y-chain in the endoplasmic reticulum associates 
with the corresponding nascent Fc receptor and that this complex, once formed is stable 
and excludes the other Fc receptor once it reaches the plasma membrane.
Although FcyRI no longer associates with the y chain in dbcAMP differentiated cells, 
surface immune complexes are still able to trigger intracellular signalling cascades as
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evidenced by the tyrosine phosphorylation. In dbcAMP differentiated cells, the low 
affinity receptor, FcyRIl, is upregulated and this receptor possesses an unusual IT AM 
and is able to couple efficiently to tyrosine kinase activation (Cambier et aL, 1995). Here 
I show that surface immune complexes require binding to both FcyRI and FcyRIl to 
initiate signalling. One possibility is that in these cells, FcyRI forms heterodimeric 
complexes with FcyRIl and this is required to induce efficient signal transduction.
The role of IgA and IgG in regulating myeloid cells is complex. Previous studies have 
shown that the two receptors co-operate on peripheral blood mononuclear cells and 
enhance phagocytosis release (Fanger, Goldstine & Shen, 1983, Shen & Fanger, 1981). 
However, serum IgA (monomeric) has also been shown to be anti-inflammatory and 
capable of inhibiting IgG mediated phagocytosis, oxidative burst and cytokine (Wolf et 
ah, 1994, Wolf et al., 1996, Nikolova & Russell, 1995). The differential levels of 
expression of the two receptors and their mutually exclusive coupling to the y-chain 
during differentiation may in part account for these different responses.
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Figure 6.1 FcyRI couples to y-chain in IFN-y primed U937 cells but not 
in dbcAMP differentiated cells.
(A) FcyRI was immunoprecipitated from U937 cells treated with IFN-y for 24 
hours or dbcAMP for 48 hours. Immunoprecipitates were subjected to SDS- 
PAGE, blotted to nitiocellulose and probed with anti-y-chain antibodies. (B) 
U937 cells were either primed with IFN-y or differentiated with dbcAMP as 
indicated. FcyRI was aggregated by incubation with either human IgG 
followed by goat anti-human IgG. Control cells were stimulated with goat IgG 
alone (control). Cells were wanned to 37°C for 1 min, lysed and subjected to 
immunoprécipitation with anti-y-chain antibodies. Immune precipitates were 
subjected to SDS-PAGE, blotted to nitrocellulose and probed with 4G10 anti- 
phosphotyrosine antibody (top panel). Blots were stripped and reprobed 
with anti-y-chain antibody (bottom panel).
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Figure 6,2 FcyRI mediated activation of signalling cascdes in dbcAMP 
differentiated cells, but not in IFN-y primed cells, requires FcyRII.
(A) IFN-y and dbcAMP treated cells were stimulated by the formation of 
surface immune complexes with human IgG, followed by goat anti-human IgG. 
The effect of blocking the ligand binding pocket of FcyRIIa was ascertainned 
by preincubating the cells with the mAh IV3 prior to formation of surface 
immune complexes (IgG + IV3). For comparison, cells were also stimulaed by 
aggregation of FcyRIIa with mAh IV3 followed by anti-mouse IgG (IV3). 
Control cells were stimulated with goat IgG alone (control). (B) The effect of 
the FcyRIIa blocldng antibody, IV3, on IgG binding was examined by FACS 
analysis. Cells differentiated with dbcAMP were loaded with IgG:FITC in the 
presence or absence of mAb IV3 as indicated. Cells with no IgGiFITC were 
included to control for autofluorescence (*). Cells were analysed as outlined in 
section 2.2.2.2.
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Figure 6.3 Expression of y-chain is increased by IFN-y and dbcAMP 
differentiation.
(A) Northern blot analysis of y-chain mRNA expression. U937 cells were 
treated with IFN-y or dbcAMP and cells harvested at the times indicated. 
Total RNA (20 jxg/sample) was subjected to Northern blot analysis as 
described in materials and methods. Blots were hybridised with a -labelled 
y-chain cDNA probe. (B) Western blot analysis of y-chain protein levels. 
Equal quantities of protein (20 pg/sample) from untreated U937 cells 
(control), cells treated with IFN-y for 24 hours and cells differentiated with 
dbcAMP for 48 hours were subjected to Western blot analysis as indicated in 
materials and methods. Blots were probed with rabbit anti-y-chain antibody.
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Figure 6.4 In cells differentiated with dbcAMP, y-chain preferentially 
associates with FcaRI.
(A) FcaRI was immunoprecipitated from U937 cells treated with IFN-y for 
24 hours or dbcAMP for 48 hours. Immunoprecipitates were Western blotted 
and probed for y-chain. (B) Aggregation of FcaRI with mAbs induces the 
tyrosine phosphorylation of multiple proteins.U937 cells were either primed 
with IFN-y or differentiated with dbcAMP as indicated. FcaRI was 
aggregated with the FcaRI specific mAh A3 followed by goat anti-mouse IgG 
for I min at 37°C. Control cells were stimulated with goat anti-mouse IgG 
alone (control). Tyrosine phosphorylation in cell lysates (20 pg/sample) was 
assessed by Western blotting with the 4G10 anti-phosphotyrosine antibody 
(bottom panel). (C) FcaRI aggregation induces the phosphorylation of y 
chain. Cells were stimulated as in (B). Following lysis, y-chain was 
precipitated from equivalent amounts of cell lysate (500 jig). 
Immunoprecipitates were subjected to SDS-PAGE, blotted to nitrocellulose 
and probed with 4G10 anti-phosphotyrosine antibody (top panel). Blots 
were stripped and reprobed with anti y-chain antibody (bottom panel).
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Figure 6.5 Differentiation with dbcAMP or priming with IFN-y alters 
relative expression of FcyRI and FcaRI
(A) Northern blot analysis of FcyRI and FcaRI expression. Cells were treated 
with either IFN-y or dbcAMP and harvested at times shown (hours) for 
isolation o f RNA. Total RNA (20 pg/sample) was subjected to Northern blot 
analysis as described in materials and methods. Blots were hybridised with 
specific ^^P-labelled cDNA probes for either FcyRI or FcaRI as indicated. (B) 
FACS analysis of FcyRI and FcaRI surface expression. Untreated U937 cells 
and cells treated with either IFN-y (24 hours) or dbcAMP (48 hours) were 
labelled with either the FcyRI specific mAh 22 (left panel), or FcaRI specific 
mAb A3 (right panel). An irrelevant mouse IgGl was used as an isotype 
control (*). A goat anti-mouse IgGiFITC was used as a secondary antibody 
and cells were subjected to FACS analysis as described in section 2.2.2.1.
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Figure 6.6 Coupling of receptors to the y-chain correlates with 
activation of PC-PLD.
PLD activity following crosslinking of FcyRI or FcaRI with specific mAbs 
was measured using the PLD-transphosphatidylation assay (section 2.4.1). 
U937 cells were treated with IFN-y or dbcAMP, labelled overnight with [^H] 
palmitic acid and preincubated with butan-l-ol for 30 min prior to the assay. 
FcyRI and FcaRI were labelled with mAh 22 and mAh A3 respectively. The 
accumulation of pH]PtdBut in cells over 30 min following the addition of goat 
anti-mouse crosslinking antibody was measui’ed. Control cells were incubated 
with crosslinking antibody but no mAb (control).
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Chapter 7 
General Discussion 
7.1. Fey receptors mediate critical immune functions
Fey receptors expressed on the surface of monocytes and macrophages mediate a number 
o f critical immune functions. These include the internalisation of immune complexes by 
endocytosis and phagocytosis, activation of the respiratory burst, release of cytokines 
and ADCC (van de Winlcel & Capel, 1993, Ravetch, 1994, Daeron, 1997a). The signalling 
pathways linking Fey receptors to these responses however have proved difficult to 
define. This is due, at least in part, to marked heterogeneity in signalling pathways 
activated by immune complexes in primary monocytes and macrophages. To overcome 
these difficulties it is necessary to use more defined model systems, such as cell lines, to 
study Fey receptor signal transduction.
7.2 Fey receptor signalling in U937 cells depends on the 
differentiation state of the cell
In this study, I have used the U937 cell line as a model for immune complex signalling in 
monocytes and macrophages. U937 cells undergo controlled differentiation when treated 
with dbcAMP into a more macrophage-like cell (Sheth et al., 1988). Alternatively, U937 
cells can be primed to behave like activated monocytes by treatment with IFN-y (Harris 
& Ralph, 1985). Using this system, previous work has shown that the signal 
transduction pathway activated by immune complexes fundamentally depends on the 
differentiation state of the cell (Melendez et a i, 1998a). Thus, in dbcAMP differentiated 
macrophage-like cells, Fey receptor aggregation induces the activation of PLCyl, 
prolonged InsP] production and sustained calcium signalling (Floto et al., 1997, Davis et 
al., 1995a). Conversely PTC is not activated in monocyte like IFN-y primed U937 cells. 
In these cells. Fey receptor aggregation activates a novel signal transduction pathway 
involving the sequential activation of PC-PLD and sphingosine kinase, resulting in a single
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transient cytosolic calcium spike (Melendez et a i, 1998b, Floto, Mahaut-Smith & Allen, 
1995). Further, the lack of PLC activation and calcium influx in response to Fey receptor 
aggregation in IFN-y primed cells is not simply a result o f differentiation dependent 
changes, as specific aggregation of the low affinity IgG receptor, FcyRIIa, with 
monoclonal Abs in the same cells results in both PLCyl activation and also prolonged 
calcium signalling (Melendez et a i, 1998a). In this thesis I have addressed a number of 
potential mechanisms which might underlie this developmental switch in signalling 
pathway activated by FcyRI.
7.3. What governs the nature of the calcium transients generated by 
Fey receptors in U937 cells?
Calcium signalling plays a central role in activation by many immune receptors in all 
immune cells studied. In these cells, calcium signalling is biphasic. Following receptor 
ligation, calcium is released from internal stores, resulting in a transient rise in cytosolic 
calcium. This, in turn, opens store operated calcium channels in the plasma membrane, 
termed Icrac^ leading to prolonged elevation of calcium or calcium oscillations (Hoth & 
Penner, 1992). The ER Ca^^ ATPase inhibitor, thapsigargin, depletes internal calcium 
stores and results in a rise in cytosolic calcium (Thastrup et al., 1990). As treatment of 
cells with thapsigargin results in the opening of Icrac calcium channels it has long been 
assumed that calcium release from internal stores was sufficient to trigger for calcium 
influx. As previous work has demonstrated that aggregation of FcyRI in IFN-y stimulated 
U937 cells results in release of calcium stores, but no calcium influx, I set out to 
investigate possible inhibitory mechanisms which might prevent the opening of I c r a c -
Looking to other immune receptors for clues, it was noted that the calcium transients 
generated by FcyRI signalling in IFN-y primed cells closely resembled calcium transients 
seen in response to ligation of the B-cell receptor (BCR) under conditions of ‘negative’ 
signalling. Aggregation of the BCR under positive signalling conditions, results in the 
activation of PLC72, InsPg production and prolonged calcium influx, resulting from both 
store release and I c r a c  opening. However, co-ligation of the BCR with the inhibitory low 
affinity receptor for IgG, FcyRIIb, results in release of calcium from internal stores but no
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calcium influx through I c r a c  (discussed in section 1.2.8.9). Here, the 5’ inositol 
phosphatase, SHIP, is recruited to FcyRIIb where it hydrolyses the major PI 3-kinase 
product, PI(3,4,5)p3 (PIP3) to PI(3,4)P2. As PIP3 is required for PLCy activation and the 
prolonged InsP3 production required to initiate calcium influx in these cells, SHIP 
provides a selective block in calcium influx while leaving many other tyrosine kinase 
dependent events intact (Scharenberg & Kinet, 1998, Sarkar et aL, 1996, Scharenberg & 
Kinet, 1996). In summary, BCR co-ligation with FcyRIIb involves the activation of 
tyrosine kinases, low PLCy activation, low InsP3 production, calcium release from 
internal stores and no calcium influx. The close identity of this signalling phenotype with 
the phenotype induced by FcyRI in IFNy primed U937s made this an attractive potential 
mechanism for investigation.
Thus, two parallel approaches were taken to investigate a possible role for the 5’inositol 
phosphatase, SHIP, in the regulation of FcyRI signalling. Firstly, a role for SHIP was 
analysed directly by immune precipitation studies and biochemical assays (see Chapter 
3). Secondly, as the low affinity receptor for IgG, FcyRIIb is the only receptor 
definitively proven to recruit SHIP Hn vivo\ I set out to investigate whether this receptor 
was expressed in U937 cells (see Chapter 4).
In chapter 3 I demonstrate that, SHIP does appear to play a role in FcyRI signalling in 
IFN-y primed U937s. Thus, following FcyRI aggregation SHIP is rapidly tyrosine 
phosphorylated and associates with the adapter protein She. Further, She translocates to 
the plasma membrane and both SHIP and She appear to be recruited to immune 
complexes. This was proposed as a potential mechanism to explain the lack of PLCy 
activation and calcium influx observed for FcyRI signalling (Cameron & Allen, 1999).
A number of points don’t however tie up with this hypothesis. Firstly, PI 3-kinase 
activation induced by FcyRI is robust with prolonged PIP3 production detectable 
following receptor ligation (Melendez et aï., 1998c). Secondly, no FcyRIIb expression 
was detectable in these IFN-y primed cells (see Chapter 4) and no other ITIM bearing 
receptor has been reported to associate with FcyRI. Finally, SHIP-Shc interactions were 
also found to occur in response to FcyRII aggregation, which induces both InsPs
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production and calcium influx. Consistent with a non-inhibitory role for SHIP-Shc 
interactions, Ingham et al recently demonstrated that SHIP expression is required for the 
correct phosphorylation of She (Ingham et al., 1999). As She phosphorylation has been 
implicated in the activation of the MAP kinase cascades (Harmer & DeFranco, 1997), this 
role for SHIP appears to be independent of the inhibitory actions mediated by FcyRIIb 
recruitment of SHIP in B-cells.
To our surprise, FcyRIIb expression was found in dbcAMP differentiated cells where Fey 
receptors couple to PLCy activation and calcium influx (Chapter 4) (Davis et al., 1995a, 
Melendez er a/., 1998a). The role of FcyRIIb in these cells remains elusive, though some 
preliminary data suggests it might temper the activation of specific signalling events, such 
as PKB, activated by FcyRIIa. This is the subject of ongoing investigation.
In IFN-y primed U937 cells, FcyRI mobilises calcium from intracellular stores via an InsP3 
independent mechanism. Here, the sequential activation of PLD and sphingosine kinase 
leads to calcium release presumably through the SCaMPER calcium channel which is 
found in the endoplasmic reticulum (section 1.4.3) (Mao et al., 1996, Melendez et a l, 
1998b). Why does this InsPg independent pathway to Ca”*”^  store release not lead to 
calcium influx through I c r a c ?  Parekh et al have extensively studied InsP] dependent 
calcium mobilisation in rat bosophilic leulcemia cells and their findings provide a possible 
explanation for our observations (Parekh & Penner, 1997, Parekh, Fleig & Penner, 1997). 
They have demonstrated in single cells that intracellular calcium store release and the 
activation of I c r a c  have very different sensitivities to InsP] (Parekh et al., 1997). Thus, 
significant calcium store release occurs at InsPs concentrations as low 60-100 nM while 
Icrac is only activated at pM concentrations of InsP]. This allows dissociation of calcium 
store release and calcium influx as is observed during FcyRIIb mediated inhibition of 
calcium entry. Parekh et al hypothesise that this difference in sensitivity results from 
functionally distinct calcium stores, one resulting in a transient rise in cytosolic calcium 
and the other resulting in I c r a c  opening. Due to the high concentrations of InsP] required 
to activate I c r a c  they further suggest that this second, less InsP] sensitive, calcium store 
is likely to lie close to the plasma membrane where local InsP] concentrations will be 
highest (Pareldi & Penner, 1997, Parekli et al., 1997). If two independent calcium stores
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do indeed exist it is possible that the novel sphingosine kinase dependent calcium 
mobilisation pathway activated by FcyRI in IFN-y primed cells is unable to mobilise the 
stores required to operate Icrac- Thus the failure of FcyRI to induce calcium influx 
through I c r a c  may depend, not on the termination of PIP3 dependent responses by S H IP , 
but rather on the failure of FcyRI to couple to PLCy activation.
7.4. What governs the switch in phospholipase pathway activated by 
Fey receptors?
In chapter 5, the reason for the failure of FcyRI to couple to PLCy activation was 
investigated. Both FcyRI and FcyRII couple to the activation of Lyn and Syk tyrosine 
kinases and patterns of tyrosine phosphorylation generated in response to aggregation of 
either receptor are very similar (Agarwal et al., 1993, Kiener et al., 1993). Further, both 
FcyRI and FcyRII induce the phosphorylation of PLCyl (Liao et al., 1992). However, it 
has been demonstrated that tyrosine phosphorylation of PLCy, though essential for 
activation, does not necessarily correlate with activity (Rhee & Bae, 1997). Thus, under 
some circumstances PLCy can be heavily phosphorylated while showing low activity. 
Recently, the mechanism governing PLCy activation by various immune receptors has 
been elucidated. PLCy activation is now known to require phosphorylation by both Syk 
and Tec family tyrosine kinases (section 1.2.4.3). Thus, in the case o f FceRI, activation 
of PLCyl is mediated by Syk and Btk (a Tec family kinase). Further, a number of 
adapter proteins have been shown to coordinate the recruitment and phosphorylation of 
PLCy by these kinases. In FceRI signalling, the membrane associated adapter, LAT, 
anchors PLCyl at the plasma membrane while the adapter protein SLP-76 coordinates the 
phosphorylation o f PLCyl by Btk (section 1.2.4.3). To investigate whether differences 
in PLCyl activation mediated by FcyRI and FcyRII in IFN-y primed U937 cells resulted 
from differences in the recruitment and correct phosphorylation of PLCyl, adapter 
protein complexes were examined. In chapter 5, I demonstrate that FcyRII appears to 
directly recruit constitutive SLP-76 :PLCyl complexes to the plasma membrane. No 
interaction of SLP-76 or PLCyl with the y-chain, the signalling subunit of FcyRI, could be 
detected. This provides a potential mechanism for the lack of PLC activity observed for 
FcyRI aggregation in IFN-y primed cells.
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In dbcAMP differentiated cells, aggregation of either FcyRI or FcyRII results in PLCy 
activation. Conversely, neither receptor couples to the activation of PC-PLD in these 
cells (Melendez et aL, 1998a). As FcyRII is upregulated in dbcAMP differentiated cells 
and as FcyRII aggregation induces PLC activation in IFN-y primed cells, it was 
hypothesised that FcyRI might couple to PLCy activation by recruiting FcyRII. Further, 
it was hypothesised that activation of PLD by FcyRI in IFN-y primed cells was 
dependent solely on a y-chain mediated signal. Consistent with this hypothesis anti­
sense oligonucleotides against FcyRIIa were found to reduce the coupling o f FcyRI to PLC 
in dbcAMP differentiated eells while anti-sense oligonucleotides to y-chain had no effect. 
Conversely, in IFN-y primed cells, anti-sense oligonucleotides to y-chain reduce FcyRI 
coupling to PLD, while FcyRIIa anti-sense had no effect (Melendez et al., 1998a). The 
reason for the failure of FcyRI to couple to PLD in dbcAMP differentiated cells was not 
clear.
In chapter 6, data is presented which explains both the coupling of FcyRI to PLC in 
dbcAMP treated cells and also explains the failure of FcyRI to couple to the activation of 
PLD. Using the mAh, IV3, which blocks IgG binding to FcyRIIa (Kavai et aL, 1991), we 
demonstrated that, in dbcAMP differentiated cells, initiation of tyrosine phosphorylation 
by immune complex was dependent on the recruitment of FcyRIIa (Figure 7.1). In IFN-y 
primed cells this was not the case as FcyRIIa blocking antibodies had no effect on 
tyrosine phosphorylation. I further demonstrated that association of FcyRI with the y- 
chain correlates with the ability of the reeeptor to activate PC-PLD. Thus in IFN-y 
treated cells, FcyRI physically and functionally associates with high levels of y-chain and 
activates PC-PLD. Conversely, in dbcAMP differentiated cells, no y-chain could be 
detected in association with FcyRI providing an explanation for the failure of FcyRI to 
activate PLD in these cells. As dbcAMP differentiated cells express very high levels of y- 
chain, it was also not clear why the y-chain failed to associate with FeyRI in these cells. 
However, as other receptors also associate with the y-chain, it was hypothesised that in 
dbcAMP cells, y-chain might preferentially associate with another receptor. Consistent 
with this argument I found that the IgA receptor, FcaRI, was upregulated in these cells
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and was associated with the y-chain. Further, I found that FcaRI activated PC-PLD in 
these cells, consistent with the y-chain specifying activation of this pathway (Figure 7.1).
These data taken together indicate that the signalling pathway activated by Fey receptors 
depends entirely on the signalling chain used to initiate signal transduetion. Thus, the y- 
chain specifies a PC-PLD pathway while FeyRIIa specifies PLCyl. Further, the ability 
of FcyRI to use these signalling chains in U937 cells is dependent on the maturation state 
o f the cells. Both y-chain and FcyRIIa initiate signal transduction by recruiting tyrosine 
k inas/ to IT AM motifs within their cytoplasmic tails. Interestingly, FcyRIIa bears an 
atypical ITAM with 14 amino acids separating the two key tyrosine residues as opposed 
to the 10 amino acid separation seen for the y-chain (section 1.2.1.1). It is tempting to 
speculate that this difference is directly responsible for the switch in phospholipase 
pathway activated.
It is still not clear, however, why FcyRI exclusively couples to PLD activation in IFN-y 
primed cells when the data from dbcAMP differentiated cells clearly demonstrates that 
FcyRI can recruit FcyRIIa to activate PLCyl. It is possible that FcyRI association with 
the y-chain might exclude FcyRIIa from signalling complexes, perhaps by inducing the 
dimérisation of FcyRI.
Recently, a dependence of phagocytosis on the activation of PLD has been proposed 
(Kusner et al., 1996, Kusner et al., 1999, Lennartz, 1999). It is perhaps surprising, 
therefore, that we observe no PC-PLD activation following specific ligation of FcyRIIa, as 
this receptor is capable of supporting phagocytosis. Some reports have indicated that 
FcyRIIa, like other Fc receptors, is capable of functional interaction with the y-chain 
(Masuda & Roos, 1993). This is, however, still the subject of some debate and we have 
found no evidence for such a mechanism in our system. Alternatively, FcyRIIa might 
activate forms of PLD with different substrate specifieity, such as the reported cytosolic 
PLD which preferentially hydrolyses phosphatidylinositol or phosphatidylethanolamine 
(Pertile et al., 1995). This possibility is currently under investigation.
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7.5. The functional consequence of two independent Fey receptor 
signalling pathways
Interestingly, in murine systems, Fey receptors rely entirely on the y-chain for tyrosine 
kinase mediated signal transduction, as a counterpart to FcyRIIa does not exist in mouse. 
This has been conclusively demonstrated by generation of y-chain deficient mice (Clynes 
et aL, 1998, Clynes et aL, 1999). Interestingly, mice which lack the y-chain show 
protection from immune complex mediated tissue damage and also show less 
susceptibility to auto-immune disease in a number of models. The reason for the 
existence of two functionally distinct IT AMs for Fey receptor signalling in human 
systems is not entirely clear. Some elues, however, aie provided by the expression 
patterns o f the different Fey receptors in human systems (section 1.1.3). Thus, FcyRIIa 
is expressed on neutrophils, monoeytes and macrophages where it appears to act as a 
major pathway for immune complex cleaiance. Interestingly, FcyRIIa has also been 
identified as the major receptor for C-reactive protein (CRP), indicating a role for this 
receptor in acute inflammatory responses and innate immunity (Bharadwaj et aL, 1999). 
FcyRI conversely is more restricted in expression, being tightly controlled by IFN-y. 
FcyRIIIa, which also associates with the y-chain is found expressed on macrophages and 
also on NK cells (section 1.1.3.3). It has been shown that FcyRI, FcyRIII and FcaRI but 
not FcyRIIa, can support ADCC implying a dependence on the y-chain ITAM for this 
process (seetion 1.1.8.3). As ADCC is a process capable of inducing tissue injury, 
separation of this effector function to a separate signalling subunit might provide a level 
of protection against incorrect activation of this process. It has also been suggested that 
FcyRI, but not FcyRIIa can support antigen presentation (Van den Herik-Oudijk et aL, 
1995b). These studies were however carried out in A20 murine B-cell transfectants so 
much caution must be taken when interpreting these data, particularly as murine systems 
entirely lack FcyRIIa.
Further to a switch in the phospholipase pathway, I have shown here, for the first time, 
that FeyRI and FcyRII couple to distinct patterns of MAP kinase activation in IFN-y 
primed cells. Thus, FcyRI aggregation activates ERK, p38 and INK MAP kinase 
cascades, while FcyRIIa activates only ERK and p38. Further, FcyRI and FcyRII appear
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to couple to the MAP kinase cascades via alternative pathways. This is discussed in 
detail in Chapter 5. When taken together with differenees in the calcium transients it 
seems likely that the two receptors will couple to distinct transcriptional responses. 
Future work will attempt to identify both transcription factors and transcriptional targets 
regulated hy these receptors, with particular reference to the produetion o f inflammatory 
mediators. These data perhaps imply that y-chain mediated and FcyRIIa mediated 
immune complex signal transduction might play distinct roles in the regulation of 
inflammation by mediating distinct transcriptional responses.
Intriguingly, different Fc receptors differ in their affinities for Ig classes and IgG 
subclasses (section 1.1.3.4). This implies that the response of monocytes and 
macrophages to immune complexes depends not only on the repertoire of Fc receptors 
expressed, but also on the composition of the immune complex. This is most strikingly 
demonstrated for IgG2 immune complexes as only FcyRIIa is capable of binding IgG2. At 
the other extreme, IgG4 immune complexes do not appear to bind FcyRIIa with any 
measurable affinity but these complexes will bind FcyRI and the inhibitory receptor, 
FcyRIIb (van de Winkel & Capel, 1993). As different Ig classes and IgG subclasses are 
associated with different types of immune response, this is likely to be of importance in 
immune system regulation.
In summary, two independent IgG immune complex signalling systems appear to exist in 
human leukocytes, one dependent on the y-chain and the other dependent on FcyRIIa. In 
U937 cells, the high affinity receptor for IgG, FcyRI is capable of interacting with both of 
these signalling subunits and this interaction is dependent on the differentiation state of 
the cell. Further, the signal transduction pathways activated by the y-chain and FcyRIIa 
in U937 cells are extremely different. By simply altering levels of expression of the 
different Fey reeeptors, along with levels of associated y-chain, human monocytes and 
macrophages can vary both their affinity for IgG complexes and their functional 
responses to these immune complexes. This versatility is likely to account for much of 
the heterogeneity of responses observed in primary monocyte and macrophage systems.
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